<?xml version="1.0" encoding="UTF-8"?><search-results xmlns="http://www.w3.org/2005/Atom" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:opensearch="http://a9.com/-/spec/opensearch/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/"><opensearch:totalResults>2992343</opensearch:totalResults><opensearch:startIndex>2100</opensearch:startIndex><opensearch:itemsPerPage>100</opensearch:itemsPerPage><opensearch:Query role="request" searchTerms="heart" startPage="2100"/><link ref="self" href="http://api.elsevier.com:80/content/search/index:scopus?start=2100&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="first" href="http://api.elsevier.com:80/content/search/index:scopus?start=0&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="prev" href="http://api.elsevier.com:80/content/search/index:scopus?start=2000&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="next" href="http://api.elsevier.com:80/content/search/index:scopus?start=2200&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="last" href="http://api.elsevier.com:80/content/search/index:scopus?start=4900&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927130265"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927130265?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927130265&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927130265&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0223523415002585"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927130265</prism:url><dc:identifier>SCOPUS_ID:84927130265</dc:identifier><eid>2-s2.0-84927130265</eid><dc:title>Design and synthesis of 3-(3-((9 H-carbazol-4-yl)oxy)-2-hydroxypropyl)-2-phenylquinazolin-4(3 H)-one derivatives to induce ACE inhibitory activity</dc:title><dc:creator>Venkatesh R.</dc:creator><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationName><prism:issn>02235234</prism:issn><prism:eIssn>17683254</prism:eIssn><prism:volume>96</prism:volume><prism:pageRange>22-29</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejmech.2015.04.009</prism:doi><pii>S0223523415002585</pii><dc:description>© 2015 Elsevier Masson SAS. In an attempt to develop a new class of cardiovascular drugs, a series of novel carbazolyloxy phenylquinazoline derivatives 9a-g have been synthesized and evaluated as angiotensin converting enzyme (ACE) inhibitors. Most of these compounds exhibited activity as significant ACE inhibitors and three compounds (9b, 9c &amp; 9e) showed maximum inhibitory potency in enzyme based assays. To render support to the experimental results, a series of quinazolinone derivatives were docked into active site of ACE and identified the probable binding modes compared to Lisinopril. Also we have identified common pharmacophore hypothesis (AAADDRR) among the best docked conformers of most potent compounds in a series of compounds. The most potent 9b, 9c, 9e compounds shared common active site with the Lisinopril binding site and retained the key active site residue interactions. The obtained results from pharmacological and molecular modeling studies can be utilized for further optimization of identified hits for selective inhibition of ACE.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023994</affiliation-url><afid>60023994</afid><affilname>Indian Institute of Chemical Technology</affilname><name-variant>Indian Inst. of Chemical Technology</name-variant><affiliation-city>Hyderabad</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023994</affiliation-url><afid>60023994</afid><affilname>Indian Institute of Chemical Technology</affilname><name-variant>Indian Inst. of Chemical Technology</name-variant><affiliation-city>Hyderabad</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023994</affiliation-url><afid>60023994</afid><affilname>Indian Institute of Chemical Technology</affilname><name-variant>Indian Inst. of Chemical Technology</name-variant><affiliation-city>Hyderabad</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55361267300</author-url><authid>55361267300</authid><authname>Venkatesh R.</authname><surname>Venkatesh</surname><given-name>Ramineni</given-name><initials>R.</initials><afid>60023994</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56587907800</author-url><authid>56587907800</authid><authname>Kasaboina S.</authname><surname>Kasaboina</surname><given-name>Suresh</given-name><initials>S.</initials><afid>60023994</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37033956800</author-url><authid>37033956800</authid><authname>Gaikwad H.</authname><surname>Gaikwad</surname><given-name>Hanmant K.</given-name><initials>H.K.</initials><afid>60023994</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55808567500</author-url><authid>55808567500</authid><authname>Janardhan S.</authname><surname>Janardhan</surname><given-name>Sridhara</given-name><initials>S.</initials><afid>60023994</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:22733823900</author-url><authid>22733823900</authid><authname>Bantu R.</authname><surname>Bantu</surname><given-name>Rajashaker</given-name><initials>R.</initials><afid>60023994</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55936836900</author-url><authid>55936836900</authid><authname>Nagarapu L.</authname><surname>Nagarapu</surname><given-name>Lingaiah</given-name><initials>L.</initials><afid>60023994</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55664734300</author-url><authid>55664734300</authid><authname>Sastry G.</authname><surname>Sastry</surname><given-name>G. Narahari</given-name><initials>G.N.</initials><afid>60023994</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:43061024900</author-url><authid>43061024900</authid><authname>Banerjee S.</authname><surname>Banerjee</surname><given-name>Sanjay K.</given-name><initials>S.K.</initials><afid>60023994</afid></author><authkeywords>ACE inhibitory activity | Docking studies | Lisinopril | Quinazolinone derivatives</authkeywords><intid>35569007</intid><source-id>17464</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929949878"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929949878?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929949878&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929949878&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929949878</prism:url><dc:identifier>SCOPUS_ID:84929949878</dc:identifier><eid>2-s2.0-84929949878</eid><dc:title>New insights into transient global amnesia | Neue aspekte zur pathophysiologie der transienten globalen amnesie</dc:title><dc:creator>Szabo K.</dc:creator><prism:publicationName>Aktuelle Neurologie</prism:publicationName><prism:issn>03024350</prism:issn><prism:eIssn>14389428</prism:eIssn><prism:volume>42</prism:volume><prism:issueIdentifier>4</prism:issueIdentifier><prism:pageRange>185-190</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1055/s-0034-1387630</prism:doi><dc:description>© Georg Thieme Verlag KG. Abstract Small hippocampal lesions are a characteristic finding in transient global amnesia (TGA) that become detectable approximately 24 hours after the clinical episode. In research into the causes and possible triggers of TGA different pathophysiological approaches have been followed in recent years. Several large trials have found no evidence for a higher incidence of stroke or vascular risk factors in TGA patients, thereby further distinguishing TGA from arterial ischemic disease. The relevance of cerebral venous abnormalities remained an important topic: Even though several studies have reported a higher prevalence of jugular venous reflux in TGA patients, hemodynamic alterations as a possible pathophysiological mechanism of TGA could not be demonstrated. Newer hypotheses have postulated a glutamate-mediated hyperexcitability with consecutive cytotoxic damage of the hippocampus and especially of the hippocampal CA1 neurons. These concepts focus on the possible role of stress and its effects on memory. New results have been obtained from functional imaging studies with respect to the memory networks affected in TGA. In this review, we describe new insights into the pathophysiology of TGA from recent scientific publications highlighting the possible role of stress-mediated processes for the development of TGA.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:107734343</affiliation-url><afid>107734343</afid><affilname>Universitätsmedizin Mannheim</affilname><name-variant>Universitätsmedizin Mannheim</name-variant><affiliation-city>Mannheim</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7102337492</author-url><authid>7102337492</authid><authname>Szabo K.</authname><surname>Szabo</surname><given-name>K.</given-name><initials>K.</initials><afid>107734343</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006758232</author-url><authid>7006758232</authid><authname>Gass A.</authname><surname>Gass</surname><given-name>A.</given-name><initials>A.</initials><afid>107734343</afid></author><authkeywords>amnesia | hippocampus | MRI | stress</authkeywords><intid>36041208</intid><source-id>130133</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930009781"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930009781?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930009781&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930009781&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378517315004433"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930009781</prism:url><dc:identifier>SCOPUS_ID:84930009781</dc:identifier><eid>2-s2.0-84930009781</eid><dc:title>Effects of formulation design on niacin therapeutics: Mechanism of action, metabolism, and drug delivery</dc:title><dc:creator>Cooper D.</dc:creator><prism:publicationName>International Journal of Pharmaceutics</prism:publicationName><prism:issn>03785173</prism:issn><prism:eIssn>18733476</prism:eIssn><prism:volume>490</prism:volume><prism:issueIdentifier>1-2</prism:issueIdentifier><prism:pageRange>55-64</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijpharm.2015.05.024</prism:doi><pii>S0378517315004433</pii><dc:description>© 2015 Elsevier B.V. Abstract Niacin is a highly effective, lipid regulating drug associated with a number of metabolically induced side effects such as prostaglandin (PG) mediated flushing and hepatic toxicity. In an attempt to reduce the development of these adverse effects, scientists have investigated differing methods of niacin delivery designed to control drug release and alter metabolism. However, despite successful formulation of various orally based capsule and tablet delivery systems, patient adherence to niacin therapy is still compromised by adverse events such as PG-induced flushing. While the primary advantage of orally dosed formulations is ease of use, alternative delivery options such as transdermal delivery or polymeric micro/nanoparticle encapsulation for oral administration have shown promise in niacin reformulation. However, the effectiveness of these alternative delivery options in reducing inimical effects of niacin and maintaining drug efficacy is still largely unknown and requires more in-depth investigation. In this paper, we present an overview of niacin applications, its metabolic pathways, and current drug delivery formulations. Focus is placed on oral immediate, sustained, and extended release niacin delivery as well as combined statin and/or prostaglandin antagonist niacin formulation. We also examine and discuss current findings involving transdermal niacin formulations and polymeric micro/nanoparticle encapsulated niacin delivery.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001426</affiliation-url><afid>60001426</afid><affilname>East Tennessee State University</affilname><name-variant>East Tennessee State University</name-variant><affiliation-city>Johnson</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55987263600</author-url><authid>55987263600</authid><authname>Cooper D.</authname><surname>Cooper</surname><given-name>Dustin L.</given-name><initials>D.L.</initials><afid>60001426</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56081347700</author-url><authid>56081347700</authid><authname>Murrell D.</authname><surname>Murrell</surname><given-name>Derek E.</given-name><initials>D.E.</initials><afid>60001426</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36834017700</author-url><authid>36834017700</authid><authname>Roane D.</authname><surname>Roane</surname><given-name>David S.</given-name><initials>D.S.</initials><afid>60001426</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8516657200</author-url><authid>8516657200</authid><authname>Harirforoosh S.</authname><surname>Harirforoosh</surname><given-name>Sam</given-name><initials>S.</initials><afid>60001426</afid></author><authkeywords>Flushing | Formulation | Hepatotoxicity | Lipoprotein | Niacin | Nicotinic acid | Triglyceride</authkeywords><intid>36048961</intid><article-number>14894</article-number><source-id>22454</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929705249"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929705249?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929705249&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929705249&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0031942214004142"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929705249</prism:url><dc:identifier>SCOPUS_ID:84929705249</dc:identifier><eid>2-s2.0-84929705249</eid><dc:title>Accessing biological actions of Ganoderma secondary metabolites by in silico profiling</dc:title><dc:creator>Grienke U.</dc:creator><prism:publicationName>Phytochemistry</prism:publicationName><prism:issn>00319422</prism:issn><prism:volume>114</prism:volume><prism:pageRange>114-124</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.phytochem.2014.10.010</prism:doi><pii>S0031942214004142</pii><dc:description>© 2014 Elsevier Ltd. All rights reserved. The species complex around the medicinal fungus Ganoderma lucidum Karst. (Ganodermataceae) is widely known in traditional medicines, as well as in modern applications such as functional food or nutraceuticals. A considerable number of publications reflects its abundance and variety in biological actions either provoked by primary metabolites, such as polysaccharides, or secondary metabolites, such as lanostane-type triterpenes. However, due to this remarkable amount of information, a rationalization of the individual Ganoderma constituents to biological actions on a molecular level is quite challenging. To overcome this issue, a database was generated containing meta-information, i.e., chemical structures and biological actions of hitherto identified Ganoderma constituents (279). This was followed by a computational approach subjecting this 3D multi-conformational molecular dataset to in silico parallel screening against an in-house collection of validated structure- and ligand-based 3D pharmacophore models. The predictive power of the evaluated in silico tools and hints from traditional application fields served as criteria for the model selection. Thus, the focus was laid on representative druggable targets in the field of viral infections (5) and diseases related to the metabolic syndrome (22). The results obtained from this in silico approach were compared to bioactivity data available from the literature. 89 and 197 Ganoderma compounds were predicted as ligands of at least one of the selected pharmacological targets in the antiviral and the metabolic syndrome screening, respectively. Among them only a minority of individual compounds (around 10%) has ever been investigated on these targets or for the associated biological activity. Accordingly, this study discloses putative ligand target interactions for a plethora of Ganoderma constituents in the empirically manifested field of viral diseases and metabolic syndrome which serve as a basis for future applications to access yet undiscovered biological actions of Ganoderma secondary metabolites on a molecular level.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009999</affiliation-url><afid>60009999</afid><affilname>University of Innsbruck</affilname><name-variant>Universität Innsbruck</name-variant><affiliation-city>Innsbruck</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009999</affiliation-url><afid>60009999</afid><affilname>University of Innsbruck</affilname><name-variant>Universität Innsbruck</name-variant><affiliation-city>Innsbruck</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025988</affiliation-url><afid>60025988</afid><affilname>Universitat Wien</affilname><name-variant>Universität Wien</name-variant><affiliation-city>Vienna</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025988</affiliation-url><afid>60025988</afid><affilname>Universitat Wien</affilname><name-variant>Universität Wien</name-variant><affiliation-city>Vienna</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35573310900</author-url><authid>35573310900</authid><authname>Grienke U.</authname><surname>Grienke</surname><given-name>Ulrike</given-name><initials>U.</initials><afid>60009999</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56436760400</author-url><authid>56436760400</authid><authname>Kaserer T.</authname><surname>Kaserer</surname><given-name>Teresa</given-name><initials>T.</initials><afid>60009999</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56436328900</author-url><authid>56436328900</authid><authname>Pfluger F.</authname><surname>Pfluger</surname><given-name>Florian</given-name><initials>F.</initials><afid>60009999</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56225442600</author-url><authid>56225442600</authid><authname>Mair C.</authname><surname>Mair</surname><given-name>Christina E.</given-name><initials>C.E.</initials><afid>60009999</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7102141949</author-url><authid>7102141949</authid><authname>Langer T.</authname><surname>Langer</surname><given-name>Thierry</given-name><initials>T.</initials><afid>60025988</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8964316200</author-url><authid>8964316200</authid><authname>Schuster D.</authname><surname>Schuster</surname><given-name>Daniela</given-name><initials>D.</initials><afid>60009999</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6701352802</author-url><authid>6701352802</authid><authname>Rollinger J.</authname><surname>Rollinger</surname><given-name>Judith M.</given-name><initials>J.M.</initials><afid>60009999</afid><afid>60025988</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6701352802</author-url><authid>6701352802</authid><authname>Rollinger J.</authname><surname>Rollinger</surname><given-name>Judith M.</given-name><initials>J.M.</initials><afid>60009999</afid><afid>60025988</afid></author><authkeywords>Antiviral targets | Ganoderma lucidum | Ganodermataceae | Metabolic syndrome | Pharmacophore profiling | Triterpenes | Virtual screening</authkeywords><intid>2035995028</intid><source-id>16534</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929702950"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929702950?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929702950&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929702950&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0006295215002178"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929702950</prism:url><dc:identifier>SCOPUS_ID:84929702950</dc:identifier><eid>2-s2.0-84929702950</eid><dc:title>Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia</dc:title><dc:creator>Shah D.</dc:creator><prism:publicationName>Biochemical Pharmacology</prism:publicationName><prism:issn>00062952</prism:issn><prism:eIssn>18732968</prism:eIssn><prism:volume>95</prism:volume><prism:issueIdentifier>4</prism:issueIdentifier><prism:pageRange>211-226</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bcp.2015.04.012</prism:doi><pii>S0006295215002178</pii><dc:description>© 2015 Elsevier Inc. All rights reserved. Preeclampsia is a pregnancy-associated disorder characterized by hypertension, and could lead to maternal and fetal morbidity and mortality; however, the pathophysiological mechanisms involved are unclear. Predisposing demographic, genetic and environmental risk factors could cause localized abnormalities in uteroplacental cytoactive factors such as integrins, matrix metalloproteinases, cytokines and major histocompatibility complex molecules leading to decreased vascular remodeling, uteroplacental vasoconstriction, trophoblast cells apoptosis, and abnormal development of the placenta. Defective placentation and decreased trophoblast invasion of the myometrium cause reduction in uteroplacental perfusion pressure (RUPP) and placental ischemia/hypoxia, an important event in preeclampsia. RUPP could stimulate the release of circulating bioactive factors such as the anti-angiogenic factors soluble fms-like tyrosine kinase-1 and soluble endoglin that cause imbalance with the pro-angiogenic factors vascular endothelial growth factor and placental growth factor, or cause the release of inflammatory cytokines, reactive oxygen species, hypoxia-induced factor-1 and AT&lt;inf&gt;1&lt;/inf&gt; angiotensin receptor agonistic autoantibodies. The circulating bioactive factors target endothelial cells causing generalized endotheliosis, endothelial dysfunction, decreased vasodilators such as nitric oxide and prostacyclin and increased vasoconstrictors such as endothelin-1 and thromboxane A&lt;inf&gt;2&lt;/inf&gt;, leading to increased vasoconstriction. The bioactive factors also stimulate the mechanisms of VSM contraction including Ca&lt;sup&gt;2+&lt;/sup&gt;, protein kinase C, and Rho-kinase and induce extracellular matrix remodeling leading to further vasoconstriction and hypertension. While therapeutic options are currently limited, understanding the underlying mechanisms could help design new interventions for management of preeclampsia.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56622109200</author-url><authid>56622109200</authid><authname>Shah D.</authname><surname>Shah</surname><given-name>Dania A.</given-name><initials>D.A.</initials><afid>60016782</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7103356363</author-url><authid>7103356363</authid><authname>Khalil R.</authname><surname>Khalil</surname><given-name>Raouf A.</given-name><initials>R.A.</initials><afid>60016782</afid><afid>60016782</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7103356363</author-url><authid>7103356363</authid><authname>Khalil R.</authname><surname>Khalil</surname><given-name>Raouf A.</given-name><initials>R.A.</initials><afid>60016782</afid><afid>60016782</afid></author><authkeywords>Endothelium | Extracellular matrix | Hypertension | Preeclampsia | Pregnancy | Vascular smooth muscle</authkeywords><intid>536000984</intid><source-id>20063</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226860"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226860?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226860&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226860&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226860</prism:url><dc:identifier>SCOPUS_ID:84930226860</dc:identifier><eid>2-s2.0-84930226860</eid><dc:title>Development of an accelerometer-linked online intervention system to promote physical activity in adolescents</dc:title><dc:creator>Guthrie N.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0128639</prism:doi><dc:description>© 2015 Guthrie et al. Most adolescents do not achieve the recommended levels of moderate-to-vigorous physical activity (MVPA), placing them at increased risk for a diverse array of chronic diseases in adulthood. There is a great need for scalable and effective interventions that can increase MVPA in adolescents. Here we report the results of a measurement validation study and a preliminary proof-of-concept experiment testing the impact of Zamzee, an accelerometer-linked online intervention system that combines proximal performance feedback and incentive motivation features to promote MVPA. In a calibration study that parametrically varied levels of physical activity in 31 12-14 year-old children, the Zamzee activity meter was shown to provide a valid measure of MVPA (sensitivity in detecting MVPA = 85.9%, specificity = 97.5%, and r = .94 correspondence with the benchmark RT3 accelerometer system; all p &lt; .0001). In a subsequent randomized controlled multi-site experiment involving 182 middle school-aged children assessed for MVPA over 6 wks, intent-to-treat analyses found that those who received access to the Zamzee intervention had average MVPA levels 54% greater than those of a passive control group (p &lt; 0.0001) and 68% greater than those of an active control group that received access to a commercially available active videogame (p &lt; .0001). Zamzee's effects on MVPA did not diminish significantly over the course of the 6-wk study period, and were statistically significant in both females and males, and in normal-vs. high-BMI subgroups. These results provide promising initial indications that combining the Zamzee activity meter with online proximal performance feedback and incentive motivation features can positively impact MVPA levels in adolescents.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112708162</affiliation-url><afid>112708162</afid><affilname>HopeLab Foundation</affilname><name-variant>HopeLab Foundation</name-variant><affiliation-city>Redwood City</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021143</affiliation-url><afid>60021143</afid><affilname>West Virginia University</affilname><name-variant>West Virginia University</name-variant><affiliation-city>Morgantown</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:107095884</affiliation-url><afid>107095884</afid><affilname>Santech, Inc.</affilname><name-variant>Santech Inc.</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032838</affiliation-url><afid>60032838</afid><affilname>Stanford University School of Medicine</affilname><name-variant>Stanford University School of Medicine</name-variant><affiliation-city>Stanford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36869183900</author-url><authid>36869183900</authid><authname>Guthrie N.</authname><surname>Guthrie</surname><given-name>Nicole</given-name><initials>N.</initials><afid>112708162</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6701665750</author-url><authid>6701665750</authid><authname>Bradlyn A.</authname><surname>Bradlyn</surname><given-name>Andrew</given-name><initials>A.</initials><afid>60021143</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56662674300</author-url><authid>56662674300</authid><authname>Thompson S.</authname><surname>Thompson</surname><given-name>Sharon K.</given-name><initials>S.K.</initials><afid>107095884</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55378109000</author-url><authid>55378109000</authid><authname>Yen S.</authname><surname>Yen</surname><given-name>Sophia</given-name><initials>S.</initials><afid>60032838</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8839686800</author-url><authid>8839686800</authid><authname>Haritatos J.</authname><surname>Haritatos</surname><given-name>Jana</given-name><initials>J.</initials><afid>112708162</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56662872300</author-url><authid>56662872300</authid><authname>Dillon F.</authname><surname>Dillon</surname><given-name>Fred</given-name><initials>F.</initials><afid>112708162</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55237592900</author-url><authid>55237592900</authid><authname>Cole S.</authname><surname>Cole</surname><given-name>Steve W.</given-name><initials>S.W.</initials><afid>112708162</afid></author><intid>1786088160</intid><article-number>e0128639</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930227347"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930227347?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930227347&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930227347&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930227347</prism:url><dc:identifier>SCOPUS_ID:84930227347</dc:identifier><eid>2-s2.0-84930227347</eid><dc:title>Src Family Kinases (SFK) mediate angiotensin II-induced myosin light chain phosphorylation and hypertension</dc:title><dc:creator>Qin B.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0127891</prism:doi><dc:description>© 2015 Qin, Zhou. Angiotensin (Ang) II is the major bioactive peptide of the renin-angiotensin system (RAS); it contributes to the pathogenesis of hypertension by inducing vascular contraction and adverse remodeling, thus elevated peripheral resistance. Ang II also activates Src family kinases (SFK) in the vascular system, which has been implicated in cell proliferation and migration. However, the role of SFK in Ang II-induced hypertension is largely unknown. In this study, we found that administration of a SFK inhibitor SU6656 markedly lowered the level of systemic BP in Ang II-treated mice, which was associated with an attenuated phosphorylation of the smooth-muscle myosin-light-chain (MLC) in the mesenteric resistant arteries. In the cultured human coronary artery smooth muscle cells (SMCs), pretreatment with SU6656 blocked Ang II-induced MLC phosphorylation and contraction. These results for the first time demonstrate that SFK directly regulate vascular contractile machinery to influence BP. Thus our study provides an additional mechanistic link between Ang II and vasoconstriction via SFK-enhanced MLC phosphorylation in SMCs, and suggests that targeted inhibition of Src may provide a new therapeutic opportunity in the treatment of hypertension.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007363</affiliation-url><afid>60007363</afid><affilname>Northwestern University</affilname><name-variant>Northwestern University</name-variant><affiliation-city>Evanston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013227</affiliation-url><afid>60013227</afid><affilname>Northwestern University Feinberg School of Medicine</affilname><name-variant>Northwestern University</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55734856300</author-url><authid>55734856300</authid><authname>Qin B.</authname><surname>Qin</surname><given-name>Bo</given-name><initials>B.</initials><afid>60007363</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35184630200</author-url><authid>35184630200</authid><authname>Zhou J.</authname><surname>Zhou</surname><given-name>Junlan</given-name><initials>J.</initials><afid>60013227</afid></author><intid>1786087908</intid><article-number>e0127891</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930200079"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930200079?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930200079&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930200079&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930200079</prism:url><dc:identifier>SCOPUS_ID:84930200079</dc:identifier><eid>2-s2.0-84930200079</eid><dc:title>Maternal age at first delivery is associated with the risk of metabolic syndrome in postmenopausal women: From 2008-2010 Korean National Health and Nutrition Examination Survey</dc:title><dc:creator>Sim J.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0127860</prism:doi><dc:description>© 2015 Sim et al. Background: Recent cross-sectional studies demonstrated that earlier maternal age at first childbirth is correlated with a higher risk of diabetes in postmenopausal women. In this study, we evaluated whether the age at first delivery is associated with the risk of metabolic syndrome (MetS) in postmenopausal women. Methods: A total of 4,261 postmenopausal women aged 45 years or older were analyzed using data generated from Korea National Health and Nutrition Examination Surveys (2008-2010). Subjects were divided into three groups according to the maternal age at first delivery as follows: ≤ 20 years (n=878), 21-25 years (n=2314), and ≥ 26 years (n=1069). Results: Approximately 37% of subjects had MetS. The prevalence of MetS showed a gradual increase as maternal age at first delivery decreased (≥ 26 years = 30.9% vs. 21-25 years = 39.9% vs. ≤ 20 years = 50.8%, respectively, p &lt; 0.001). Central obesity indices such as trunk fat mass and waist circumference were significantly higher in the group aged ≤ 20 years than other groups. After adjustments for confounding factors, the odds ratios (ORs) for predicting the presence of MetS increased gradually as first delivery age decreased (≥ 26 years vs. 21-25 years vs. ≤ 20 years: OR [95% CI] = 1 vs. 1.324 [1.118-1.567] vs. 1.641 [1.322-2.036], respectively). Among components of MetS, younger maternal age at first delivery (≤ 20 years) was significantly associated with increased waist circumference (OR [95% CI] = 1.735 [1.41-2.13]), elevated blood pressure (1.261 [1.02-1.57]), high triglyceride (1.333 [1.072-1.659]), and low HDL-cholesterol (1.335[1.084-1.643]). Conclusions: Our findings suggest that younger maternal age at first delivery is independently associated with a higher risk of central obesity and MetS in postmenopausal women.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016912</affiliation-url><afid>60016912</afid><affilname>Yonsei University</affilname><name-variant>Yonsei University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016912</affiliation-url><afid>60016912</afid><affilname>Yonsei University</affilname><name-variant>Yonsei University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662747600</author-url><authid>56662747600</authid><authname>Sim J.</authname><surname>Sim</surname><given-name>Jeong Han</given-name><initials>J.H.</initials><afid>60016912</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662689400</author-url><authid>56662689400</authid><authname>Chung D.</authname><surname>Chung</surname><given-name>Dawn</given-name><initials>D.</initials><afid>60016912</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55475193400</author-url><authid>55475193400</authid><authname>Lim J.</authname><surname>Lim</surname><given-name>Jung Soo</given-name><initials>J.S.</initials><afid>60016912</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56297094100</author-url><authid>56297094100</authid><authname>Lee M.</authname><surname>Lee</surname><given-name>Mi Young</given-name><initials>M.Y.</initials><afid>60016912</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:25926341700</author-url><authid>25926341700</authid><authname>Chung C.</authname><surname>Chung</surname><given-name>Choon Hee</given-name><initials>C.H.</initials><afid>60016912</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:16305352400</author-url><authid>16305352400</authid><authname>Shin J.</authname><surname>Shin</surname><given-name>Jang Yel</given-name><initials>J.Y.</initials><afid>60016912</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56533158700</author-url><authid>56533158700</authid><authname>Huh J.</authname><surname>Huh</surname><given-name>Ji Hye</given-name><initials>J.H.</initials><afid>60016912</afid></author><intid>1786088249</intid><article-number>e0127860</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930001391"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930001391?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930001391&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930001391&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0928493115300941"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930001391</prism:url><dc:identifier>SCOPUS_ID:84930001391</dc:identifier><eid>2-s2.0-84930001391</eid><dc:title>Vascularisation in regenerative therapeutics and surgery</dc:title><dc:creator>Jeyaraj R.</dc:creator><prism:publicationName>Materials Science and Engineering C</prism:publicationName><prism:issn>09284931</prism:issn><prism:volume>54</prism:volume><prism:pageRange>225-238</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.msec.2015.05.045</prism:doi><pii>S0928493115300941</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Vascularisation is often deemed the holy grail of tissue engineering because it is one of the key preconditions that determine the in vivo viability of tissue constructs. Given that a well-developed vascular network allows greater complexity in tissue design and helps regulate tissue metabolism, it appears that the overall outcome of engineered tissue implants depends on the success of microvessel formation, maturation and patterning. Current approaches to vascularising tissue include both in vivo and ex vivo techniques, where blood vessel formation is either spontaneous or guided by physical or biochemical factors. The success of these strategies can then be monitored and evaluated for clinical benefit through numerous standard and novel strategies. Despite the impressive progress in the field of tissue engineering in recent times, there are still numerous technical, immunological, surgical and ethical challenges to overcome. Future prospects in this field are likely to depend on the adoption of a wide-ranging approach incorporating a combination of salient themes such as genetic manipulation, modular assembly and bioreactor coupling. Where applicable, the potential contributions of nanobiotechnology to tissue vascularisation will be discussed as appropriate.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029950</affiliation-url><afid>60029950</afid><affilname>UCL Medical School</affilname><name-variant>UCL Medical School</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60100632</affiliation-url><afid>60100632</afid><affilname>King's College Cambridge</affilname><name-variant>University of Cambridge</name-variant><affiliation-city>Chichester</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032838</affiliation-url><afid>60032838</afid><affilname>Stanford University School of Medicine</affilname><name-variant>Stanford University School of Medicine</name-variant><affiliation-city>Stanford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029204</affiliation-url><afid>60029204</afid><affilname>NHS Foundation Trust</affilname><name-variant>NHS Foundation Trust</name-variant><affiliation-city>Leeds</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022148</affiliation-url><afid>60022148</afid><affilname>UCL</affilname><name-variant>University College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56658648000</author-url><authid>56658648000</authid><authname>Jeyaraj R.</authname><surname>Jeyaraj</surname><given-name>Rebecca</given-name><initials>R.</initials><afid>60029950</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55921966800</author-url><authid>55921966800</authid><authname>Natasha G.</authname><surname>Natasha</surname><given-name>G.</given-name><initials>G.</initials><afid>60029950</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56658367600</author-url><authid>56658367600</authid><authname>Kirby G.</authname><surname>Kirby</surname><given-name>Georgia</given-name><initials>G.</initials><afid>60029950</afid><afid>60100632</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56658367600</author-url><authid>56658367600</authid><authname>Kirby G.</authname><surname>Kirby</surname><given-name>Georgia</given-name><initials>G.</initials><afid>60029950</afid><afid>60100632</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:23971332600</author-url><authid>23971332600</authid><authname>Rajadas J.</authname><surname>Rajadas</surname><given-name>Jayakumar</given-name><initials>J.</initials><afid>60032838</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55400189300</author-url><authid>55400189300</authid><authname>Mosahebi A.</authname><surname>Mosahebi</surname><given-name>Ash</given-name><initials>A.</initials><afid>60029204</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005344804</author-url><authid>7005344804</authid><authname>Seifalian A.</authname><surname>Seifalian</surname><given-name>Alexander M.</given-name><initials>A.M.</initials><afid>60022148</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:36931163300</author-url><authid>36931163300</authid><authname>Tan A.</authname><surname>Tan</surname><given-name>Aaron</given-name><initials>A.</initials><afid>60029950</afid><afid>60032838</afid><afid>60022148</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:36931163300</author-url><authid>36931163300</authid><authname>Tan A.</authname><surname>Tan</surname><given-name>Aaron</given-name><initials>A.</initials><afid>60029950</afid><afid>60032838</afid><afid>60022148</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:36931163300</author-url><authid>36931163300</authid><authname>Tan A.</authname><surname>Tan</surname><given-name>Aaron</given-name><initials>A.</initials><afid>60029950</afid><afid>60032838</afid><afid>60022148</afid></author><authkeywords>Biomaterials | Nanotechnology | Regenerative therapeutics | Surgery | Tissue engineering | Vascularisation</authkeywords><intid>2036044755</intid><source-id>17813</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225128"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225128?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225128&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225128&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225128</prism:url><dc:identifier>SCOPUS_ID:84930225128</dc:identifier><eid>2-s2.0-84930225128</eid><dc:title>Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue</dc:title><dc:creator>Hoffmann L.</dc:creator><prism:publicationName>Nature Communications</prism:publicationName><prism:eIssn>20411723</prism:eIssn><prism:volume>6</prism:volume><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1038/ncomms8235</prism:doi><pii>ncomms8235</pii><dc:description>© 2015 Macmillan Publishers Limited. All rights reserved. Obesity is characterized by a positive energy balance and expansion of white adipose tissue (WAT). In contrast, brown adipose tissue (BAT) combusts energy to produce heat. Here we show that a small molecule stimulator (BAY 41-8543) of soluble guanylyl cyclase (sGC), which produces the second messenger cyclic GMP (cGMP), protects against diet-induced weight gain, induces weight loss in established obesity, and also improves the diabetic phenotype. Mechanistically, the haeme-dependent sGC stimulator BAY 41-8543 enhances lipid uptake into BAT and increases whole-body energy expenditure, whereas ablation of the haeme-containing β&lt;inf&gt;1&lt;/inf&gt;-subunit of sGC severely impairs BAT function. Notably, the sGC stimulator enhances differentiation of human brown adipocytes as well as induces 'browning' of primary white adipocytes. Taken together, our data suggest that sGC is a potential pharmacological target for the treatment of obesity and its comorbidities.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030465</affiliation-url><afid>60030465</afid><affilname>Universitats-Klinikum Bonn und Medizinische Fakultat</affilname><affiliation-city>Bonn</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012797</affiliation-url><afid>60012797</afid><affilname>Deutsche Sporthochschule Koln</affilname><name-variant>German Sport University</name-variant><affiliation-city>Koln</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007493</affiliation-url><afid>60007493</afid><affilname>Universitat Bonn</affilname><name-variant>Universität Bonn</name-variant><affiliation-city>Bonn</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005036</affiliation-url><afid>60005036</afid><affilname>Universitatsklinikum Hamburg-Eppendorf und Medizinische Fakultat</affilname><name-variant>University Medical Center Hamburg-Eppendorf</name-variant><affiliation-city>Hamburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006680</affiliation-url><afid>60006680</afid><affilname>Bayer</affilname><name-variant>Bayer AG</name-variant><affiliation-city>Leverkusen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014059</affiliation-url><afid>60014059</afid><affilname>Martin-Universitat Halle-Wittenberg</affilname><name-variant>Martin-Luther-Univ. Halle-Wittenberg</name-variant><affiliation-city>Halle</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012689</affiliation-url><afid>60012689</afid><affilname>Julius-Maximilians-Universitat Wurzburg</affilname><name-variant>University of Würzburg</name-variant><affiliation-city>Wurzburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007493</affiliation-url><afid>60007493</afid><affilname>Universitat Bonn</affilname><name-variant>Universität Bonn</name-variant><affiliation-city>Bonn</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008658</affiliation-url><afid>60008658</afid><affilname>Uniklinik Koln</affilname><affiliation-city>Koln</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35082094600</author-url><authid>35082094600</authid><authname>Hoffmann L.</authname><surname>Hoffmann</surname><given-name>Linda S.</given-name><initials>L.S.</initials><afid>60030465</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56663145900</author-url><authid>56663145900</authid><authname>Etzrodt J.</authname><surname>Etzrodt</surname><given-name>Jennifer</given-name><initials>J.</initials><afid>60030465</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24171935700</author-url><authid>24171935700</authid><authname>Willkomm L.</authname><surname>Willkomm</surname><given-name>Lena</given-name><initials>L.</initials><afid>60012797</afid><afid>60008658</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24171935700</author-url><authid>24171935700</authid><authname>Willkomm L.</authname><surname>Willkomm</surname><given-name>Lena</given-name><initials>L.</initials><afid>60012797</afid><afid>60008658</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662776500</author-url><authid>56662776500</authid><authname>Sanyal A.</authname><surname>Sanyal</surname><given-name>Abhishek</given-name><initials>A.</initials><afid>60030465</afid><afid>60007493</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662776500</author-url><authid>56662776500</authid><authname>Sanyal A.</authname><surname>Sanyal</surname><given-name>Abhishek</given-name><initials>A.</initials><afid>60030465</afid><afid>60007493</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6507392804</author-url><authid>6507392804</authid><authname>Scheja L.</authname><surname>Scheja</surname><given-name>Ludger</given-name><initials>L.</initials><afid>60005036</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56662663000</author-url><authid>56662663000</authid><authname>Fischer A.</authname><surname>Fischer</surname><given-name>Alexander W C</given-name><initials>A.W.C.</initials><afid>60005036</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7005852546</author-url><authid>7005852546</authid><authname>Stasch J.</authname><surname>Stasch</surname><given-name>Johannes Peter</given-name><initials>J.P.</initials><afid>60006680</afid><afid>60014059</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7005852546</author-url><authid>7005852546</authid><authname>Stasch J.</authname><surname>Stasch</surname><given-name>Johannes Peter</given-name><initials>J.P.</initials><afid>60006680</afid><afid>60014059</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35481516500</author-url><authid>35481516500</authid><authname>Bloch W.</authname><surname>Bloch</surname><given-name>Wilhelm</given-name><initials>W.</initials><afid>60012797</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6603867469</author-url><authid>6603867469</authid><authname>Friebe A.</authname><surname>Friebe</surname><given-name>Andreas</given-name><initials>A.</initials><afid>60012689</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7004229436</author-url><authid>7004229436</authid><authname>Heeren J.</authname><surname>Heeren</surname><given-name>Joerg</given-name><initials>J.</initials><afid>60005036</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7005761209</author-url><authid>7005761209</authid><authname>Pfeifer A.</authname><surname>Pfeifer</surname><given-name>Alexander</given-name><initials>A.</initials><afid>60030465</afid><afid>60007493</afid><afid>60007493</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7005761209</author-url><authid>7005761209</authid><authname>Pfeifer A.</authname><surname>Pfeifer</surname><given-name>Alexander</given-name><initials>A.</initials><afid>60030465</afid><afid>60007493</afid><afid>60007493</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7005761209</author-url><authid>7005761209</authid><authname>Pfeifer A.</authname><surname>Pfeifer</surname><given-name>Alexander</given-name><initials>A.</initials><afid>60030465</afid><afid>60007493</afid><afid>60007493</afid></author><intid>36086198</intid><article-number>7235</article-number><source-id>19700182758</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929992940"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929992940?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929992940&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929992940&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0091305715001483"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929992940</prism:url><dc:identifier>SCOPUS_ID:84929992940</dc:identifier><eid>2-s2.0-84929992940</eid><dc:title>Efficacy of Cilostazol a selective phosphodiesterase-3 inhibitor in rat model of Streptozotocin diabetes induced vascular dementia</dc:title><dc:creator>Kumar A.</dc:creator><prism:publicationName>Pharmacology Biochemistry and Behavior</prism:publicationName><prism:issn>00913057</prism:issn><prism:eIssn>18735177</prism:eIssn><prism:volume>135</prism:volume><prism:pageRange>20-30</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.pbb.2015.05.006</prism:doi><pii>S0091305715001483</pii><dc:description>© 2015 Elsevier Inc. All rights reserved. The present study has been designed to investigate the potential of Cilostazol a phosphodiesterase-3 (PDE-3) inhibitor in diabetes-induced vascular dementia (Vad) employing Wistar rats. A single dose of Streptozotocin (STZ) was used for the induction of diabetes and subsequent Vad in rats. Memory and learning abilities of rats were evaluated with Morris water maze (MWM) test. Serum glucose, body weight, vascular endothelial function, serum nitrite/nitrate levels, brain oxidative stress levels (viz. brain thiobarbituric acid reactive species and reduced glutathione levels), inflammatory markers (viz. brain myeloperoxidase activity and neutrophil infiltration in the brain hippocampal area) and brain acetylcholinesterase activity were also tested. Donepezil was used as positive control. Streptozotocin treated animals showed poor performance on MWM indicating impairment of learning and memory abilities with a significant reduction in body weight, vascular endothelial function, serum nitrite/nitrate levels, along with an increase in serum glucose, brain oxidative stress levels, inflammatory changes and brain acetylcholinesterase activity. Treatment with selective PDE-3 inhibitor, Cilostazol significantly attenuated, diabetes-induced impairment of learning and memory; endothelial dysfunction, and changes in various biochemical parameters. It is concluded that selective PDE-3 inhibitor, Cilostazol may be considered as the potential pharmacological agent for the management of diabetes-induced vascular dementia.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000690</affiliation-url><afid>60000690</afid><affilname>Punjabi University Patiala</affilname><name-variant>Punjabi University</name-variant><affiliation-city>Patiala</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35107452700</author-url><authid>35107452700</authid><authname>Kumar A.</authname><surname>Kumar</surname><given-name>Ashwani</given-name><initials>A.</initials><afid>60000690</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56270193200</author-url><authid>56270193200</authid><authname>Kumar A.</authname><surname>Kumar</surname><given-name>Amit</given-name><initials>A.</initials><afid>60000690</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16417160500</author-url><authid>16417160500</authid><authname>Jaggi A.</authname><surname>Jaggi</surname><given-name>Amteshwar S.</given-name><initials>A.S.</initials><afid>60000690</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35600106100</author-url><authid>35600106100</authid><authname>Singh N.</authname><surname>Singh</surname><given-name>Nirmal</given-name><initials>N.</initials><afid>60000690</afid></author><authkeywords>Diabetes | Morris water maze | Nitrite/nitrate | Oxidative stress | Streptozotocin | Vascular dementia</authkeywords><intid>1036044650</intid><source-id>21197</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930216507"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930216507?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930216507&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930216507&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930216507</prism:url><dc:identifier>SCOPUS_ID:84930216507</dc:identifier><eid>2-s2.0-84930216507</eid><dc:title>Efficient multiple genome modifications induced by the crRNAs, tracrRNA and Cas9 protein complex in zebrafish</dc:title><dc:creator>Kotani H.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0128319</prism:doi><dc:description>© 2015 Kotani et al. The type II clustered regularly interspaced short palindromic repeats (CRISPR) associated with Cas9 endonuclease (CRISPR/Cas9) has become a powerful genetic tool for understanding the function of a gene of interest. In zebrafish, the injection of Cas9 mRNA and guide-RNA (gRNA), which are prepared using an in vitro transcription system, efficiently induce DNA double-strand breaks (DSBs) at the targeted genomic locus. Because gRNA was originally constructed by fusing two short RNAs CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA), we examined the effect of synthetic crRNAs and tracrRNA with Cas9 mRNA or Cas9 protein on the genome editing activity. We previously reported that the disruption of tyrosinase (tyr) by tyr-gRNA/Cas9 mRNA causes a retinal pigment defect, whereas the disruption of spns2 by spns2-gRNA1/Cas9 mRNA leads to a cardiac progenitor migration defect in zebrafish. Here, we found that the injection of spns2-crRNA1, tyrcrRNA and tracrRNA with Cas9 mRNA or Cas9 protein simultaneously caused a migration defect in cardiac progenitors and a pigment defect in retinal epithelial cells. A time course analysis demonstrated that the injection of crRNAs and tracrRNA with Cas9 protein rapidly induced genome modifications compared with the injection of crRNAs and tracrRNA with Cas9 mRNA. We further show that the crRNA-tracrRNA-Cas9 protein complex is functional for the visualization of endogenous gene expression; therefore, this is a very powerful, ready-to-use system in zebrafish.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009064</affiliation-url><afid>60009064</afid><affilname>University of Yamanashi</affilname><name-variant>Yamanashi University</name-variant><affiliation-city>Kofu</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662809900</author-url><authid>56662809900</authid><authname>Kotani H.</authname><surname>Kotani</surname><given-name>Hirohito</given-name><initials>H.</initials><afid>60009064</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56641741000</author-url><authid>56641741000</authid><authname>Taimatsu K.</authname><surname>Taimatsu</surname><given-name>Kiyohito</given-name><initials>K.</initials><afid>60009064</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6508325853</author-url><authid>6508325853</authid><authname>Ohga R.</authname><surname>Ohga</surname><given-name>Rie</given-name><initials>R.</initials><afid>60009064</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55648956100</author-url><authid>55648956100</authid><authname>Ota S.</authname><surname>Ota</surname><given-name>Satoshi</given-name><initials>S.</initials><afid>60009064</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006670190</author-url><authid>7006670190</authid><authname>Kawahara A.</authname><surname>Kawahara</surname><given-name>Atsuo</given-name><initials>A.</initials><afid>60009064</afid></author><intid>536088239</intid><article-number>e0128319</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225089"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225089?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225089&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225089&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225089</prism:url><dc:identifier>SCOPUS_ID:84930225089</dc:identifier><eid>2-s2.0-84930225089</eid><dc:title>AMP-activated protein kinase regulates the cell surface proteome and integrin membrane traffic</dc:title><dc:creator>Ross E.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0128013</prism:doi><dc:description>© 2015 Ross et al. The cell surface proteome controls numerous cellular functions including cell migration and adhesion, intercellular communication and nutrient uptake. Cell surface proteins are controlled by acute changes in protein abundance at the plasma membrane through regulation of endocytosis and recycling (endomembrane traffic). Many cellular signals regulate endo-membrane traffic, including metabolic signaling; however, the extent to which the cell surface proteome is controlled by acute regulation of endomembrane traffic under various conditions remains incompletely understood. AMP-activated protein kinase (AMPK) is a key metabolic sensor that is activated upon reduced cellular energy availability. AMPK activation alters the endomembrane traffic of a few specific proteins, as part of an adaptive response to increase energy intake and reduce energy expenditure. How increased AMPK activity during energy stress may globally regulate the cell surface proteome is not well understood. To study how AMPK may regulate the cell surface proteome, we used cellimpermeable biotinylation to selectively purify cell surface proteins under various conditions. Using ESI-MS/MS, we found that acute (90 min) treatment with the AMPK activator A-769662 elicits broad control of the cell surface abundance of diverse proteins. In particular, A-769662 treatment depleted from the cell surface proteins with functions in cell migration and adhesion. To complement our mass spectrometry results, we used other methods to show that A-769662 treatment results in impaired cell migration. Further, A-769662 treatment reduced the cell surface abundance of β1-integrin, a key cell migration protein, and AMPK gene silencing prevented this effect. While the control of the cell surface abundance of various proteins by A-769662 treatment was broad, it was also selective, as this treatment did not change the cell surface abundance of the transferrin receptor. Hence, the cell surface proteome is subject to acute regulation by treatment with A-769662, at least some of which is mediated by the metabolic sensor AMPK.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030838</affiliation-url><afid>60030838</afid><affilname>Ryerson University</affilname><name-variant>Ryerson University</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55628530874</author-url><authid>55628530874</authid><authname>Ross E.</authname><surname>Ross</surname><given-name>Eden</given-name><initials>E.</initials><afid>60030838</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56663100400</author-url><authid>56663100400</authid><authname>Ata R.</authname><surname>Ata</surname><given-name>Rehman</given-name><initials>R.</initials><afid>60030838</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55180642900</author-url><authid>55180642900</authid><authname>Thavarajah T.</authname><surname>Thavarajah</surname><given-name>Thanusi</given-name><initials>T.</initials><afid>60030838</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7101846709</author-url><authid>7101846709</authid><authname>Medvedev S.</authname><surname>Medvedev</surname><given-name>Sergei</given-name><initials>S.</initials><afid>60030838</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:15845293900</author-url><authid>15845293900</authid><authname>Bowden P.</authname><surname>Bowden</surname><given-name>Peter</given-name><initials>P.</initials><afid>60030838</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55214257900</author-url><authid>55214257900</authid><authname>Marshall J.</authname><surname>Marshall</surname><given-name>John G.</given-name><initials>J.G.</initials><afid>60030838</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:8660899800</author-url><authid>8660899800</authid><authname>Antonescu C.</authname><surname>Antonescu</surname><given-name>Costin N.</given-name><initials>C.N.</initials><afid>60030838</afid></author><intid>1536087579</intid><article-number>e0128013</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927639049"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927639049?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927639049&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927639049&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0223523415002305"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927639049</prism:url><dc:identifier>SCOPUS_ID:84927639049</dc:identifier><eid>2-s2.0-84927639049</eid><dc:title>Bond-based bilinear indices for computational discovery of novel trypanosomicidal drug-like compounds through virtual screening</dc:title><dc:creator>Castillo-Garit J.</dc:creator><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationName><prism:issn>02235234</prism:issn><prism:eIssn>17683254</prism:eIssn><prism:volume>96</prism:volume><prism:pageRange>238-244</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejmech.2015.03.063</prism:doi><pii>S0223523415002305</pii><dc:description>© 2015 Elsevier Masson SAS. Two-dimensional bond-based bilinear indices and linear discriminant analysis are used in this report to perform a quantitative structureeactivity relationship study to identify new trypanosomicidal compounds. A data set of 440 organic chemicals, 143 with antitrypanosomal activity and 297 having other clinical uses, is used to develop the theoretical models. Two discriminant models, computed using bondbased bilinear indices, are developed and both show accuracies higher than 86% for training and test sets. The stochastic model correctly indentifies nine out of eleven compounds of a set of organic chemicals obtained from our synthetic collaborators. The in vitro antitrypanosomal activity of this set against epimastigote forms of Trypanosoma cruzi is assayed. Both models show a good agreement between theoretical predictions and experimental results. Three compounds showed IC&lt;inf&gt;50&lt;/inf&gt; values for epimastigote elimination (AE) lower than 50 μM, while for the benznidazole the IC&lt;inf&gt;50&lt;/inf&gt; = 54.7 μM which was used as reference compound. The value of IC&lt;inf&gt;50&lt;/inf&gt; for cytotoxicity of these compounds is at least 5 times greater than their value of IC&lt;inf&gt;50&lt;/inf&gt; for AE. Finally, we can say that, the present algorithm constitutes a step forward in the search for efficient ways of discovering new antitrypanosomal compounds.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60052951</affiliation-url><afid>60052951</afid><affilname>Universidad Central de Las Villas</affilname><name-variant>Universidad Central de Las Villas</name-variant><affiliation-city>Santa Clara</affiliation-city><affiliation-country>Cuba</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60052951</affiliation-url><afid>60052951</afid><affilname>Universidad Central de Las Villas</affilname><name-variant>Universidad Central de Las Villas</name-variant><affiliation-city>Santa Clara</affiliation-city><affiliation-country>Cuba</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002644</affiliation-url><afid>60002644</afid><affilname>Universitat de ValEncia</affilname><name-variant>Universitat de València</name-variant><affiliation-city>Valencia</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002644</affiliation-url><afid>60002644</afid><affilname>Universitat de ValEncia</affilname><name-variant>Universitat de València</name-variant><affiliation-city>Valencia</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60104943</affiliation-url><afid>60104943</afid><affilname>Centro Para El Desarrollo de la Investigaciin Cientifica CEDIC</affilname><name-variant>Centro Para El Desarrollo de la Investigación Científica (CEDIC)</name-variant><affiliation-city>Asuncion</affiliation-city><affiliation-country>Paraguay</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114733475</affiliation-url><afid>114733475</afid><affilname>Ministerio de Ciencias Tecnología y Medio Ambiente (CITMA</affilname><name-variant>Ministerio de Ciencias Tecnología y Medio Ambiente (CITMA</name-variant><affiliation-city/><affiliation-country>Cuba</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027282</affiliation-url><afid>60027282</afid><affilname>Universidad Complutense de Madrid</affilname><name-variant>Universidad Complutense</name-variant><affiliation-city>Madrid</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60055678</affiliation-url><afid>60055678</afid><affilname>Universidad de Cartagena</affilname><name-variant>University of Cartagena</name-variant><affiliation-city>Cartagena</affiliation-city><affiliation-country>Colombia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7801470655</author-url><authid>7801470655</authid><authname>Castillo-Garit J.</authname><surname>Castillo-Garit</surname><given-name>Juan Alberto</given-name><initials>J.A.</initials><afid>60052951</afid><afid>60052951</afid><afid>60002644</afid><afid>60002644</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7801470655</author-url><authid>7801470655</authid><authname>Castillo-Garit J.</authname><surname>Castillo-Garit</surname><given-name>Juan Alberto</given-name><initials>J.A.</initials><afid>60052951</afid><afid>60052951</afid><afid>60002644</afid><afid>60002644</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7801470655</author-url><authid>7801470655</authid><authname>Castillo-Garit J.</authname><surname>Castillo-Garit</surname><given-name>Juan Alberto</given-name><initials>J.A.</initials><afid>60052951</afid><afid>60052951</afid><afid>60002644</afid><afid>60002644</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7801470655</author-url><authid>7801470655</authid><authname>Castillo-Garit J.</authname><surname>Castillo-Garit</surname><given-name>Juan Alberto</given-name><initials>J.A.</initials><afid>60052951</afid><afid>60052951</afid><afid>60002644</afid><afid>60002644</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55197260900</author-url><authid>55197260900</authid><authname>Del Toro-Cortés O.</authname><surname>Del Toro-Cortés</surname><given-name>Oremia</given-name><initials>O.</initials><afid>60052951</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8918456600</author-url><authid>8918456600</authid><authname>Vega M.</authname><surname>Vega</surname><given-name>Maria C.</given-name><initials>M.C.</initials><afid>60104943</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7801554945</author-url><authid>7801554945</authid><authname>Rolón M.</authname><surname>Rolón</surname><given-name>Miriam</given-name><initials>M.</initials><afid>60104943</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6603032586</author-url><authid>6603032586</authid><authname>Rojas De Arias A.</authname><surname>Rojas De Arias</surname><given-name>Antonieta</given-name><initials>A.</initials><afid>60104943</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:9434652400</author-url><authid>9434652400</authid><authname>Casañola-Martin G.</authname><surname>Casañola-Martin</surname><given-name>Gerardo M.</given-name><initials>G.M.</initials><afid>60052951</afid><afid>60002644</afid><afid>114733475</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:9434652400</author-url><authid>9434652400</authid><authname>Casañola-Martin G.</authname><surname>Casañola-Martin</surname><given-name>Gerardo M.</given-name><initials>G.M.</initials><afid>60052951</afid><afid>60002644</afid><afid>114733475</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:9434652400</author-url><authid>9434652400</authid><authname>Casañola-Martin G.</authname><surname>Casañola-Martin</surname><given-name>Gerardo M.</given-name><initials>G.M.</initials><afid>60052951</afid><afid>60002644</afid><afid>114733475</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6701385242</author-url><authid>6701385242</authid><authname>Escario J.</authname><surname>Escario</surname><given-name>José A.</given-name><initials>J.A.</initials><afid>60027282</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7003908874</author-url><authid>7003908874</authid><authname>Gómez-Barrio A.</authname><surname>Gómez-Barrio</surname><given-name>Alicia</given-name><initials>A.</initials><afid>60027282</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55665599200</author-url><authid>55665599200</authid><authname>Marrero-Ponce Y.</authname><surname>Marrero-Ponce</surname><given-name>Yovani</given-name><initials>Y.</initials><afid>60055678</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7004872108</author-url><authid>7004872108</authid><authname>Torrens F.</authname><surname>Torrens</surname><given-name>Francisco</given-name><initials>F.</initials><afid>60002644</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7103043662</author-url><authid>7103043662</authid><authname>Abad C.</authname><surname>Abad</surname><given-name>Concepción</given-name><initials>C.</initials><afid>60002644</afid></author><authkeywords>Bond-based bilinear indices | In vitro cytotoxicity | LDA-assisted QSAR model | Trypanosomicidal | Virtual screening</authkeywords><intid>1035641371</intid><source-id>17464</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930203397"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930203397?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930203397&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930203397&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930203397</prism:url><dc:identifier>SCOPUS_ID:84930203397</dc:identifier><eid>2-s2.0-84930203397</eid><dc:title>Chronic intermittent hypoxia is independently associated with reduced postoperative opioid consumption in bariatric patients suffering from sleep-disordered breathing</dc:title><dc:creator>Turan A.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0127809</prism:doi><dc:description>© 2015 Turan et al. Background: Evidence suggests that recurrent nocturnal hypoxemia may affect pain response and/or the sensitivity to opioid analgesia. We tested the hypothesis that nocturnal hypoxemia, quantified by sleep time spent at an arterial saturation (SaO&lt;inf&gt;2&lt;/inf&gt;) &lt; 90% and minimum nocturnal SaO&lt;inf&gt;2&lt;/inf&gt; on polysomnography, are associated with decreased pain and reduced opioid consumption during the initial 72 postoperative hours in patients having laparoscopic bariatric surgery. Methods: With Institutional Review Board approval, we examined the records of all patients who underwent laparoscopic bariatric surgery between 2004 and 2010 and had an available nocturnal polysomnography study. We assessed the relationships between the time-weighted average of pain score and total opioid consumption during the initial 72 postoperative hours, and: (a) the percentage of total sleep time spent at SaO&lt;inf&gt;2&lt;/inf&gt; &lt; 90%, (b) the minimum nocturnal SaO&lt;inf&gt;2&lt;/inf&gt;, and (c) the number of apnea/hypopnea episodes per hour of sleep. We used multivariable regression models to adjust for both clinical and sleep-related confounders. Results: Two hundred eighteen patients were included in the analysis. Percentage of total sleep time spent at SaO&lt;inf&gt;2&lt;/inf&gt; &lt; 90% was inversely associated with total postoperative opioid consumption; a 5-%- absolute increase in the former would relatively decrease median opioid consumption by 16% (98.75% CI: 2% to 28%, P = 0.006). However, the percentage of total sleep time spent at SaO&lt;inf&gt;2&lt;/inf&gt; &lt; 90% was not associated with pain. The minimum nocturnal SaO&lt;inf&gt;2&lt;/inf&gt; was associated neither with total postoperative opioid consumption nor with pain. In addition, neither pain nor total opioid consumption was significantly associated with the number of apnea/hypopnea episodes per hour of sleep. Conclusions: Preoperative nocturnal intermittent hypoxia may enhance sensitivity to opioids.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021160</affiliation-url><afid>60021160</afid><affilname>Cleveland Clinic Foundation</affilname><name-variant>Cleveland Clinic Foundation</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021160</affiliation-url><afid>60021160</afid><affilname>Cleveland Clinic Foundation</affilname><name-variant>Cleveland Clinic Foundation</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021160</affiliation-url><afid>60021160</afid><affilname>Cleveland Clinic Foundation</affilname><name-variant>Cleveland Clinic Foundation</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032838</affiliation-url><afid>60032838</afid><affilname>Stanford University School of Medicine</affilname><name-variant>Stanford University School of Medicine</name-variant><affiliation-city>Stanford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:109881907</affiliation-url><afid>109881907</afid><affilname>Outcomes Research Consortium</affilname><name-variant>Outcome Research Consortium</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019674</affiliation-url><afid>60019674</afid><affilname>Boston University</affilname><name-variant>Boston University</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016733</affiliation-url><afid>60016733</afid><affilname>Oregon Health and Science University</affilname><name-variant>Oregon Health and Science University</name-variant><affiliation-city>Portland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000305</affiliation-url><afid>60000305</afid><affilname>Case Western Reserve University</affilname><name-variant>Case Western Reserve University</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:109557623</affiliation-url><afid>109557623</afid><affilname>St. Vincent Charity Medical Center</affilname><name-variant>St. Vincent Charity Medical Center</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">18</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7004533485</author-url><authid>7004533485</authid><authname>Turan A.</authname><surname>Turan</surname><given-name>Alparslan</given-name><initials>A.</initials><afid>60021160</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662679400</author-url><authid>56662679400</authid><authname>You J.</authname><surname>You</surname><given-name>Jing</given-name><initials>J.</initials><afid>60021160</afid><afid>60021160</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662679400</author-url><authid>56662679400</authid><authname>You J.</authname><surname>You</surname><given-name>Jing</given-name><initials>J.</initials><afid>60021160</afid><afid>60021160</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:49961353800</author-url><authid>49961353800</authid><authname>Egan C.</authname><surname>Egan</surname><given-name>Cameron</given-name><initials>C.</initials><afid>60021160</afid><afid>60019674</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:49961353800</author-url><authid>49961353800</authid><authname>Egan C.</authname><surname>Egan</surname><given-name>Cameron</given-name><initials>C.</initials><afid>60021160</afid><afid>60019674</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56435553900</author-url><authid>56435553900</authid><authname>Fu A.</authname><surname>Fu</surname><given-name>Alex</given-name><initials>A.</initials><afid>60021160</afid><afid>60016733</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56435553900</author-url><authid>56435553900</authid><authname>Fu A.</authname><surname>Fu</surname><given-name>Alex</given-name><initials>A.</initials><afid>60021160</afid><afid>60016733</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:34968180100</author-url><authid>34968180100</authid><authname>Khanna A.</authname><surname>Khanna</surname><given-name>Ashish</given-name><initials>A.</initials><afid>60021160</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:23984441800</author-url><authid>23984441800</authid><authname>Eshraghi Y.</authname><surname>Eshraghi</surname><given-name>Yashar</given-name><initials>Y.</initials><afid>60021160</afid><afid>60000305</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:23984441800</author-url><authid>23984441800</authid><authname>Eshraghi Y.</authname><surname>Eshraghi</surname><given-name>Yashar</given-name><initials>Y.</initials><afid>60021160</afid><afid>60000305</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35317357700</author-url><authid>35317357700</authid><authname>Ghosh R.</authname><surname>Ghosh</surname><given-name>Raktim</given-name><initials>R.</initials><afid>60021160</afid><afid>109557623</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35317357700</author-url><authid>35317357700</authid><authname>Ghosh R.</authname><surname>Ghosh</surname><given-name>Raktim</given-name><initials>R.</initials><afid>60021160</afid><afid>109557623</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7401626522</author-url><authid>7401626522</authid><authname>Bose S.</authname><surname>Bose</surname><given-name>Somnath</given-name><initials>S.</initials><afid>60021160</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56436865700</author-url><authid>56436865700</authid><authname>Qavi S.</authname><surname>Qavi</surname><given-name>Shahbaz</given-name><initials>S.</initials><afid>60021160</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56436436400</author-url><authid>56436436400</authid><authname>Arora L.</authname><surname>Arora</surname><given-name>Lovkesh</given-name><initials>L.</initials><afid>60021160</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:35405204300</author-url><authid>35405204300</authid><authname>Sessler D.</authname><surname>Sessler</surname><given-name>Daniel I.</given-name><initials>D.I.</initials><afid>60021160</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7004052863</author-url><authid>7004052863</authid><authname>Doufas A.</authname><surname>Doufas</surname><given-name>Anthony G.</given-name><initials>A.G.</initials><afid>60032838</afid><afid>109881907</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7004052863</author-url><authid>7004052863</authid><authname>Doufas A.</authname><surname>Doufas</surname><given-name>Anthony G.</given-name><initials>A.G.</initials><afid>60032838</afid><afid>109881907</afid></author><intid>2036082381</intid><article-number>e0127809</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926511996"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926511996?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926511996&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926511996&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115001671"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926511996</prism:url><dc:identifier>SCOPUS_ID:84926511996</dc:identifier><eid>2-s2.0-84926511996</eid><dc:title>Hypaconitine-induced QT prolongation mediated through inhibition of KCNH2 (hERG) potassium channels in conscious dogs</dc:title><dc:creator>Xie S.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>166</prism:volume><prism:pageRange>375-379</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.03.023</prism:doi><pii>S0378874115001671</pii><dc:description>© 2015 Elsevier Ireland Ltd. All rights reserved. Ethnopharmacological relevance Hypaconitine is one of the main aconitum alkaloids in traditional Chinese medicines prepared with herbs from the genus Acotinum. These herbs are widely used for the treatment of cardiac insufficiency and arrhythmias. However, Acotinum alkaloids are known for their toxicity as well as their pharmacological activity, especially cardiotoxicity including QT prolongation, and the mechanism of this toxicity is not clear. Material and methods In this study, hypaconitine was administered orally to conscious Beagle dogs, and electrocardiograms were recorded by telemetry. Pharmacokinetic studies (6 h) were conducted to evaluate the relationship between QT prolongation and exposure level. HEK293 cells stably transfected with KCNH2 (hERG) cDNA were used to examine the effects of hypaconitine on the KCNH2 channel by using the manual patch clamp technique. Results In the conscious dogs, all doses of hypaconitine induced QTcV (QT interval corrected according to the Van de Water formula) prolongation by more than 23% (67 ms) of control in a dose-dependent manner. The maximum QTcV prolongation was observed at 2 h after dosing. Maximum prolongation percentages were plotted against plasma concentrations of hypaconitine and showed a strong correlation (R&lt;sup&gt;2&lt;/sup&gt;=0.789). In the in vitro study in HEK293 cells, hypaconitine inhibited the KCNH2 currents in a concentration-dependent manner with an IC&lt;inf&gt;50&lt;/inf&gt; of 8.1 nM. Conclusion These data suggest that hypaconitine inhibits KCNH2 potassium channels and this effect might be the molecular mechanism underlying QT prolongation in conscious dogs.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024542</affiliation-url><afid>60024542</afid><affilname>South China University of Technology</affilname><name-variant>South China University of Technology</name-variant><affiliation-city>Guangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031419</affiliation-url><afid>60031419</afid><affilname>Ningbo University</affilname><name-variant>Ningbo University</name-variant><affiliation-city>Ningbo</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25960506000</author-url><authid>25960506000</authid><authname>Xie S.</authname><surname>Xie</surname><given-name>Shuilin</given-name><initials>S.</initials><afid>60024542</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56583195600</author-url><authid>56583195600</authid><authname>Jia Y.</authname><surname>Jia</surname><given-name>Ying</given-name><initials>Y.</initials><afid>60024542</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56583182400</author-url><authid>56583182400</authid><authname>Liu A.</authname><surname>Liu</surname><given-name>Aiming</given-name><initials>A.</initials><afid>60031419</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7103309757</author-url><authid>7103309757</authid><authname>Dai R.</authname><surname>Dai</surname><given-name>Renke</given-name><initials>R.</initials><afid>60024542</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56477641100</author-url><authid>56477641100</authid><authname>Huang L.</authname><surname>Huang</surname><given-name>Lizhen</given-name><initials>L.</initials><afid>60024542</afid></author><authkeywords>ECG telemetry | hERG channels | Hypaconitine | QT prolongation | Safety assessment</authkeywords><intid>2035449795</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226401"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226401?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226401&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226401&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226401</prism:url><dc:identifier>SCOPUS_ID:84930226401</dc:identifier><eid>2-s2.0-84930226401</eid><dc:title>Multibow: Digital spectral barcodes for cell tracing</dc:title><dc:creator>Xiong F.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0127822</prism:doi><dc:description>© 2015 Xiong et al. We introduce a multicolor labeling strategy (Multibow) for cell tracing experiments in developmental and regenerative processes. Building on Brainbow-based approaches that produce colors by differential expression levels of different fluorescent proteins, Multibow adds a layer of label diversity by introducing a binary code in which reporters are initially OFF and then probabilistically ON or OFF following Cre recombination. We have developed a library of constructs that contains seven different colors and three different subcellular localizations. Combining constructs from this library in the presence of Cre generates cells labeled with multiple independently expressed colors based on if each construct is ON or OFF following recombination. These labels form a unique "barcode" that allows the tracking of the cell and its clonal progenies in addition to expression level differences of each color. We tested Multibow in zebrafish which validates its design concept and suggests its utility for cell tracing applications in development and regeneration.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002746</affiliation-url><afid>60002746</afid><affilname>Harvard Medical School</affilname><name-variant>Harvard Medical School</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55088033100</author-url><authid>55088033100</authid><authname>Xiong F.</authname><surname>Xiong</surname><given-name>Fengzhu</given-name><initials>F.</initials><afid>60002746</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35797361500</author-url><authid>35797361500</authid><authname>Obholzer N.</authname><surname>Obholzer</surname><given-name>Nikolaus D.</given-name><initials>N.D.</initials><afid>60002746</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6506906400</author-url><authid>6506906400</authid><authname>Noche R.</authname><surname>Noche</surname><given-name>Ramil R.</given-name><initials>R.R.</initials><afid>60002746</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6506248083</author-url><authid>6506248083</authid><authname>Megason S.</authname><surname>Megason</surname><given-name>Sean G.</given-name><initials>S.G.</initials><afid>60002746</afid></author><intid>36085473</intid><article-number>e0127822</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930203898"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930203898?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930203898&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930203898&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1043661815000869"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930203898</prism:url><dc:identifier>SCOPUS_ID:84930203898</dc:identifier><eid>2-s2.0-84930203898</eid><dc:title>Kaempferol and inflammation: From chemistry to medicine</dc:title><dc:creator>Devi K.</dc:creator><prism:publicationName>Pharmacological Research</prism:publicationName><prism:issn>10436618</prism:issn><prism:eIssn>10961186</prism:eIssn><prism:volume>99</prism:volume><prism:pageRange>1-10</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.phrs.2015.05.002</prism:doi><pii>S1043661815000869</pii><dc:description>© 2015 Elsevier Ltd. All rights reserved. Inflammation is an important process of human healing response, wherein the tissues respond to injuries induced by many agents including pathogens. It is characterized by pain, redness and heat in the injured tissues. Chronic inflammation seems to be associated with different types of diseases such as arthritis, allergies, atherosclerosis, and even cancer. In recent years natural product based drugs are considered as the novel therapeutic strategy for prevention and treatment of inflammatory diseases. Among the different types of phyto-constituents present in natural products, flavonoids which occur in many vegetable foods and herbal medicines are considered as the most active constituent, which has the potency to ameliorate inflammation under both in vitro and in vivo conditions. Kaempferol is a natural flavonol present in different plant species, which has been described to possess potent anti-inflammatory properties. Despite the voluminous literature on the anti-inflammatory effects of kaempferol, only very limited review articles has been published on this topic. Hence the present review is aimed to provide a critical overview on the anti-inflammatory effects and the mechanisms of action of kaempferol, based on the current scientific literature. In addition, emphasis is also given on the chemistry, natural sources, bioavailability and toxicity of kaempferol.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016712</affiliation-url><afid>60016712</afid><affilname>Alagappa University</affilname><name-variant>Alagappa University</name-variant><affiliation-city>Karaikudi</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010017</affiliation-url><afid>60010017</afid><affilname>Baqiyatallah Medical Sciences University</affilname><name-variant>Baqiyatallah University of Medical Sciences</name-variant><affiliation-city>Tehran</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009780</affiliation-url><afid>60009780</afid><affilname>Universitat de les Illes Balears</affilname><name-variant>Universitat de les Illes Balears</name-variant><affiliation-city>Palma</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072902</affiliation-url><afid>60072902</afid><affilname>Macau University of Science and Technology</affilname><name-variant>Macao University of Science and Technology</name-variant><affiliation-city>Taipa</affiliation-city><affiliation-country>Macao</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012689</affiliation-url><afid>60012689</afid><affilname>Julius-Maximilians-Universitat Wurzburg</affilname><name-variant>University of Würzburg</name-variant><affiliation-city>Wurzburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015197</affiliation-url><afid>60015197</afid><affilname>Universita degli Studi di Pavia</affilname><name-variant>Università di Pavia</name-variant><affiliation-city>Pavia</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8579055100</author-url><authid>8579055100</authid><authname>Devi K.</authname><surname>Devi</surname><given-name>Kasi Pandima</given-name><initials>K.P.</initials><afid>60016712</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56367539200</author-url><authid>56367539200</authid><authname>Malar D.</authname><surname>Malar</surname><given-name>Dicson Sheeja</given-name><initials>D.S.</initials><afid>60016712</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14008765800</author-url><authid>14008765800</authid><authname>Nabavi S.</authname><surname>Nabavi</surname><given-name>Seyed Fazel</given-name><initials>S.F.</initials><afid>60010017</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006806333</author-url><authid>7006806333</authid><authname>Sureda A.</authname><surname>Sureda</surname><given-name>Antoni</given-name><initials>A.</initials><afid>60009780</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56662621200</author-url><authid>56662621200</authid><authname>Xiao J.</authname><surname>Xiao</surname><given-name>Jianbo</given-name><initials>J.</initials><afid>60072902</afid><afid>60012689</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56662621200</author-url><authid>56662621200</authid><authname>Xiao J.</authname><surname>Xiao</surname><given-name>Jianbo</given-name><initials>J.</initials><afid>60072902</afid><afid>60012689</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55621554100</author-url><authid>55621554100</authid><authname>Nabavi S.</authname><surname>Nabavi</surname><given-name>Seyed Mohammad</given-name><initials>S.M.</initials><afid>60010017</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602560687</author-url><authid>6602560687</authid><authname>Daglia M.</authname><surname>Daglia</surname><given-name>Maria</given-name><initials>M.</initials><afid>60015197</afid></author><authkeywords>Anti-inflammatory activity | Flavonoids | Kaempferol | Pro-inflammatory cytokines</authkeywords><intid>2036082356</intid><source-id>21169</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226859"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226859?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226859&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226859&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226859</prism:url><dc:identifier>SCOPUS_ID:84930226859</dc:identifier><eid>2-s2.0-84930226859</eid><dc:title>Flavonoid intake in European adults (18 to 64 Years)</dc:title><dc:creator>Vogiatzoglou A.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0128132</prism:doi><dc:description>© 2015 Vogiatzoglou et al. Background: Flavonoids are a group of phenolic secondary plant metabolites that are ubiquitous in plant-based diets. Data from anthropological, observational and intervention studies have shown that many flavonoids are bioactive. For this reason, there is an increasing interest in investigating the potential health effects of these compounds. The translation of these findings into the context of the health of the general public requires detailed information on habitual dietary intake. However, only limited data are currently available for European populations. Objective: The objective of this study is to determine the habitual intake and main sources of anthocyanidins, flavanols, flavanones, flavones, flavonols, proanthocyanidins, theaflavins and thearubigins in the European Union. Design: We use food consumption data from the European Food Safety Authority (EFSA) and the FLAVIOLA Food Composition Database to estimate intake of flavonoids. Results: Mean (±SEM) intake of total flavonoids in Europe was 428±49 mg/d, of which 136±14 mg/d were monomeric compounds. Gallated flavan-3-ols (53±12 mg/d) were the main contributor. The lowest flavonoid intake was observed in Mediterranean countries (monomeric compounds: 95±11 mg/d). The distribution of intake was skewed in many countries, especially in Germany (monomeric flavonoids; mean intake: 181 mg/d; median intake: 3 mg/d). Conclusions: The habitual intake of flavonoids in Europe is below the amounts found to have a significant health effect.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012197</affiliation-url><afid>60012197</afid><affilname>University of Reading</affilname><name-variant>University of Reading</name-variant><affiliation-city>Reading</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031101</affiliation-url><afid>60031101</afid><affilname>University of Cambridge</affilname><name-variant>University of Cambridge</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002182</affiliation-url><afid>60002182</afid><affilname>Mars Incorporated</affilname><name-variant>Mars Incorporated</name-variant><affiliation-city>Hackettstown</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031101</affiliation-url><afid>60031101</afid><affilname>University of Cambridge</affilname><name-variant>University of Cambridge</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25121715200</author-url><authid>25121715200</authid><authname>Vogiatzoglou A.</authname><surname>Vogiatzoglou</surname><given-name>Anna</given-name><initials>A.</initials><afid>60012197</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004246941</author-url><authid>7004246941</authid><authname>Mulligan A.</authname><surname>Mulligan</surname><given-name>Angela A.</given-name><initials>A.A.</initials><afid>60031101</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35261917400</author-url><authid>35261917400</authid><authname>Lentjes M.</authname><surname>Lentjes</surname><given-name>Marleen A H</given-name><initials>M.A.H.</initials><afid>60031101</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004585179</author-url><authid>7004585179</authid><authname>Luben R.</authname><surname>Luben</surname><given-name>Robert N.</given-name><initials>R.N.</initials><afid>60031101</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35449673700</author-url><authid>35449673700</authid><authname>Spencer J.</authname><surname>Spencer</surname><given-name>Jeremy P E</given-name><initials>J.P.E.</initials><afid>60012197</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004322659</author-url><authid>7004322659</authid><authname>Schroeter H.</authname><surname>Schroeter</surname><given-name>Hagen</given-name><initials>H.</initials><afid>60002182</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35354760500</author-url><authid>35354760500</authid><authname>Khaw K.</authname><surname>Khaw</surname><given-name>Kay Tee</given-name><initials>K.T.</initials><afid>60031101</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7003769113</author-url><authid>7003769113</authid><authname>Kuhnle G.</authname><surname>Kuhnle</surname><given-name>Gunter G C</given-name><initials>G.G.C.</initials><afid>60012197</afid><afid>60031101</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7003769113</author-url><authid>7003769113</authid><authname>Kuhnle G.</authname><surname>Kuhnle</surname><given-name>Gunter G C</given-name><initials>G.G.C.</initials><afid>60012197</afid><afid>60031101</afid></author><intid>1536087181</intid><article-number>e0128132</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930195699"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930195699?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930195699&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930195699&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930195699</prism:url><dc:identifier>SCOPUS_ID:84930195699</dc:identifier><eid>2-s2.0-84930195699</eid><dc:title>Depression affects the scores of all facets of the WHOQOL-BREF and may mediate the effects of physical disability among community-dwelling older adults</dc:title><dc:creator>Chang Y.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0128356</prism:doi><dc:description>© 2015 Chang et al. Background: Geriatric depression is associated with the overall quality of life (QOL). However, how depressive symptoms affect the different domains and facets of QOL in older adults, and whether depressive symptoms mediate the relationship between physical disability and QOL in older adults are unclear. Methods: A total of 490 ambulatory community-dwelling older adults aged 65 years or above were interviewed using the brief version of the World Health Organisation Quality of Life instrument (WHOQOL-BREF), the Modified Barthel Index (MBI), the 15-item Geriatric Depression Scale (GDS-15), and the Mini-Mental State Examination (MMSE). Sequential models for multiple linear regressions were analysed to determine if the MBI, GDS-15 and MMSE scores predict the WHOQOL-BREF scores. The potential mediation effects of depression (as determined by the GDS-15) on the relationship between MBI and WHOQOL-BREF were also analysed. Results: The GDS-15 score was predictive of the scores of the four domains and all 26 facets of the WHOQOL-BREF. The significant predictive effects of the MBI score on 15 of the 26 facets of the WHOQOL-BREF were reduced to three after the adjustment for the GDS-15 score. Depression (as assessed by the GDS-15) is a mediator of the relationship between MBI and the physical, psychological and environmental domains of the WHOQOL-BREF. Conclusions: Depression (assessed by the GDS-15) may affect the scores of every domain and all facets of the WHOQOL-BREF in the elderly. Furthermore, it may mediate the relationship between the MBI and on QOL scores. We recommend taking depressive symptoms into consideration when measuring community-dwelling older adults' QOL and providing active ageing programs.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072370</affiliation-url><afid>60072370</afid><affilname>Chiayi Christian Hospital</affilname><name-variant>Chiayi Christian Hospital</name-variant><affiliation-city>Chiayi</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072370</affiliation-url><afid>60072370</afid><affilname>Chiayi Christian Hospital</affilname><name-variant>Chiayi Christian Hospital</name-variant><affiliation-city>Chiayi</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005429</affiliation-url><afid>60005429</afid><affilname>National Taiwan University</affilname><name-variant>National Taiwan University</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014982</affiliation-url><afid>60014982</afid><affilname>National Cheng Kung University</affilname><name-variant>National Cheng Kung University</name-variant><affiliation-city>Tainan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014982</affiliation-url><afid>60014982</afid><affilname>National Cheng Kung University</affilname><name-variant>National Cheng Kung University</name-variant><affiliation-city>Tainan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662573400</author-url><authid>56662573400</authid><authname>Chang Y.</authname><surname>Chang</surname><given-name>Yu Chen</given-name><initials>Y.C.</initials><afid>60072370</afid><afid>60072370</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662573400</author-url><authid>56662573400</authid><authname>Chang Y.</authname><surname>Chang</surname><given-name>Yu Chen</given-name><initials>Y.C.</initials><afid>60072370</afid><afid>60072370</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7201887940</author-url><authid>7201887940</authid><authname>Yao G.</authname><surname>Yao</surname><given-name>Grace</given-name><initials>G.</initials><afid>60005429</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56662596400</author-url><authid>56662596400</authid><authname>Hu S.</authname><surname>Hu</surname><given-name>Susan C.</given-name><initials>S.C.</initials><afid>60014982</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8051265800</author-url><authid>8051265800</authid><authname>Wang J.</authname><surname>Wang</surname><given-name>Jung Der</given-name><initials>J.D.</initials><afid>60014982</afid><afid>60014982</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8051265800</author-url><authid>8051265800</authid><authname>Wang J.</authname><surname>Wang</surname><given-name>Jung Der</given-name><initials>J.D.</initials><afid>60014982</afid><afid>60014982</afid></author><intid>1036081849</intid><article-number>e0128356</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929879990"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929879990?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929879990&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929879990&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929879990</prism:url><dc:identifier>SCOPUS_ID:84929879990</dc:identifier><eid>2-s2.0-84929879990</eid><dc:title>Cost–Utility of First-Line Actinic Keratosis Treatments in Finland</dc:title><dc:creator>Soini E.</dc:creator><prism:publicationName>Advances in Therapy</prism:publicationName><prism:issn>0741238X</prism:issn><prism:eIssn>18658652</prism:eIssn><prism:volume>32</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>455-476</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12325-015-0211-7</prism:doi><dc:description>© 2015, The Author(s). Introduction: Cost–utility assessment of first-line actinic keratosis (AK) treatments for max 25 cm&lt;sup&gt;2&lt;/sup&gt; AK field. Methods: A probabilistic, 2-year decision tree model was used to assess costs, quality-adjusted life-years (QALY), incremental cost-effectiveness ratio (ICER), cost-effectiveness efficiency frontier, cost-effectiveness acceptability frontier (CEAF), and expected value of perfect information (EVPI) of AK treatments from the Finnish health care payer perspective with 3% discounting per annum. In the model, the first-line AK treatment resulted in complete clearance (CC) or non-CC with or without local skin responses (LSR), or AK recurrence. Non-CC AK was treated with methyl aminolevulinate + photodynamic therapy (MAL + PDT), and AK recurrence was retreated with the previous effective treatment. Costs included primary and secondary health care, outpatient drugs, and LSR management. QALYs were assessed with the EuroQol (EQ-5D-3L). Result robustness was assessed with sensitivity analyses. Results: The mean simulated per patient QALYs (costs) were 1.526 (€982) for MAL + PDT, 1.524 (€794) for ingenol mebutate gel (IngMeb) 0.015% (3 days), 1.522 (€869) for IngMeb 0.05% (2 days), 1.520 (€1062) for diclofenac 3% (12 weeks), 1.518 (€885) for imiquimod 3.75% (6 weeks), 1.517 (€781) for imiquimod 5% (4/8 weeks), and 1.514 (€1114) for cryosurgery when treating AK affecting any body part. IngMeb 0.015% was less costly and more effective (dominating) than other AK treatments indicated for face and scalp area with the exception of imiquimod 5% for which the ICER was estimated at €1933/QALY gained and MAL + PDT, which had an ICER of €82,607/QALY gained against IngMeb 0.015%. With willingness-to-pay €2526–18,809/QALY gained, IngMeb 0.015% had &gt;50% probability for cost-effectiveness on the CEAF. IngMeb 0.05% dominated AK treatments indicated for trunk and extremities. EVPIs for face and scalp (trunk and extremities) analyses were €26 (€0), €86 (€58), and €250 (€169) per patient with the willingness-to-pay of €0, €15,000, and €30,000 per QALY gained, respectively. Conclusion: IngMebs were cost-effective AK treatments in Finland. Funding: LEO Pharma.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60098050</affiliation-url><afid>60098050</afid><affilname>Esior Oy</affilname><name-variant>ESiOR Ltd</name-variant><affiliation-city>Kuopio</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101577410</affiliation-url><afid>101577410</afid><affilname>LEO Pharma Oy</affilname><name-variant>Leo Pharma Oy</name-variant><affiliation-city>Vantaa</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023781</affiliation-url><afid>60023781</afid><affilname>Paijat-Hame Central Hospital</affilname><name-variant>Päijät-Häme Central Hospital</name-variant><affiliation-city>Lahti</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36936831500</author-url><authid>36936831500</authid><authname>Soini E.</authname><surname>Soini</surname><given-name>Erkki J.</given-name><initials>E.J.</initials><afid>60098050</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8849909100</author-url><authid>8849909100</authid><authname>Hallinen T.</authname><surname>Hallinen</surname><given-name>Taru</given-name><initials>T.</initials><afid>60098050</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:9248826600</author-url><authid>9248826600</authid><authname>Sokka A.</authname><surname>Sokka</surname><given-name>Anna Leena</given-name><initials>A.L.</initials><afid>101577410</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56656153000</author-url><authid>56656153000</authid><authname>Saarinen K.</authname><surname>Saarinen</surname><given-name>Kari</given-name><initials>K.</initials><afid>60023781</afid></author><authkeywords>Actinic keratosis | Cost-effectiveness | Cryosurgery | Diclofenac | Economic evaluation | Imiquimod | Ingenol mebutate | Modeling | Photodynamic therapy | Solar keratosis</authkeywords><intid>1036032234</intid><source-id>26915</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930216496"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930216496?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930216496&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930216496&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930216496</prism:url><dc:identifier>SCOPUS_ID:84930216496</dc:identifier><eid>2-s2.0-84930216496</eid><dc:title>Inhibition of the metabolic degradation of filtered albumin is a major determinant of albuminuria</dc:title><dc:creator>Vuchkova J.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0127853</prism:doi><dc:description>© 2015 Vuchkova, Comper. Inhibition of the degradation of filtered albumin has been proposed as a widespread, benign form of albuminuria. There have however been recent reports that radiolabeled albumin fragments in urine are not exclusively generated by the kidney and that in albuminuric states albumin fragment excretion is not inhibited. In order to resolve this controversy we have examined the fate of various radiolabeled low molecular weight protein degradation products (LMWDPs) introduced into the circulation in rats. The influence of puromycin aminonucleoside nephrosis on the processing and excretion of LMWDPs is also examined. The status and destinies of radiolabeled LMWDPs in the circulation are complex. A major finding is that LMWDPs are rapidly eliminated from the circulation (&gt;97% in 2 h) but only small quantities (&lt;4%) are excreted in urine. Small (&lt;4%) but significant amounts of LMWDPs may have prolonged elimination (&gt;24 h) due to binding to high molecular weight components in the circulation. If LMWDPs of albumin seen in the urine are produced by extra renal degradation it would require the degradation to far exceed the known catabolic rate of albumin. Alternatively, if an estimate of the role of extra renal degradation is made from the limit of detection of LMWDPs in plasma, then extra renal degradation would only contribute &lt;1% of the total excretion of LMWDPs of albumin. We confirm that the degradation process for albumin is specifically associated with filtered albumin and this is inhibited in albuminuric states. This inhibition is also the primary determinant of the massive change in intact albuminuria in nephrotic states.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019578</affiliation-url><afid>60019578</afid><affilname>Monash University</affilname><name-variant>Monash University</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113968699</affiliation-url><afid>113968699</afid><affilname>SalAqua Diagnostics Inc.</affilname><name-variant>Sal Aqua</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35747533300</author-url><authid>35747533300</authid><authname>Vuchkova J.</authname><surname>Vuchkova</surname><given-name>Julijana</given-name><initials>J.</initials><afid>60019578</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006709456</author-url><authid>7006709456</authid><authname>Comper W.</authname><surname>Comper</surname><given-name>Wayne D.</given-name><initials>W.D.</initials><afid>113968699</afid></author><intid>2036081485</intid><article-number>e0127853</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930203771"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930203771?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930203771&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930203771&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930203771</prism:url><dc:identifier>SCOPUS_ID:84930203771</dc:identifier><eid>2-s2.0-84930203771</eid><dc:title>Adoption of telemedicine services in post-hospital stroke care: A qualitative analysis of factors influencing the adoption from a patient's perspective | Adoption telemedizinischer leistungen in der poststationären schlaganfallversorgung: Eine qualitative analyse der adoptionsfaktoren aus sicht von patientinnen und patienten</dc:title><dc:creator>Dockweiler C.</dc:creator><prism:publicationName>Aktuelle Neurologie</prism:publicationName><prism:issn>03024350</prism:issn><prism:eIssn>14389428</prism:eIssn><prism:volume>42</prism:volume><prism:issueIdentifier>4</prism:issueIdentifier><prism:pageRange>197-204</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1055/s-0035-1548876</prism:doi><dc:description>© Georg Thieme Verlag KG. Abstract Background:Stroke is the most frequent cause of death worldwide, one of the central indication-related reasons for disability and thus a major challenge for health-care services. Teleneurological strategies in preclincal, clinical and rehabilitation management have demonstrated their efficacy with regard to improving health-related endpoints as well as reducing health-care costs. Decisive for the sustainable implementation of telemedical health-care is its acceptance by the user. Question:The selected, qualitative research efforts have investigated which attitudes, motives and opinions of the patients influence the behavioural intention to use telemedical health-care options for secondary prevention after stroke. Materials and Methods:In the framework of inpatient rehabilitation, 8 focus groups with altogether 40 patients were established and analysed for content. In order to illustrate the adoption process in comparison to technical use, the participants were presented with telemedical health-care settings. As structural underlying theory the present study used the "unified theory of acceptance and use of technology" (UTAUT). Results:Attitudes and opinions on the use of telemedical procedures in the post-clinical care of patients are unequivocally oriented on their usefulness - even when latent anxieties (e.g., with regard to data protection or lack of personal contact to the physician) are present. The process of decision-making can be characterised by the adoptors "expected performance", "expected expenditure", "social influences" and "easier-to-use general conditions". Conclusions:The attitudes and opinions of patients need to be taken into consideration in a target group-specific manner for the further development of telemedical health-care services. Because of the clear usefulness orientation, evidence-based development and implementation of telemedicine will be particularly important.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015595</affiliation-url><afid>60015595</afid><affilname>Universitat Bielefeld</affilname><name-variant>Bielefeld University</name-variant><affiliation-city>Bielefeld</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112367083</affiliation-url><afid>112367083</afid><affilname>Median Klinikum für Rehabilitation</affilname><name-variant>Median Klinikum für Rehabilitation</name-variant><affiliation-city/><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56663205000</author-url><authid>56663205000</authid><authname>Dockweiler C.</authname><surname>Dockweiler</surname><given-name>Christoph</given-name><initials>C.</initials><afid>60015595</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56663150200</author-url><authid>56663150200</authid><authname>Filius J.</authname><surname>Filius</surname><given-name>J.</given-name><initials>J.</initials><afid>60015595</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663238400</author-url><authid>56663238400</authid><authname>Dockweiler U.</authname><surname>Dockweiler</surname><given-name>U.</given-name><initials>U.</initials><afid>112367083</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003570222</author-url><authid>7003570222</authid><authname>Hornberg C.</authname><surname>Hornberg</surname><given-name>C.</given-name><initials>C.</initials><afid>60015595</afid></author><authkeywords>acceptance | adoption | secondary prevention | stroke | telemedicine</authkeywords><intid>2036081724</intid><source-id>130133</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928159232"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928159232?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928159232&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928159232&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0223523415002743"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928159232</prism:url><dc:identifier>SCOPUS_ID:84928159232</dc:identifier><eid>2-s2.0-84928159232</eid><dc:title>Design, synthesis and structure - activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors</dc:title><dc:creator>Zhao Y.</dc:creator><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationName><prism:issn>02235234</prism:issn><prism:eIssn>17683254</prism:eIssn><prism:volume>96</prism:volume><prism:pageRange>369-380</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejmech.2015.04.025</prism:doi><pii>S0223523415002743</pii><dc:description>© 2015 Elsevier Masson SAS. All rights reserved. Abstract A novel series of potent and efficacious factor Xa inhibitors which possesses pyrrole/indole/thiazole moieties as S4 binding element was identified. Compound 7b showed strong human factor Xa inhibitory activity (IC&lt;inf&gt;50&lt;/inf&gt; = 2.01 nM) and anticoagulant activities in both human (PTCT&lt;inf&gt;2&lt;/inf&gt; = 0.15 μM, APPTCT&lt;inf&gt;2&lt;/inf&gt; = 0.30 μM) and rabbit plasma (PTCT&lt;inf&gt;2&lt;/inf&gt; = 0.46 μM, APPTCT&lt;inf&gt;2&lt;/inf&gt; = 0.75 μM). The SARs analyses indicated that the size and water solubility of different alkylamino group at the position of S4 ligand were responsible for the anticoagulant activity.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007269</affiliation-url><afid>60007269</afid><affilname>Shenyang Pharmaceutical University</affilname><name-variant>Shenyang Pharmaceutical University</name-variant><affiliation-city>Shenyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7406635207</author-url><authid>7406635207</authid><authname>Zhao Y.</authname><surname>Zhao</surname><given-name>Yanfang</given-name><initials>Y.</initials><afid>60007269</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7401861438</author-url><authid>7401861438</authid><authname>Jiang M.</authname><surname>Jiang</surname><given-name>Mingyan</given-name><initials>M.</initials><afid>60007269</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56246464400</author-url><authid>56246464400</authid><authname>Zhou S.</authname><surname>Zhou</surname><given-name>Shunguang</given-name><initials>S.</initials><afid>60007269</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55808848300</author-url><authid>55808848300</authid><authname>Wu S.</authname><surname>Wu</surname><given-name>Shasha</given-name><initials>S.</initials><afid>60007269</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55715153300</author-url><authid>55715153300</authid><authname>Zhang X.</authname><surname>Zhang</surname><given-name>Xiaolong</given-name><initials>X.</initials><afid>60007269</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56493542100</author-url><authid>56493542100</authid><authname>Ma L.</authname><surname>Ma</surname><given-name>Longsheng</given-name><initials>L.</initials><afid>60007269</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7404451070</author-url><authid>7404451070</authid><authname>Zhang K.</authname><surname>Zhang</surname><given-name>Kai</given-name><initials>K.</initials><afid>60007269</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55779921400</author-url><authid>55779921400</authid><authname>Gong P.</authname><surname>Gong</surname><given-name>Ping</given-name><initials>P.</initials><afid>60007269</afid></author><authkeywords>Anticoagulant activity | Factor Xa inhibitors | Oxazolidinone derivatives | Synthesis</authkeywords><intid>1785734753</intid><article-number>7840</article-number><source-id>17464</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929991594"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929991594?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929991594&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929991594&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929991594</prism:url><dc:identifier>SCOPUS_ID:84929991594</dc:identifier><eid>2-s2.0-84929991594</eid><dc:title>Intraoperative bleeding during thoracic surgery: Avoidance strategies and surgical treatment concepts | Intraoperative Blutungen in der Thoraxchirurgie: Vermeidungsstrategien und chirurgische Therapiekonzepte</dc:title><dc:creator>Schirren M.</dc:creator><prism:publicationName>Chirurg</prism:publicationName><prism:issn>00094722</prism:issn><prism:volume>86</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>453-458</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00104-015-2999-8</prism:doi><dc:description>© 2015, Springer-Verlag Berlin Heidelberg. Background: As a direct result of the thoracic anatomy, heavy bleeding is possible during nearly all central resections in thoracic surgery. Objective: Description of the incidence of intraoperative bleeding including avoidance strategies and treatment concepts. Presentation of special anatomical features of pulmonary arteries. Material and methods: A literature search was performed in Pubmed, medline and by manual searching. Publications from the last 60 years were analyzed and the results are summarized in a structured review. Results: Little data is available on the incidence of intraoperative bleeding during thoracic surgery. Most data were collected retrospectively. For mediastinoscopy the incidence of severe bleeding is 0.2 %, for minimally invasive anatomical resections the incidence of intraoperative bleeding is 4.7 % and for open surgery 5 %. Bleeding from the central pulmonary artery can take a dramatic course and requires rapid and targeted therapy. Discussion: Knowledge of the anatomical topographic details, the structure, the course and the specific features of the vessels of the lungs is essential to prevent and treat bleeding. Avoidance strategies include techniques of proximal and distal vessel control, intrapericardial preparation and sharp preparation in general. Techniques of forward-looking preparation and well-prepared exit strategies in case of bleeding have to be part of the training in thoracic surgery.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073790</affiliation-url><afid>60073790</afid><affilname>Dr. Horst Schmidt Klinik GmbH</affilname><name-variant>Dr. Horst Schmidt Klinik</name-variant><affiliation-city>Wiesbaden</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:42962329100</author-url><authid>42962329100</authid><authname>Schirren M.</authname><surname>Schirren</surname><given-name>M.</given-name><initials>M.</initials><afid>60073790</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56076085800</author-url><authid>56076085800</authid><authname>Sponholz S.</authname><surname>Sponholz</surname><given-name>S.</given-name><initials>S.</initials><afid>60073790</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56658673600</author-url><authid>56658673600</authid><authname>Oguhzan S.</authname><surname>Oguhzan</surname><given-name>S.</given-name><initials>S.</initials><afid>60073790</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36150863000</author-url><authid>36150863000</authid><authname>Kudelin N.</authname><surname>Kudelin</surname><given-name>N.</given-name><initials>N.</initials><afid>60073790</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56658401900</author-url><authid>56658401900</authid><authname>Ruf C.</authname><surname>Ruf</surname><given-name>C.</given-name><initials>C.</initials><afid>60073790</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6506674656</author-url><authid>6506674656</authid><authname>Trainer S.</authname><surname>Trainer</surname><given-name>S.</given-name><initials>S.</initials><afid>60073790</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003902571</author-url><authid>7003902571</authid><authname>Schirren J.</authname><surname>Schirren</surname><given-name>J.</given-name><initials>J.</initials><afid>60073790</afid></author><authkeywords>Intraoperative bleeding | Management | Prevention | Pulmonary artery | Thoracic bleeding</authkeywords><intid>1536049633</intid><article-number>2999</article-number><source-id>20999</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930224905"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930224905?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930224905&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930224905&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930224905</prism:url><dc:identifier>SCOPUS_ID:84930224905</dc:identifier><eid>2-s2.0-84930224905</eid><dc:title>Nonplanar nanoscale fin field effect transistors on textile, paper, wood, stone, and vinyl via soft material-enabled double-transfer printing</dc:title><dc:creator>Rojas J.</dc:creator><prism:publicationName>ACS Nano</prism:publicationName><prism:issn>19360851</prism:issn><prism:eIssn>1936086X</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>5255-5263</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1021/acsnano.5b00686</prism:doi><dc:description>© 2015 American Chemical Society. The ability to incorporate rigid but high-performance nanoscale nonplanar complementary metal-oxide semiconductor (CMOS) electronics with curvilinear, irregular, or asymmetric shapes and surfaces is an arduous but timely challenge in enabling the production of wearable electronics with an in situ information-processing ability in the digital world. Therefore, we are demonstrating a soft-material enabled double-transfer-based process to integrate flexible, silicon-based, nanoscale, nonplanar, fin-shaped field effect transistors (FinFETs) and planar metal-oxide-semiconductor field effect transistors (MOSFETs) on various asymmetric surfaces to study their compatibility and enhanced applicability in various emerging fields. FinFET devices feature sub-20 nm dimensions and state-of-the-art, high-κ/metal gate stacks, showing no performance alteration after the transfer process. A further analysis of the transferred MOSFET devices, featuring 1 μm gate length, exhibits an I&lt;inf&gt;ON&lt;/inf&gt; value of nearly 70 μA/μm (V&lt;inf&gt;DS&lt;/inf&gt; = 2 V, V&lt;inf&gt;GS&lt;/inf&gt; = 2 V) and a low subthreshold swing of around 90 mV/dec, proving that a soft interfacial material can act both as a strong adhesion/interposing layer between devices and final substrate as well as a means to reduce strain, which ultimately helps maintain the devices performance with insignificant deterioration even at a high bending state.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60092945</affiliation-url><afid>60092945</afid><affilname>King Abdullah University of Science and Technology</affilname><name-variant>King Abdullah University of Science and Technology (KAUST)</name-variant><affiliation-city>Jeddah</affiliation-city><affiliation-country>Saudi Arabia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60092945</affiliation-url><afid>60092945</afid><affilname>King Abdullah University of Science and Technology</affilname><name-variant>King Abdullah University of Science and Technology (KAUST)</name-variant><affiliation-city>Jeddah</affiliation-city><affiliation-country>Saudi Arabia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54983756500</author-url><authid>54983756500</authid><authname>Rojas J.</authname><surname>Rojas</surname><given-name>Jhonathan P.</given-name><initials>J.P.</initials><afid>60092945</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55605643000</author-url><authid>55605643000</authid><authname>Torres Sevilla G.</authname><surname>Torres Sevilla</surname><given-name>Galo A.</given-name><initials>G.A.</initials><afid>60092945</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663247000</author-url><authid>56663247000</authid><authname>Alfaraj N.</authname><surname>Alfaraj</surname><given-name>Nasir</given-name><initials>N.</initials><afid>60092945</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55698747600</author-url><authid>55698747600</authid><authname>Ghoneim M.</authname><surname>Ghoneim</surname><given-name>Mohamed T.</given-name><initials>M.T.</initials><afid>60092945</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56205285300</author-url><authid>56205285300</authid><authname>Kutbee A.</authname><surname>Kutbee</surname><given-name>Arwa T.</given-name><initials>A.T.</initials><afid>60092945</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56662833200</author-url><authid>56662833200</authid><authname>Sridharan A.</authname><surname>Sridharan</surname><given-name>Ashvitha</given-name><initials>A.</initials><afid>60092945</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55318991400</author-url><authid>55318991400</authid><authname>Hussain M.</authname><surname>Hussain</surname><given-name>Muhammad Mustafa</given-name><initials>M.M.</initials><afid>60092945</afid></author><authkeywords>asymmetric surface | double-transfer | FinFETs | nonplanar | soft material</authkeywords><intid>536088233</intid><source-id>11500153511</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929704864"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929704864?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929704864&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929704864&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0168927415000161"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929704864</prism:url><dc:identifier>SCOPUS_ID:84929704864</dc:identifier><eid>2-s2.0-84929704864</eid><dc:title>Application of optimal control to the cardiac defibrillation problem using a physiological model of cellular dynamics</dc:title><dc:creator>Chamakuri N.</dc:creator><prism:publicationName>Applied Numerical Mathematics</prism:publicationName><prism:issn>01689274</prism:issn><prism:volume>95</prism:volume><prism:pageRange>130-139</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.apnum.2015.01.006</prism:doi><pii>S0168927415000161</pii><dc:description>© 2015 IMACS. Published by Elsevier B.V. All rights reserved. Optimal control techniques are investigated with the goal of terminating reentry waves in cardiac tissue models. In this computational study the Luo-Rudy phase-I ventricular action potential model is adopted which accounts for more biophysical details of cellular dynamics as compared to previously used phenomenological models. The parabolic and ordinary differential equations are solved as a coupled system and an AMG preconditioner is used to solve the discretized elliptic equation. The numerical results demonstrate that defibrillation is possible by delivering a single strong shock. The optimal control approach also leads to successful defibrillation and demands less total current. The present study motivates us to further investigate optimal control techniques on realistic geometries by incorporating the structural heterogeneity in the cardiac tissue.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112824939</affiliation-url><afid>112824939</afid><affilname>Radon Institute for Computational and Applied Mathematics</affilname><name-variant>Radon Institute for Computational and Applied Mathematics</name-variant><affiliation-city>Linz</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022457</affiliation-url><afid>60022457</afid><affilname>Karl-Franzens-Universitat Graz</affilname><name-variant>University of Graz</name-variant><affiliation-city>Graz</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006224</affiliation-url><afid>60006224</afid><affilname>Medizinische Universitat Graz</affilname><name-variant>Medical University Graz</name-variant><affiliation-city>Graz</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55799251600</author-url><authid>55799251600</authid><authname>Chamakuri N.</authname><surname>Chamakuri</surname><given-name>Nagaiah</given-name><initials>N.</initials><afid>112824939</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56249494900</author-url><authid>56249494900</authid><authname>Kunisch K.</authname><surname>Kunisch</surname><given-name>Karl</given-name><initials>K.</initials><afid>112824939</afid><afid>60022457</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56249494900</author-url><authid>56249494900</authid><authname>Kunisch K.</authname><surname>Kunisch</surname><given-name>Karl</given-name><initials>K.</initials><afid>112824939</afid><afid>60022457</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003297659</author-url><authid>7003297659</authid><authname>Plank G.</authname><surname>Plank</surname><given-name>Gernot</given-name><initials>G.</initials><afid>60006224</afid></author><authkeywords>Bidomain model | Defibrillation | Luo-Rudy model | Neumann boundary stimulation | Optimal control | Parallel FEM</authkeywords><intid>1035995325</intid><source-id>28067</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930196842"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930196842?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930196842&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930196842&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0939641115001964"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930196842</prism:url><dc:identifier>SCOPUS_ID:84930196842</dc:identifier><eid>2-s2.0-84930196842</eid><dc:title>In vitro study of sirolimus release from a drug-eluting stent: Comparison of the release profiles obtained using different test setups</dc:title><dc:creator>Seidlitz A.</dc:creator><prism:publicationName>European Journal of Pharmaceutics and Biopharmaceutics</prism:publicationName><prism:issn>09396411</prism:issn><prism:eIssn>18733441</prism:eIssn><prism:volume>93</prism:volume><prism:pageRange>328-338</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejpb.2015.04.016</prism:doi><pii>S0939641115001964</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. In this study drug release from the CYPHER™ stent, the gold standard in drug-eluting stent therapy until the end of its marketing in 2011/2012, was systematically evaluated using different in vitro release tests. The test systems included incubations setups, the reciprocating holder apparatus (USP 7), the flow-through cell apparatus (USP 4) and the vessel-simulating flow-through cell (vFTC) specifically designed for stent testing. The results obtained show a large variability regarding the fractions released into the media after 7 d ranging from 38.6% ± 4.5% to 74.6% ± 1.2%. The lowest fraction released was observed in the vFTC and the highest in an incubation setup with frequently changed media of a volume of 2 mL. Differences were even observed when using fairly similar and simple incubations setups with mere changes of the media volume, under maintenance of sink conditions, and of the vessel geometry. From these data it can be concluded, that in vitro release even from a slow releasing drug-eluting stent is greatly influenced by the experimental conditions and care must be taken when choosing a suitable setup. Comparison of the obtained in vitro release profiles to published in vivo data did not result in a distinct superiority of any of the tested methods regarding the predictability for the situation in vivo due to large differences in the reported in vivo data. However, this comparison yielded that the release observed in vitro using the 2 mL incubation setup and the reciprocating holder apparatus may be faster than the reported in vivo release. The results of this study also emphasize the necessity to use highly standardized release tests when comparisons between results from different experiments or even different labs are to be performed. In this context, the compendial methods are most likely offering the highest degree of standardization.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021311</affiliation-url><afid>60021311</afid><affilname>Ernst-Moritz-Arndt-Universitat Greifswald</affilname><name-variant>University of Greifswald</name-variant><affiliation-city>Greifswald</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003615</affiliation-url><afid>60003615</afid><affilname>Universitat Rostock</affilname><name-variant>University of Rostock</name-variant><affiliation-city>Rostock</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8555168200</author-url><authid>8555168200</authid><authname>Seidlitz A.</authname><surname>Seidlitz</surname><given-name>Anne</given-name><initials>A.</initials><afid>60021311</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56663031100</author-url><authid>56663031100</authid><authname>Schick W.</authname><surname>Schick</surname><given-name>Wiebke</given-name><initials>W.</initials><afid>60021311</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16029410400</author-url><authid>16029410400</authid><authname>Reske T.</authname><surname>Reske</surname><given-name>Thomas</given-name><initials>T.</initials><afid>60003615</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602838876</author-url><authid>6602838876</authid><authname>Senz V.</authname><surname>Senz</surname><given-name>Volkmar</given-name><initials>V.</initials><afid>60003615</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8628488400</author-url><authid>8628488400</authid><authname>Grabow N.</authname><surname>Grabow</surname><given-name>Niels</given-name><initials>N.</initials><afid>60003615</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:24391278900</author-url><authid>24391278900</authid><authname>Petersen S.</authname><surname>Petersen</surname><given-name>Svea</given-name><initials>S.</initials><afid>60003615</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:36929115400</author-url><authid>36929115400</authid><authname>Nagel S.</authname><surname>Nagel</surname><given-name>Stefan</given-name><initials>S.</initials><afid>60021311</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7003817206</author-url><authid>7003817206</authid><authname>Weitschies W.</authname><surname>Weitschies</surname><given-name>Werner</given-name><initials>W.</initials><afid>60021311</afid></author><authkeywords>CYPHER™ sirolimus-eluting stent | Flow-through cell | In vitro release testing | Reciprocating holder | Vessel-simulating flow-through cell</authkeywords><intid>2036081737</intid><source-id>21332</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929705496"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929705496?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929705496&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929705496&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929705496</prism:url><dc:identifier>SCOPUS_ID:84929705496</dc:identifier><eid>2-s2.0-84929705496</eid><dc:title>The Variations of Glycolysis and TCA Cycle Intermediate Levels Grown in Iron and Copper Mediums of Trichoderma harzianum</dc:title><dc:creator>Tavsan Z.</dc:creator><prism:publicationName>Applied Biochemistry and Biotechnology</prism:publicationName><prism:issn>02732289</prism:issn><prism:eIssn>15590291</prism:eIssn><prism:volume>176</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>76-85</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12010-015-1535-0</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. The efficiency of optimal metabolic function by microorganism depends on various parameters, especially essential metal supplementation. In the present study, the effects of iron and copper metals on metabolism were investigated by determination of glycolysis and tricarboxylic acid (TCA) cycle metabolites’ levels with respect to the metal concentrations and incubation period in Trichoderma harzianum. The pyruvate and citrate levels of T. harzianum increased up to 15 mg/L of copper via redirection of carbon flux though glycolysis by suppression of pentose phosphate pathway (PPP). However, the α-ketoglutarate levels decreased at concentration higher than 5 mg/L of copper to overcome damage of oxidative stress. The fumarate levels correlated with the α-ketoglutarate levels because of substrate limitation. Besides, in T. harzianum cells grown in various concentrations of iron-containing medium, the intracellular pyruvate, citrate, and α-ketoglutarate levels showed positive correlation with iron concentration due to modifying of expression of glycolysis and TCA cycle enzymes via a mechanism involving cofactor or allosteric regulation. However, as a result of consuming of prior substrates required for fumarate production, its levels rose up to 10 mg/L.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014930</affiliation-url><afid>60014930</afid><affilname>Dokuz Eylul Universitesi</affilname><name-variant>Dokuz Eylül University</name-variant><affiliation-city>Izmir</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014930</affiliation-url><afid>60014930</afid><affilname>Dokuz Eylul Universitesi</affilname><name-variant>Dokuz Eylül University</name-variant><affiliation-city>Izmir</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55745723100</author-url><authid>55745723100</authid><authname>Tavsan Z.</authname><surname>Tavsan</surname><given-name>Zehra</given-name><initials>Z.</initials><afid>60014930</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506238068</author-url><authid>6506238068</authid><authname>Ayar Kayali H.</authname><surname>Ayar Kayali</surname><given-name>Hulya</given-name><initials>H.</initials><afid>60014930</afid></author><authkeywords>Biosynthesis | Citric acid | Copper | Filamentous fungi | Fructose | Iron</authkeywords><intid>1786000756</intid><article-number>1535</article-number><source-id>110291</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929628107"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929628107?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929628107&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929628107&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929628107</prism:url><dc:identifier>SCOPUS_ID:84929628107</dc:identifier><eid>2-s2.0-84929628107</eid><dc:title>Use of a 1.0 Tesla open scanner for evaluation of pediatric and congenital heart disease: A retrospective cohort study</dc:title><dc:creator>Lu J.</dc:creator><prism:publicationName>Journal of Cardiovascular Magnetic Resonance</prism:publicationName><prism:issn>10976647</prism:issn><prism:eIssn>1532429X</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-25</prism:coverDate><prism:coverDisplayDate>25 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s12968-015-0144-y</prism:doi><dc:description>© 2015 Lu et al.; licensee BioMed Central. Background: Open cardiovascular magnetic resonance (CMR) scanners offer the potential for imaging patients with claustrophobia or large body size, but at a lower 1.0 Tesla magnetic field. This study aimed to evaluate the efficacy of open CMR for evaluation of pediatric and congenital heart disease. Methods: This retrospective, cross-sectional study included all patients ≤18 years old or with congenital heart disease who underwent CMR on an open 1.0 Tesla scanner at two centers from 2012-2014. Indications for CMR and clinical questions were extracted from the medical record. Studies were qualitatively graded for image quality and diagnostic utility. In a subset of 25 patients, signal-to-noise (SNR) and contrast-to-noise (CNR) ratios were compared to size- and diagnosis-matched patients with CMR on a 1.5 Tesla scanner. Results: A total of 65 patients (median 17.3 years old, 60% male) were included. Congenital heart disease was present in 32 (50%), with tetralogy of Fallot and bicuspid aortic valve the most common diagnoses. Open CMR was used due to scheduling/equipment issues in 51 (80%), claustrophobia in 7 (11%), and patient size in 3 (5%); 4 patients with claustrophobia had failed CMR on a different scanner, but completed the study on open CMR without sedation. All patients had good or excellent image quality on black blood, phase contrast, magnetic resonance angiography, and late gadolinium enhancement imaging. There was below average image quality in 3/63 (5%) patients with cine images, and 4/15 (27%) patients with coronary artery imaging. SNR and CNR were decreased in cine and magnetic resonance angiography images compared to 1.5 Tesla. The clinical question was answered adequately in all but 2 patients; 1 patient with a Fontan had artifact from an embolization coil limiting RV volume analysis, and in 1 patient the right coronary artery origin was not well seen. Conclusions: Open 1.0 Tesla scanners can effectively evaluate pediatric and congenital heart disease, including patients with claustrophobia and larger body size. Despite minor artifacts and differences in SNR and CNR, the majority of clinical questions can be answered adequately, with some limitations with coronary artery imaging. Further evaluation is necessary to optimize protocols and image quality.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033182</affiliation-url><afid>60033182</afid><affilname>University of Michigan Medical School</affilname><name-variant>University of Michigan Medical School</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033182</affiliation-url><afid>60033182</afid><affilname>University of Michigan Medical School</affilname><name-variant>University of Michigan Medical School</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026415</affiliation-url><afid>60026415</afid><affilname>Stony Brook University State University of New York</affilname><name-variant>State University of New York at Stony Brook</name-variant><affiliation-city>Stony Brook</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026415</affiliation-url><afid>60026415</afid><affilname>Stony Brook University State University of New York</affilname><name-variant>State University of New York at Stony Brook</name-variant><affiliation-city>Stony Brook</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033182</affiliation-url><afid>60033182</afid><affilname>University of Michigan Medical School</affilname><name-variant>University of Michigan Medical School</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:34978967700</author-url><authid>34978967700</authid><authname>Lu J.</authname><surname>Lu</surname><given-name>Jimmy C.</given-name><initials>J.C.</initials><afid>60033182</afid><afid>60033182</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:34978967700</author-url><authid>34978967700</authid><authname>Lu J.</authname><surname>Lu</surname><given-name>Jimmy C.</given-name><initials>J.C.</initials><afid>60033182</afid><afid>60033182</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7404067346</author-url><authid>7404067346</authid><authname>Nielsen J.</authname><surname>Nielsen</surname><given-name>James C.</given-name><initials>J.C.</initials><afid>60026415</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56610296000</author-url><authid>56610296000</authid><authname>Morowitz L.</authname><surname>Morowitz</surname><given-name>Layne</given-name><initials>L.</initials><afid>60026415</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56618607900</author-url><authid>56618607900</authid><authname>Musani M.</authname><surname>Musani</surname><given-name>Muzammil</given-name><initials>M.</initials><afid>60026415</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56652218200</author-url><authid>56652218200</authid><authname>Ghadimi Mahani M.</authname><surname>Ghadimi Mahani</surname><given-name>Maryam</given-name><initials>M.</initials><afid>60033182</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:9336296300</author-url><authid>9336296300</authid><authname>Agarwal P.</authname><surname>Agarwal</surname><given-name>Prachi P.</given-name><initials>P.P.</initials><afid>60033182</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:8346344500</author-url><authid>8346344500</authid><authname>Ibrahim E.</authname><surname>Ibrahim</surname><given-name>El Sayed H</given-name><initials>E.S.H.</initials><afid>60033182</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7102085362</author-url><authid>7102085362</authid><authname>Dorfman A.</authname><surname>Dorfman</surname><given-name>Adam L.</given-name><initials>A.L.</initials><afid>60033182</afid><afid>60033182</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7102085362</author-url><authid>7102085362</authid><authname>Dorfman A.</authname><surname>Dorfman</surname><given-name>Adam L.</given-name><initials>A.L.</initials><afid>60033182</afid><afid>60033182</afid></author><authkeywords>1.0 Tesla | Congenital heart disease | Open scanner</authkeywords><intid>1535989510</intid><article-number>144</article-number><source-id>23845</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929996071"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929996071?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929996071&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929996071&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929996071</prism:url><dc:identifier>SCOPUS_ID:84929996071</dc:identifier><eid>2-s2.0-84929996071</eid><dc:title>Variation of plasma levels of endothelin, calcitonin gene-related peptide, nitric oxide, and malondialdehyde in acute myocardial ischemia reperfusion injury in a rabbit model</dc:title><dc:creator>Zhao Y.</dc:creator><prism:publicationName>Genetics and Molecular Research</prism:publicationName><prism:eIssn>16765680</prism:eIssn><prism:volume>14</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>5577-5584</prism:pageRange><prism:coverDate>2015-05-25</prism:coverDate><prism:coverDisplayDate>25 May 2015</prism:coverDisplayDate><prism:doi>10.4238/2015.May.25.9</prism:doi><dc:description>©FUNPEC-RP. We examined the variation in plasma levels of endothelin (ET), calcitonin gene-related peptide (CGRP), nitric oxide (NO), and malondialdehyde (MDA), as well as superoxide dismutase (SOD) activity, in acute myocardial ischemia reperfusion injury in a rabbit model. Seventy rabbits were randomly assigned into 3 groups. Open-chest surgery (OCS) was performed for all rabbits. Group A (N = 20) received sham-surgery, group B (N = 25) was the reperfusion group, and group C (N = 25) was the infarction group. At 12 h after chest closure, plasma ET levels in groups B and C were clearly increased, while CGRP levels were clearly decreased, particularly in group B. At 24 h after chest closure, ET levels were higher than before OCS, while there was no significant difference between groups B and C. ET in group B was decreased, while that in group C was increased at 12 h. No significant difference in CGRP was observed between 12 and 24 h after chest closure. NO levels in groups B and C at 12 h after chest closure were significantly decreased compared to those before OCS. NO levels in group B at 24, 48, and 72 h were significantly lower than those at 12 h, while those of group C were not significantly changed after 12 h. Dy-namic monitoring and comparison of plasma levels of ET, CGRP, NO, and MDA as well as SOD activity revealed that appropriate intervention of these factors may reduce reperfusion injury.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009884</affiliation-url><afid>60009884</afid><affilname>Hebei Medical University</affilname><name-variant>Hebei Medical University</name-variant><affiliation-city>Shijiazhuang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60082175</affiliation-url><afid>60082175</afid><affilname>Hebei General Hospital</affilname><name-variant>Hebei Provincial People's Hospital</name-variant><affiliation-city>Shijiazhuang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60082175</affiliation-url><afid>60082175</afid><affilname>Hebei General Hospital</affilname><name-variant>Hebei Provincial People's Hospital</name-variant><affiliation-city>Shijiazhuang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56465164300</author-url><authid>56465164300</authid><authname>Zhao Y.</authname><surname>Zhao</surname><given-name>Y. B.</given-name><initials>Y.B.</initials><afid>60009884</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56658798400</author-url><authid>56658798400</authid><authname>Wang Y.</authname><surname>Wang</surname><given-name>Y. Z.</given-name><initials>Y.Z.</initials><afid>60082175</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56465380000</author-url><authid>56465380000</authid><authname>Yue Y.</authname><surname>Yue</surname><given-name>Y. H.</given-name><initials>Y.H.</initials><afid>60082175</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56465220800</author-url><authid>56465220800</authid><authname>Zhao W.</authname><surname>Zhao</surname><given-name>W. C.</given-name><initials>W.C.</initials><afid>60009884</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56465322100</author-url><authid>56465322100</authid><authname>Feng G.</authname><surname>Feng</surname><given-name>G. X.</given-name><initials>G.X.</initials><afid>60009884</afid></author><authkeywords>Myocardial ischemia | Reperfusion injury</authkeywords><intid>1536049507</intid><source-id>22190</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925450841"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925450841?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925450841&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925450841&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0928098715000834"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925450841</prism:url><dc:identifier>SCOPUS_ID:84925450841</dc:identifier><eid>2-s2.0-84925450841</eid><dc:title>Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: Role of pharmaceutical formulation</dc:title><dc:creator>Fretellier N.</dc:creator><prism:publicationName>European Journal of Pharmaceutical Sciences</prism:publicationName><prism:issn>09280987</prism:issn><prism:eIssn>18790720</prism:eIssn><prism:volume>72</prism:volume><prism:pageRange>46-56</prism:pageRange><prism:coverDate>2015-05-25</prism:coverDate><prism:coverDisplayDate>25 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejps.2015.02.016</prism:doi><pii>S0928098715000834</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. While not acutely toxic, chronic hepatic effect of certain gadolinium chelates (GC), used as contrast agent for magnetic resonance imaging, might represent a risk in renally-impaired patients due to free gadolinium accumulation in the liver. To answer this question, this study investigated the consequences of the presence of small amounts of either a soluble gadolinium salt ("free" Gd) or low-stability chelating impurity in the pharmaceutical solution of gadoteric acid, a macrocyclic GC with high thermodynamic and kinetic stabilities, were investigated in renally-impaired rats. Renal failure was induced by adding 0.75% adenine in the diet for three weeks. The pharmaceutical and commercial solution of gadoteric acid was administered (5 daily intravenous injections of 2.5 mmol Gd/kg) either alone or after being spiked with either "free" gadolinium (i.e., 0.04% w/v) or low-stability impurity (i.e., 0.06 w/v). Another GC, gadodiamide (low thermodynamic and kinetic stabilities) was given as its commercial solution at a similar dose. Non-chelated gadolinium was tested at two doses (0.005 and 0.01 mmol Gd/kg) as acetate salt. Gadodiamide induced systemic toxicity (mortality, severe epidermal and dermal lesions) and substantial tissue Gd retention. The addition of very low amounts of "free", non-chelated gadolinium or low thermodynamic stability impurity to the pharmaceutical solution of the thermodynamically stable GC gadoteric acid resulted in substantial capture of metal by the liver, similar to what was observed in "free" gadolinium salt-treated rats. Relaxometry studies strongly suggested the presence of free and soluble gadolinium in the liver. Electron microscopy examinations revealed the presence of free and insoluble gadolinium deposits in hepatocytes and Kupffer cells of rats treated with gadoteric acid solution spiked with low-stability impurity, free gadolinium and gadodiamide, but not in rats treated with the pharmaceutical solution of gadoteric acid. The presence of impurities in the GC pharmaceutical solution may have long-term biological consequences.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60084322</affiliation-url><afid>60084322</afid><affilname>Laboratoire Guerbet</affilname><name-variant>Laboratoire Guerbet</name-variant><affiliation-city>Val-d'Oise</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020016</affiliation-url><afid>60020016</afid><affilname>Klinikum der Universitat Regensburg und Medizinische Fakultat</affilname><name-variant>Universitätsklinikum Regensburg</name-variant><affiliation-city>Regensburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030857</affiliation-url><afid>60030857</afid><affilname>Hopital Europeen Georges-Pompidou</affilname><name-variant>Hôpital Européen Georges Pompidou</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030857</affiliation-url><afid>60030857</afid><affilname>Hopital Europeen Georges-Pompidou</affilname><name-variant>Hôpital Européen Georges Pompidou</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36537047100</author-url><authid>36537047100</authid><authname>Fretellier N.</authname><surname>Fretellier</surname><given-name>Nathalie</given-name><initials>N.</initials><afid>60084322</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56567820300</author-url><authid>56567820300</authid><authname>Salhi M.</authname><surname>Salhi</surname><given-name>Mariem</given-name><initials>M.</initials><afid>60084322</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7403195038</author-url><authid>7403195038</authid><authname>Schroeder J.</authname><surname>Schroeder</surname><given-name>Josef</given-name><initials>J.</initials><afid>60020016</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:21743600100</author-url><authid>21743600100</authid><authname>Siegmund H.</authname><surname>Siegmund</surname><given-name>Heiko</given-name><initials>H.</initials><afid>60020016</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56567826000</author-url><authid>56567826000</authid><authname>Chevalier T.</authname><surname>Chevalier</surname><given-name>Thibaut</given-name><initials>T.</initials><afid>60084322</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35414804500</author-url><authid>35414804500</authid><authname>Bruneval P.</authname><surname>Bruneval</surname><given-name>Patrick</given-name><initials>P.</initials><afid>60030857</afid><afid>60030857</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35414804500</author-url><authid>35414804500</authid><authname>Bruneval P.</authname><surname>Bruneval</surname><given-name>Patrick</given-name><initials>P.</initials><afid>60030857</afid><afid>60030857</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56440190700</author-url><authid>56440190700</authid><authname>Jestin-Mayer G.</authname><surname>Jestin-Mayer</surname><given-name>Gaëlle</given-name><initials>G.</initials><afid>60084322</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6507396729</author-url><authid>6507396729</authid><authname>Delaloge F.</authname><surname>Delaloge</surname><given-name>Francette</given-name><initials>F.</initials><afid>60084322</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:37085151900</author-url><authid>37085151900</authid><authname>Factor C.</authname><surname>Factor</surname><given-name>Cécile</given-name><initials>C.</initials><afid>60084322</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55464466000</author-url><authid>55464466000</authid><authname>Mayer J.</authname><surname>Mayer</surname><given-name>Jean François</given-name><initials>J.F.</initials><afid>60084322</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56568292500</author-url><authid>56568292500</authid><authname>Fabicki J.</authname><surname>Fabicki</surname><given-name>Jean Michel</given-name><initials>J.M.</initials><afid>60084322</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:15840829500</author-url><authid>15840829500</authid><authname>Robic C.</authname><surname>Robic</surname><given-name>Caroline</given-name><initials>C.</initials><afid>60084322</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7003888950</author-url><authid>7003888950</authid><authname>Bonnemain B.</authname><surname>Bonnemain</surname><given-name>Bruno</given-name><initials>B.</initials><afid>60084322</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7003904147</author-url><authid>7003904147</authid><authname>Idée J.</authname><surname>Idée</surname><given-name>Jean Marc</given-name><initials>J.M.</initials><afid>60084322</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:7006329920</author-url><authid>7006329920</authid><authname>Corot C.</authname><surname>Corot</surname><given-name>Claire</given-name><initials>C.</initials><afid>60084322</afid></author><authkeywords>Contrast agents | Drug impurities | Gadolinium | Gadolinium chelates | Magnetic resonance imaging | Pharmaceutical solution</authkeywords><intid>1785296286</intid><source-id>21331</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929773631"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929773631?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929773631&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929773631&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929773631</prism:url><dc:identifier>SCOPUS_ID:84929773631</dc:identifier><eid>2-s2.0-84929773631</eid><dc:title>Carnivore diversity at a montane rainforest site in Ecuador's Gran Sumaco Biosphere Reserve</dc:title><dc:creator>Hodge A.</dc:creator><prism:publicationName>ORYX</prism:publicationName><prism:issn>00306053</prism:issn><prism:eIssn>13653008</prism:eIssn><prism:coverDate>2015-05-25</prism:coverDate><prism:coverDisplayDate>25 May 2015</prism:coverDisplayDate><prism:doi>10.1017/S0030605315000101</prism:doi><pii>S0030605315000101</pii><dc:description>Copyright © Fauna &amp; Flora International 2015 Ecuador harbours a diverse assemblage of tropical mammals, yet the natural history and local-scale distributions of many species remain poorly understood. We conducted the first systematic camera-trap survey of terrestrial mammalian carnivores at Wildsumaco Wildlife Sanctuary, a mid-elevation (1,250–1,450 m), montane rainforest site on the slopes of Sumaco Volcano, in the heart of the Tropical Andes biodiversity hotspot. We quantified trap success, latency to detection and temporal activity patterns for each species detected. We recorded nine carnivore species (four felids, two procyonids and three mustelids), including the first verified record of the jaguarundi Puma yagouaroundi in the region. These species comprise one-third of all terrestrial carnivore species known to occur in Ecuador and 82% of those thought to occur at mid-elevation. All except one of the carnivores we detected have reported elevational ranges ≤ 1,500 m; the one exception, the puma Puma concolor, occurs throughout mainland Ecuador at 0–4,500 m. No cloud forest or highland species (i.e. those with a reported lower elevational limit of ≥ 1,500 m) were detected. Trap success was highest, and latency to detection smallest, for the margay Leopardis wiedii, and temporal activity patterns for all species were consistent with those reported previously in the literature. Our results demonstrate that the mid-elevation montane rainforests of Sumaco Volcano support an exceptionally high diversity of co-existing mammalian carnivores, many of which appear to be near their upper elevational limits, and emphasize the conservation value of this area.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029194</affiliation-url><afid>60029194</afid><affilname>The University of North Carolina Wilmington</affilname><name-variant>University of North Carolina Wilmington</name-variant><affiliation-city>Wilmington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54083281100</author-url><authid>54083281100</authid><authname>Hodge A.</authname><surname>Hodge</surname><given-name>Anne Marie C</given-name><initials>A.M.C.</initials><afid>60029194</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004649801</author-url><authid>7004649801</authid><authname>Arbogast B.</authname><surname>Arbogast</surname><given-name>Brian S.</given-name><initials>B.S.</initials><afid>60029194</afid></author><authkeywords>Biodiversity | camera survey | Ecuador | Felidae | mammals | South America | Tropical Andes | wildlife monitoring</authkeywords><intid>1536019891</intid><source-id>23287</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930079453"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930079453?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930079453&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930079453&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930079453</prism:url><dc:identifier>SCOPUS_ID:84930079453</dc:identifier><eid>2-s2.0-84930079453</eid><dc:title>Label-free immunosensor for monitoring vitellogenin as a biomarker for exogenous oestrogen compounds in amphibian species</dc:title><dc:creator>Majer-Baranyi K.</dc:creator><prism:publicationName>International Journal of Environmental Analytical Chemistry</prism:publicationName><prism:issn>03067319</prism:issn><prism:eIssn>10290397</prism:eIssn><prism:coverDate>2015-05-25</prism:coverDate><prism:coverDisplayDate>25 May 2015</prism:coverDisplayDate><prism:doi>10.1080/03067319.2015.1048434</prism:doi><dc:description>© 2015 Taylor &amp; Francis A label-free, optical waveguide lightmode spectroscopy based immunosensor was developed for frog (Bombina orientalis) vitellogenin (Vtg) determination in biological samples as a biomarker for exogenous oestrogen compounds. Antibody against Vtg was produced in rabbits immunised with purified lipovitellin (Lpv), a precursor of Vtg, from the homogenised ovary of oriental fire-bellied toads (B. orientalis). The purified protein and Lpv/Vtg-specific serum were applied in both competitive and direct immunoassay formats using optical waveguide lightmode spectroscopy immunosensor. When measuring Vtg in direct manner, the Lpv antibody (1.76 µg mL&lt;sup&gt;−1&lt;/sup&gt;) was immobilised on the sensor surface, and the linear measuring range for Vtg was 0.1–10 µg mL&lt;sup&gt;−1&lt;/sup&gt;. During the competitive measurement, 100 ng mL&lt;sup&gt;−1&lt;/sup&gt; Lpv was applied for the immobilisation. The linear measuring range for Vtg was 0.5–50 ng mL&lt;sup&gt;−1&lt;/sup&gt;. We studied the relative substrate specificity of the antibody, and it was concluded that the method is suitable for the sensitive and selective determination of Vtg levels in toads. Heart, liver and gonad samples from male animals were spiked with Vtg and were analysed using the newly developed method, and female toads and spawn samples were tested and compared to the calibration curve obtained by the spiked samples.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115285117</affiliation-url><afid>115285117</afid><affilname>National Agricultural Research and Innovation Centre</affilname><name-variant>National Agricultural Research and Innovation Centre</name-variant><affiliation-city>Budapest</affiliation-city><affiliation-country>Hungary</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115285217</affiliation-url><afid>115285217</afid><affilname>DoubleDelta Kft.</affilname><name-variant>DoubleDelta Kft.</name-variant><affiliation-city/><affiliation-country>Hungary</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100535958</affiliation-url><afid>100535958</afid><affilname>MicroVacuum Ltd.</affilname><name-variant>Micro Vacuum Ltd.</name-variant><affiliation-city>Budapest</affiliation-city><affiliation-country>Hungary</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115285117</affiliation-url><afid>115285117</afid><affilname>National Agricultural Research and Innovation Centre</affilname><name-variant>National Agricultural Research and Innovation Centre</name-variant><affiliation-city>Budapest</affiliation-city><affiliation-country>Hungary</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24463526900</author-url><authid>24463526900</authid><authname>Majer-Baranyi K.</authname><surname>Majer-Baranyi</surname><given-name>Krisztina</given-name><initials>K.</initials><afid>115285117</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603170012</author-url><authid>6603170012</authid><authname>Adányi N.</authname><surname>Adányi</surname><given-name>Nóra</given-name><initials>N.</initials><afid>115285117</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56660303800</author-url><authid>56660303800</authid><authname>Nagy A.</authname><surname>Nagy</surname><given-name>András</given-name><initials>A.</initials><afid>115285117</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56660630700</author-url><authid>56660630700</authid><authname>Bukovskaya O.</authname><surname>Bukovskaya</surname><given-name>Olga</given-name><initials>O.</initials><afid>115285217</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6507814591</author-url><authid>6507814591</authid><authname>Szendrő I.</authname><surname>Szendrő</surname><given-name>István</given-name><initials>I.</initials><afid>100535958</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6701772622</author-url><authid>6701772622</authid><authname>Székács A.</authname><surname>Székács</surname><given-name>András</given-name><initials>A.</initials><afid>115285117</afid></author><authkeywords>ELISA | endocrine disruption | immunosensors | lipovitellin | optical waveguide lightmode spectroscopy (OWLS) | vitellogenin</authkeywords><intid>1786061545</intid><source-id>24012</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929629763"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929629763?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929629763&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929629763&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929629763</prism:url><dc:identifier>SCOPUS_ID:84929629763</dc:identifier><eid>2-s2.0-84929629763</eid><dc:title>Changes in Health-Related Quality of Life After Gastric Bypass in Patients With and Without Obesity-Related Disease</dc:title><dc:creator>Risstad H.</dc:creator><prism:publicationName>Obesity Surgery</prism:publicationName><prism:issn>09608923</prism:issn><prism:eIssn>17080428</prism:eIssn><prism:coverDate>2015-05-25</prism:coverDate><prism:coverDisplayDate>25 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s11695-015-1717-4</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Background: A substantial proportion of severely obese patients undergoing bariatric surgery have not developed disease as a consequence of obesity. Little is known about the effects of bariatric surgery on health-related quality of life (HRQL) in this patient group. In a prospective study at a public hospital, we compared HRQL in gastric bypass patients with and without obesity-related disease before and 2 years after surgery. Methods: HRQL was assessed in 232 severely obese patients before, 1 year, and 2 years after Roux-en-Y gastric bypass. We used a general HRQL questionnaire, the Short Form 36, and an obesity-specific questionnaire, the Obesity-related Problems scale. The patients were divided into two groups based on the presence of obesity-related disease (n = 146) or not (n = 86) before surgery. We defined obesity-related disease as having at least one of the following conditions: type 2 diabetes mellitus, hypertension, dyslipidemia, coronary heart disease, obstructive sleep apnea, gastroesophageal reflux disease, or osteoarthritis. Linear mixed models were used to analyze the HRQL outcomes. Results: Before surgery, patients with no obesity-related disease reported equal HRQL compared with patients with obesity-related disease. Two years after gastric bypass, substantial improvements in all subscales of Short Form 36 and in Obesity-related Problems scale were observed in both groups, and the improvements were similar in 7 out of 8 subscales of Short Form 36 as well as for the Obesity-related Problems scale. Conclusions: Baseline HRQL was similar in patients with and without obesity-related disease prior to gastric bypass. After surgery, patients with no comorbidity had similar positive changes in HRQL as patients with one or several comorbidities. These findings indicate that other factors than obesity-related disease are at least as important for severely obese patients’ impaired HRQL.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60105037</affiliation-url><afid>60105037</afid><affilname>Oslo University Hospital</affilname><name-variant>Oslo University Hospital</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60105037</affiliation-url><afid>60105037</afid><affilname>Oslo University Hospital</affilname><name-variant>Oslo University Hospital</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60105037</affiliation-url><afid>60105037</afid><affilname>Oslo University Hospital</affilname><name-variant>Oslo University Hospital</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030955</affiliation-url><afid>60030955</afid><affilname>Sykehuset Telemark</affilname><name-variant>Telemark Central Hospital</name-variant><affiliation-city>Skien</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55823100000</author-url><authid>55823100000</authid><authname>Risstad H.</authname><surname>Risstad</surname><given-name>Hilde</given-name><initials>H.</initials><afid>60105037</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:15761012600</author-url><authid>15761012600</authid><authname>Søvik T.</authname><surname>Søvik</surname><given-name>Torgeir T.</given-name><initials>T.T.</initials><afid>60105037</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14624022400</author-url><authid>14624022400</authid><authname>Hewitt S.</authname><surname>Hewitt</surname><given-name>Stephen</given-name><initials>S.</initials><afid>60105037</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003602344</author-url><authid>7003602344</authid><authname>Kristinsson J.</authname><surname>Kristinsson</surname><given-name>Jon A.</given-name><initials>J.A.</initials><afid>60105037</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24757871700</author-url><authid>24757871700</authid><authname>Fagerland M.</authname><surname>Fagerland</surname><given-name>Morten W.</given-name><initials>M.W.</initials><afid>60105037</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603187743</author-url><authid>6603187743</authid><authname>Bernklev T.</authname><surname>Bernklev</surname><given-name>Tomm</given-name><initials>T.</initials><afid>60030955</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56564189500</author-url><authid>56564189500</authid><authname>Mala T.</authname><surname>Mala</surname><given-name>Tom</given-name><initials>T.</initials><afid>60105037</afid></author><authkeywords>Bariatric surgery | Comorbidity | Gastric bypass | Health-related quality of life | Morbid obesity | OP-scale | Severe obesity | SF-36</authkeywords><intid>1535988603</intid><source-id>22130</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926649365"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926649365?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926649365&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926649365&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009279715000988"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926649365</prism:url><dc:identifier>SCOPUS_ID:84926649365</dc:identifier><eid>2-s2.0-84926649365</eid><dc:title>Nordihydroguiaretic acid attenuates skin tumorigenesis in Swiss albino mice with the condition of topical co-administration of an immunosuppressant</dc:title><dc:creator>Rahman S.</dc:creator><prism:publicationName>Chemico-Biological Interactions</prism:publicationName><prism:issn>00092797</prism:issn><prism:eIssn>18727786</prism:eIssn><prism:volume>233</prism:volume><prism:pageRange>106-114</prism:pageRange><prism:coverDate>2015-05-25</prism:coverDate><prism:coverDisplayDate>25 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbi.2015.03.006</prism:doi><pii>S0009279715000988</pii><dc:description>© 2015 Elsevier Ireland Ltd. All rights reserved. Abstract Drug and chemically-induced immunosuppression has been implicated as a confounding factor for cancer development. Management of cancer in such situation is often a challenging task. We tested the efficacy of nordihydroguiaretic acid (NDGA) against immunosuppressant tacrolimus-induced augmentation of mouse skin tumorigenesis. It was observed that topical administration of tacrolimus significantly accelerated the tumor promotion events in dimethylbenz(a)anthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA) promoted two-stage mouse skin carcinogenesis, which were accompanied by reduced CD4&lt;sup&gt;+&lt;/sup&gt;/CD8&lt;sup&gt;+&lt;/sup&gt; ratio of lymph nodes and serum IL-2 level. NDGA pre-treatment before each TPA application reduced the tumor incidence, its multiplicity and volume together with improvement in histopathological alterations and decrease in proliferating cell nuclear antigen (PCNA) labeling index (LI). However, NDGA had no significant influence on the immunosuppressive effect of tacrolimus. The present study demonstrates chemopreventive effect of NDGA in normal as well as in the condition of immunosuppression. Thus, NDGA has the potential to inhibit or delay the onset of tumor development during immunosuppressive regimen.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025589</affiliation-url><afid>60025589</afid><affilname>Jamia Hamdard University</affilname><name-variant>Hamdard University</name-variant><affiliation-city>New Delhi</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005159</affiliation-url><afid>60005159</afid><affilname>Institute of Nuclear Medicine and Allied Sciences India</affilname><name-variant>Institute of Nuclear Medicine and Allied Sciences</name-variant><affiliation-city>New Delhi</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005353</affiliation-url><afid>60005353</afid><affilname>King Saud University College of Science</affilname><name-variant>King Saud University</name-variant><affiliation-city>Riyadh</affiliation-city><affiliation-country>Saudi Arabia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15122881200</author-url><authid>15122881200</authid><authname>Rahman S.</authname><surname>Rahman</surname><given-name>Shakilur</given-name><initials>S.</initials><afid>60025589</afid><afid>60005353</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15122881200</author-url><authid>15122881200</authid><authname>Rahman S.</authname><surname>Rahman</surname><given-name>Shakilur</given-name><initials>S.</initials><afid>60025589</afid><afid>60005353</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35757404400</author-url><authid>35757404400</authid><authname>Farooque A.</authname><surname>Farooque</surname><given-name>Abdullah</given-name><initials>A.</initials><afid>60005159</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37033376300</author-url><authid>37033376300</authid><authname>Anjum S.</authname><surname>Anjum</surname><given-name>Sameya</given-name><initials>S.</initials><afid>60025589</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15121917000</author-url><authid>15121917000</authid><authname>Ansari R.</authname><surname>Ansari</surname><given-name>Rizwan Ahmad</given-name><initials>R.A.</initials><afid>60025589</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6603710190</author-url><authid>6603710190</authid><authname>Adhikari J.</authname><surname>Adhikari</surname><given-name>Jawahar S.</given-name><initials>J.S.</initials><afid>60005159</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35452100300</author-url><authid>35452100300</authid><authname>Dwarakanath B.</authname><surname>Dwarakanath</surname><given-name>Bilikere S.</given-name><initials>B.S.</initials><afid>60005159</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003903976</author-url><authid>7003903976</authid><authname>Raisuddin S.</authname><surname>Raisuddin</surname><given-name>Sheikh</given-name><initials>S.</initials><afid>60025589</afid></author><authkeywords>Chemoprevention | Immunosuppression | Nordihydroguaiaretic acid | Skin cancer | Tacrolimus</authkeywords><intid>35483995</intid><article-number>7305</article-number><source-id>24652</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926641942"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926641942?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926641942&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926641942&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S000927971500126X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926641942</prism:url><dc:identifier>SCOPUS_ID:84926641942</dc:identifier><eid>2-s2.0-84926641942</eid><dc:title>3,4-Dihydroxy-benzohydroxamic acid (Didox) suppresses pro-inflammatory profiles and oxidative stress in TLR4-activated RAW264.7 murine macrophages</dc:title><dc:creator>Matsebatlela T.</dc:creator><prism:publicationName>Chemico-Biological Interactions</prism:publicationName><prism:issn>00092797</prism:issn><prism:eIssn>18727786</prism:eIssn><prism:volume>233</prism:volume><prism:pageRange>95-105</prism:pageRange><prism:coverDate>2015-05-25</prism:coverDate><prism:coverDisplayDate>25 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbi.2015.03.027</prism:doi><pii>S000927971500126X</pii><dc:description>© 2015 Elsevier Ireland Ltd. All rights reserved. Abstract Didox (3,4-dihydroxy-benzohydroxamic acid), is a synthetic ribonucleotide reductase (RR) inhibitor derived from polyhydroxy-substituted benzohydroxamic acid, and originally developed as an anti-cancer agent. Some studies indicate that didox may have anti-oxidative stress-like properties, while other studies hint that didox may have anti-inflammatory properties. Using nitric oxide production in response to LPS treatment as a sensitive screening assay for anti-inflammatory compounds, we show that didox is very potent at levels as low as 6.25 μM, with maximal inhibition at 100 μM. A qRT-PCR array was then employed to screen didox for other potential anti-inflammatory and anti-oxidative stress-related properties. Didox was very potent in suppressing the expression of these arrayed mRNA in response to LPS, and in some cases didox alone suppressed expression. Using qRT-PCR as a follow up to the array, we demonstrated that didox suppresses LPS-induced mRNA levels of iNOS, IL-6, IL-1, TNF-α, NF-κβ (p65), and p38-α, after 24 h of treatment. Treatment with didox also suppresses the secretion of nitric oxide, IL-6, and IL-10. Furthermore, oxidative stress, as quantified by intracellular ROS levels in response to macrophage activators LPS and phorbol ester (PMA), and the glutathione depleting agent BSO, is reduced by treatment with didox. Moreover, we demonstrate that nuclear translocation of NF-κβ (p65) in response to LPS is inhibited by didox. These findings were supported by qRT-PCR for oxidative stress genes SOD1 and catalase. Overall, this study supports the conclusion that didox may have a future role in managing acute and chronic inflammatory diseases and oxidative stress due to high production of ROS.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017614</affiliation-url><afid>60017614</afid><affilname>University of Limpopo</affilname><name-variant>University of Limpopo</name-variant><affiliation-city>Sovenga</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026610</affiliation-url><afid>60026610</afid><affilname>Clemson University</affilname><name-variant>Clemson Univ</name-variant><affiliation-city>Clemson</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106567542</affiliation-url><afid>106567542</afid><affilname>Molecules for Health</affilname><name-variant>Molecules for Health</name-variant><affiliation-city>Richmond</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8954370400</author-url><authid>8954370400</authid><authname>Matsebatlela T.</authname><surname>Matsebatlela</surname><given-name>Thabe M.</given-name><initials>T.M.</initials><afid>60017614</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37020837900</author-url><authid>37020837900</authid><authname>Anderson A.</authname><surname>Anderson</surname><given-name>Amy L.</given-name><initials>A.L.</initials><afid>60026610</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005131860</author-url><authid>7005131860</authid><authname>Gallicchio V.</authname><surname>Gallicchio</surname><given-name>Vincent S.</given-name><initials>V.S.</initials><afid>60026610</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004510905</author-url><authid>7004510905</authid><authname>Elford H.</authname><surname>Elford</surname><given-name>Howard</given-name><initials>H.</initials><afid>106567542</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7201456683</author-url><authid>7201456683</authid><authname>Rice C.</authname><surname>Rice</surname><given-name>Charles D.</given-name><initials>C.D.</initials><afid>60026610</afid></author><authkeywords>Didox | Inflammation | iNOS | Oxidative stress | RAW264.7 cells | TLR-4</authkeywords><intid>535486634</intid><article-number>7326</article-number><source-id>24652</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929403947"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929403947?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929403947&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929403947&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929403947</prism:url><dc:identifier>SCOPUS_ID:84929403947</dc:identifier><eid>2-s2.0-84929403947</eid><dc:title>A bibliometric analysis of the 100 most influential papers on COPD</dc:title><dc:creator>Gu W.</dc:creator><prism:publicationName>International Journal of COPD</prism:publicationName><prism:issn>11769106</prism:issn><prism:eIssn>11782005</prism:eIssn><prism:volume>10</prism:volume><prism:pageRange>667-676</prism:pageRange><prism:coverDate>2015-05-25</prism:coverDate><prism:coverDisplayDate>25 May 2015</prism:coverDisplayDate><prism:doi>10.2147/COPD.S74911</prism:doi><dc:description>© 2015 Gu et al. Objective: We aimed to identify the 100 top-cited articles published on chronic obstructive pulmonary disease (COPD) and to analyze their characteristics so as to provide information on the achievement and development in COPD research over the past decades. Methods and materials: A comprehensive list of citation classics in COPD was generated by searching the Science Citation Index expanded database, using the keywords “COPD” or “chronic obstructive pulmonary disease” or “chronic obstructive pulmonary diseases”. The 100 top-cited research papers were retrieved by reading the abstract or full text if needed. All eligible articles were read for basic information, including country of origin, organizations, article type, journals, research field, and authors. Results: The 100 top-cited articles on COPD were published between 1966 and 2010. The number of citations ranged from 254 to 2,164, with a mean of 450 citations for each article. These citation classics were from 32 countries, with 38 from the United States. The Imperial College London led the list of classics, with 16 papers. The 100 top-cited articles were distributed in 18 journals, with the American Journal of Respiratory, Critical Care Medicine, and Journal of the American Medical Association topping the list. Among the various fields, both respiratory system (63%) and general internal medicine (63%) were the most common fields of study for the 100 articles. Conclusion: Our bibliometric analysis provides a historical perspective on the progress of scientific research on COPD. Articles originating from the United States and published in high-impact specialized respiratory journals are most likely to be cited in the field of COPD research.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115246050</affiliation-url><afid>115246050</afid><affilname>People’s Hospital of Shanghai</affilname><name-variant>People’s Hospital of Shanghai</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073453</affiliation-url><afid>60073453</afid><affilname>Beijing Tongren Hospital</affilname><name-variant>Beijing Hospital</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55553646100</author-url><authid>55553646100</authid><authname>Gu W.</authname><surname>Gu</surname><given-name>Wenchao</given-name><initials>W.</initials><afid>115246050</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56645350200</author-url><authid>56645350200</authid><authname>Yuan Y.</authname><surname>Yuan</surname><given-name>Yaping</given-name><initials>Y.</initials><afid>115246050</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56645242800</author-url><authid>56645242800</authid><authname>Yang H.</authname><surname>Yang</surname><given-name>Hua</given-name><initials>H.</initials><afid>115246050</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56645789800</author-url><authid>56645789800</authid><authname>Qi G.</authname><surname>Qi</surname><given-name>Guangsheng</given-name><initials>G.</initials><afid>115246050</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56645396600</author-url><authid>56645396600</authid><authname>Jin X.</authname><surname>Jin</surname><given-name>Xiaoyan</given-name><initials>X.</initials><afid>60073453</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56645309200</author-url><authid>56645309200</authid><authname>Yan J.</authname><surname>Yan</surname><given-name>Jin</given-name><initials>J.</initials><afid>60073453</afid></author><authkeywords>Chronic obstructive pulmonary disease | Citation analysis | Top-cited</authkeywords><intid>1535954632</intid><source-id>6200180178</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929617951"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929617951?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929617951&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929617951&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0891584915001598"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929617951</prism:url><dc:identifier>SCOPUS_ID:84929617951</dc:identifier><eid>2-s2.0-84929617951</eid><dc:title>The involvement of p62-Keap1-Nrf2 antioxidative signaling pathway and JNK in the protection of natural flavonoid quercetin against hepatotoxicity</dc:title><dc:creator>Ji L.</dc:creator><prism:publicationName>Free Radical Biology and Medicine</prism:publicationName><prism:issn>08915849</prism:issn><prism:eIssn>18734596</prism:eIssn><prism:volume>85</prism:volume><prism:pageRange>12-33</prism:pageRange><prism:coverDate>2015-05-25</prism:coverDate><prism:coverDisplayDate>25 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.freeradbiomed.2015.03.035</prism:doi><pii>S0891584915001598</pii><dc:description>© 2015 Elsevier Inc.All rights reserved. Quercetin, one of the most abundant dietary flavonoids, is reported to have protective function against various hepatotoxicant-induced hepatotoxicity. The present study aims to investigate the critical role of the nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidative signaling pathway in the protection of quercetin against hepatotoxicity. Quercetin prevented the cytotoxicity induced by a variety of hepatotoxicants including clivorine (Cliv), acetaminophen (APAP), ethanol, carbon tetrachloride (CCl&lt;inf&gt;4&lt;/inf&gt;), and toosendanin (TSN) in human normal liver L-02 cells. Quercetin induced the nuclear translocation of Nrf2, along with the increased expression of the antioxidant responsive element (ARE)-dependent genes like catalytic or modify subunit of glutamate-cysteine ligase (GCLC/GCLM), and heme oxygenase-1 (HO-1). In addition, the HO-1 inhibitor zinc protoporphyrin (ZnPP) and the GCL inhibitor L-buthionine-(S,R)-sulfoximine (BSO) both reduced the hepatoprotection induced by quercetin. Quercetin had no effect on kelch-like ECH-associated protein-1(Keap1) expression, but molecular docking results indicated the potential interaction of quercetin with the Nrf2-binding site in Keap1 protein. Quercetin increased the expression of p62, and p62 siRNA decreased quercetin-induced hepatoprotection. Quercetin induced the activation of c-Jun N-terminal kinase (JNK) in hepatocytes. JNK inhibitor SP600125 and JNK siRNA both reduced quercetin-induced hepatoprotection. SP600125 and JNK siRNA decreased the increased p62 expression induced by quercetin. In addition, SP600125 also decreased the increased mRNA and protein expression of GCLC, GCLM, and HO-1 induced by quercetin. Taken together, our present study demonstrates that quercetin prevents hepatotoxicity by inducing p62 expression, inhibiting the binding of Keap1 to Nrf2, and thus leading to the increased expression of antioxidative genes dependent on Nrf2. Meanwhile, our study indicates that JNK plays some regulation in this process.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010170</affiliation-url><afid>60010170</afid><affilname>Shanghai University of Traditional Chinese Medicine</affilname><name-variant>Shanghai University of Traditional Chinese Medicine</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010170</affiliation-url><afid>60010170</afid><affilname>Shanghai University of Traditional Chinese Medicine</affilname><name-variant>Shanghai University of Traditional Chinese Medicine</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7201378010</author-url><authid>7201378010</authid><authname>Ji L.</authname><surname>Ji</surname><given-name>Li Li</given-name><initials>L.L.</initials><afid>60010170</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36191266800</author-url><authid>36191266800</authid><authname>Sheng Y.</authname><surname>Sheng</surname><given-name>Yu Chen</given-name><initials>Y.C.</initials><afid>60010170</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7403007378</author-url><authid>7403007378</authid><authname>Zheng Z.</authname><surname>Zheng</surname><given-name>Zhi Yong</given-name><initials>Z.Y.</initials><afid>60010170</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7401640600</author-url><authid>7401640600</authid><authname>Shi L.</authname><surname>Shi</surname><given-name>Liang</given-name><initials>L.</initials><afid>60010170</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55140583100</author-url><authid>55140583100</authid><authname>Wang Z.</authname><surname>Wang</surname><given-name>Zheng Tao</given-name><initials>Z.T.</initials><afid>60010170</afid></author><authkeywords>Hepatotoxicity | JNK | Keap1 | Nrf2 | p62 | Quercetin</authkeywords><intid>2035983562</intid><source-id>15095</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924559960"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924559960?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924559960&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924559960&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0928098715000627"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924559960</prism:url><dc:identifier>SCOPUS_ID:84924559960</dc:identifier><eid>2-s2.0-84924559960</eid><dc:title>Effect of continuous vs pulsed iontophoresis of treprostinil on skin blood flow</dc:title><dc:creator>Kotzki S.</dc:creator><prism:publicationName>European Journal of Pharmaceutical Sciences</prism:publicationName><prism:issn>09280987</prism:issn><prism:eIssn>18790720</prism:eIssn><prism:volume>72</prism:volume><prism:pageRange>21-26</prism:pageRange><prism:coverDate>2015-05-25</prism:coverDate><prism:coverDisplayDate>25 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejps.2015.02.012</prism:doi><pii>S0928098715000627</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Introduction Systemic sclerosis (SSc) is a rare disease affecting digital microcirculation, leading to finger ulcers and in some cases to amputation. Prostacyclin analogues can be used intravenously but their therapeutic effect is counterbalanced by potentially serious vasodilatation-induced side effects. Iontophoresis of treprostinil could be a promising local therapeutic alternative for SSc-related digital ulcers. Iontophoretic drug delivery is complex, and whether continuous or periodic current should be used remains debated. The objective of the present work is to compare the effect of continuous vs pulsed iontophoresis of treprostinil in rats. Materials and methods Treprostinil (0.64 mM and 0.064 mM) and NaCl were delivered by cathodal iontophoresis onto the hindquarters of anaesthetized rats. Three protocols delivering the same quantity of current were compared: one was continuous (100 μA during 20 min) and two were periodic (B: twenty 1-min cycles with 200 μA during 30 s followed by 30 s Off; and C: twenty 1-min cycles with 600 μA during 10 s followed by 50 s Off) (n = 8 for each protocol with each concentration). Skin blood flow was quantified using laser Doppler imaging and skin resistance was calculated with Ohm's law. Results All protocols induced a significant increase in skin blood flow. At the lower concentration (0.064 mM treprostinil) the pulsed 10/50 sequence significantly enhanced cutaneous blood flow (Table 1; Fig. 1B) compared to continuous iontophoresis or the 30/30 sequence. We noted that the pulsed iontophoresis of NaCl (10/50 sequence) induced a significant early increase in cutaneous blood flow in comparison with continuous iontophoresis. Skin resistance measures were negatively correlated with current intensity delivered. Conclusion In conclusion, pulsed iontophoresis of treprostinil with a 10 s/50 s (On/Off) protocol at 600 μA increases the efficacy of iontophoresis at 0.064 mM but not at a tenfold higher concentration. Pulsed iontophoresis could be used to optimize treprostinil iontophoresis, to provide similar efficacy with decreased costs, and should now be tested on humans.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005851</affiliation-url><afid>60005851</afid><affilname>Centre Hospitalier Universitaire de Grenoble</affilname><name-variant>CHU</name-variant><affiliation-city>Grenoble</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000905</affiliation-url><afid>60000905</afid><affilname>Inserm</affilname><name-variant>INSERM</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60104653</affiliation-url><afid>60104653</afid><affilname>Universite Grenoble Alpes</affilname><name-variant>Univ. Grenoble Alpes</name-variant><affiliation-city>Grenoble</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55827444600</author-url><authid>55827444600</authid><authname>Kotzki S.</authname><surname>Kotzki</surname><given-name>Sylvain</given-name><initials>S.</initials><afid>60005851</afid><afid>60104653</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55827444600</author-url><authid>55827444600</authid><authname>Kotzki S.</authname><surname>Kotzki</surname><given-name>Sylvain</given-name><initials>S.</initials><afid>60005851</afid><afid>60104653</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24512490500</author-url><authid>24512490500</authid><authname>Roustit M.</authname><surname>Roustit</surname><given-name>Matthieu</given-name><initials>M.</initials><afid>60005851</afid><afid>60000905</afid><afid>60104653</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24512490500</author-url><authid>24512490500</authid><authname>Roustit M.</authname><surname>Roustit</surname><given-name>Matthieu</given-name><initials>M.</initials><afid>60005851</afid><afid>60000905</afid><afid>60104653</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24512490500</author-url><authid>24512490500</authid><authname>Roustit M.</authname><surname>Roustit</surname><given-name>Matthieu</given-name><initials>M.</initials><afid>60005851</afid><afid>60000905</afid><afid>60104653</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8898327100</author-url><authid>8898327100</authid><authname>Arnaud C.</authname><surname>Arnaud</surname><given-name>Claire</given-name><initials>C.</initials><afid>60000905</afid><afid>60104653</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8898327100</author-url><authid>8898327100</authid><authname>Arnaud C.</authname><surname>Arnaud</surname><given-name>Claire</given-name><initials>C.</initials><afid>60000905</afid><afid>60104653</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701848028</author-url><authid>6701848028</authid><authname>Godin-Ribuot D.</authname><surname>Godin-Ribuot</surname><given-name>Diane</given-name><initials>D.</initials><afid>60000905</afid><afid>60104653</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701848028</author-url><authid>6701848028</authid><authname>Godin-Ribuot D.</authname><surname>Godin-Ribuot</surname><given-name>Diane</given-name><initials>D.</initials><afid>60000905</afid><afid>60104653</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005878536</author-url><authid>7005878536</authid><authname>Cracowski J.</authname><surname>Cracowski</surname><given-name>Jean Luc</given-name><initials>J.L.</initials><afid>60005851</afid><afid>60000905</afid><afid>60104653</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005878536</author-url><authid>7005878536</authid><authname>Cracowski J.</authname><surname>Cracowski</surname><given-name>Jean Luc</given-name><initials>J.L.</initials><afid>60005851</afid><afid>60000905</afid><afid>60104653</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005878536</author-url><authid>7005878536</authid><authname>Cracowski J.</authname><surname>Cracowski</surname><given-name>Jean Luc</given-name><initials>J.L.</initials><afid>60005851</afid><afid>60000905</afid><afid>60104653</afid></author><authkeywords>Continuous current | Iontophoresis | Microcirculation | Periodic current | Prostacyclin</authkeywords><intid>1035163544</intid><source-id>21331</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929630662"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929630662?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929630662&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929630662&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0040403915001641"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929630662</prism:url><dc:identifier>SCOPUS_ID:84929630662</dc:identifier><eid>2-s2.0-84929630662</eid><dc:title>Studies on the regio- and diastereo-selective epoxidation of daphnanes and tiglianes</dc:title><dc:creator>Boudreault P.</dc:creator><prism:publicationName>Tetrahedron Letters</prism:publicationName><prism:issn>00404039</prism:issn><prism:eIssn>18733581</prism:eIssn><prism:volume>56</prism:volume><prism:issueIdentifier>23</prism:issueIdentifier><prism:pageRange>3423-3427</prism:pageRange><prism:coverDate>2015-05-25</prism:coverDate><prism:coverDisplayDate>25 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.tetlet.2015.01.126</prism:doi><pii>S0040403915001641</pii><dc:description>© 2015 Elsevier Ltd.All rights reserved. Daphnanes and tiglianes are diterpenes with a shared tricyclic 5-7-6 ring system. Many members exhibit significant biological activities often associated with protein kinase C signaling. Many of these natural products (∼100) have a C6-C7 α-epoxide whose influence on biological activity is little studied. Using the more readily available phorbol ester PDBu as a test substrate, we report an efficient, and potentially general, α-epoxidation method based on a vanadium-catalyzed asymmetric epoxidation with bishydroxamic acid (BHA) ligands.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012708</affiliation-url><afid>60012708</afid><affilname>Stanford University</affilname><name-variant>Stanford University</name-variant><affiliation-city>Palo Alto</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012708</affiliation-url><afid>60012708</afid><affilname>Stanford University</affilname><name-variant>Stanford University</name-variant><affiliation-city>Palo Alto</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56652092400</author-url><authid>56652092400</authid><authname>Boudreault P.</authname><surname>Boudreault</surname><given-name>Pierre Luc</given-name><initials>P.L.</initials><afid>60012708</afid><afid>60012708</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56652092400</author-url><authid>56652092400</authid><authname>Boudreault P.</authname><surname>Boudreault</surname><given-name>Pierre Luc</given-name><initials>P.L.</initials><afid>60012708</afid><afid>60012708</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56652327400</author-url><authid>56652327400</authid><authname>Mattler J.</authname><surname>Mattler</surname><given-name>Jennifer K.</given-name><initials>J.K.</initials><afid>60012708</afid><afid>60012708</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56652327400</author-url><authid>56652327400</authid><authname>Mattler J.</authname><surname>Mattler</surname><given-name>Jennifer K.</given-name><initials>J.K.</initials><afid>60012708</afid><afid>60012708</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7102386745</author-url><authid>7102386745</authid><authname>Wender P.</authname><surname>Wender</surname><given-name>Paul A.</given-name><initials>P.A.</initials><afid>60012708</afid><afid>60012708</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7102386745</author-url><authid>7102386745</authid><authname>Wender P.</authname><surname>Wender</surname><given-name>Paul A.</given-name><initials>P.A.</initials><afid>60012708</afid><afid>60012708</afid></author><authkeywords>Daphnane | Epoxidation | Protein kinase C | Tigliane</authkeywords><intid>2035983134</intid><source-id>26514</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929649792"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929649792?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929649792&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929649792&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929649792</prism:url><dc:identifier>SCOPUS_ID:84929649792</dc:identifier><eid>2-s2.0-84929649792</eid><dc:title>Impact of cardiac resynchronization therapy-defibrillator implantation on the association between body mass index and prognosis in patients with heart failure</dc:title><dc:creator>Yanagisawa S.</dc:creator><prism:publicationName>Journal of Interventional Cardiac Electrophysiology</prism:publicationName><prism:issn>1383875X</prism:issn><prism:eIssn>15728595</prism:eIssn><prism:coverDate>2015-05-24</prism:coverDate><prism:coverDisplayDate>24 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10840-015-0015-3</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Purpose: This study aimed to examine the association between body mass index (BMI) and prognosis in heart failure patients after cardiac resynchronization therapy-defibrillator (CRT-D) implantation. Methods: We retrospectively investigated 125 patients (33 overweight [BMI ≥25 kg/m&lt;sup&gt;2&lt;/sup&gt;], 75 normal weight [BMI 18.5–24.9 kg/m&lt;sup&gt;2&lt;/sup&gt;], and 17 underweight patients [BMI &lt;18.5 kg/m&lt;sup&gt;2&lt;/sup&gt;]) who underwent CRT-D implantation. The clinical outcome endpoints were all-cause death and appropriate shock therapy. Results: During the follow-up period (mean 3.1 ± 1.8 years), 23 patients died (1 [3.0 %] overweight, 17 [22.7 %] normal weight, and 5 [29.4 %] underweight patients), and appropriate shock events were observed in 14 patients (2 [6.1 %] overweight, 10 [13.3 %] normal weight, and 2 [11.8 %] underweight patients). All patients survived shock therapy. After adjusting for confounding factors, overweight patients had significantly fewer outcomes relating to all-cause death and appropriate shock events (hazard ratio 0.27, 95 % confidence interval 0.08–0.91, p = 0.034) than normal weight patients. However, the prognostic difference between overweight and normal weight patients could be diminished as a result of the successful shock therapies (p = 0.067). Additionally, prognosis did not differ between overweight and normal weight patients among the responders, but did differ among the non-responders. The underweight patients had a poorer prognosis after CRT-D implantation compared with the other groups. Conclusions: Although high BMI was associated with better outcomes among heart failure patients with CRT-D implantations, the difference in the prognosis between overweight and normal weight patients was reduced because of defibrillator therapy and the improvement in cardiac function provided by CRT-D implantation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020492</affiliation-url><afid>60020492</afid><affilname>Nagoya University School of Medicine</affilname><name-variant>Nagoya University School of Medicine</name-variant><affiliation-city>Nagoya</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100768065</affiliation-url><afid>100768065</afid><affilname>Chunichi Hospital</affilname><name-variant>Chunichi Hospital</name-variant><affiliation-city>Nagoya</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000264</affiliation-url><afid>60000264</afid><affilname>Nagoya University</affilname><name-variant>Nagoya University</name-variant><affiliation-city>Nagoya</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:27568226800</author-url><authid>27568226800</authid><authname>Yanagisawa S.</authname><surname>Yanagisawa</surname><given-name>Satoshi</given-name><initials>S.</initials><afid>60020492</afid><afid>100768065</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:27568226800</author-url><authid>27568226800</authid><authname>Yanagisawa S.</authname><surname>Yanagisawa</surname><given-name>Satoshi</given-name><initials>S.</initials><afid>60020492</afid><afid>100768065</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6701828486</author-url><authid>6701828486</authid><authname>Inden Y.</authname><surname>Inden</surname><given-name>Yasuya</given-name><initials>Y.</initials><afid>60020492</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23486796000</author-url><authid>23486796000</authid><authname>Shimano M.</authname><surname>Shimano</surname><given-name>Masayuki</given-name><initials>M.</initials><afid>60020492</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56478036700</author-url><authid>56478036700</authid><authname>Yoshida N.</authname><surname>Yoshida</surname><given-name>Naoki</given-name><initials>N.</initials><afid>60020492</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55619315066</author-url><authid>55619315066</authid><authname>Ishikawa S.</authname><surname>Ishikawa</surname><given-name>Shinji</given-name><initials>S.</initials><afid>60020492</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56477809000</author-url><authid>56477809000</authid><authname>Kato H.</authname><surname>Kato</surname><given-name>Hiroyuki</given-name><initials>H.</initials><afid>60020492</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56400310900</author-url><authid>56400310900</authid><authname>Okumura S.</authname><surname>Okumura</surname><given-name>Satoshi</given-name><initials>S.</initials><afid>60020492</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56652228500</author-url><authid>56652228500</authid><authname>Miyoshi-Fujii A.</authname><surname>Miyoshi-Fujii</surname><given-name>Aya</given-name><initials>A.</initials><afid>60020492</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56478167400</author-url><authid>56478167400</authid><authname>Nagao T.</authname><surname>Nagao</surname><given-name>Tomoyuki</given-name><initials>T.</initials><afid>60020492</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55903777400</author-url><authid>55903777400</authid><authname>Yamamoto T.</authname><surname>Yamamoto</surname><given-name>Toshihiko</given-name><initials>T.</initials><afid>60020492</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56651763300</author-url><authid>56651763300</authid><authname>Mizutani Y.</authname><surname>Mizutani</surname><given-name>Yoshiaki</given-name><initials>Y.</initials><afid>60020492</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56651405400</author-url><authid>56651405400</authid><authname>Ito T.</authname><surname>Ito</surname><given-name>Tadahiro</given-name><initials>T.</initials><afid>60020492</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56651721600</author-url><authid>56651721600</authid><authname>Hirai M.</authname><surname>Hirai</surname><given-name>Makoto</given-name><initials>M.</initials><afid>60000264</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7005982703</author-url><authid>7005982703</authid><authname>Murohara T.</authname><surname>Murohara</surname><given-name>Toyoaki</given-name><initials>T.</initials><afid>60020492</afid></author><authkeywords>Body mass index | Cardiac resynchronization therapy | Heart failure | Implantable cardioverter-defibrillator | Obesity paradox | Prognosis</authkeywords><intid>1535988742</intid><source-id>23879</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929631110"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929631110?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929631110&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929631110&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929631110</prism:url><dc:identifier>SCOPUS_ID:84929631110</dc:identifier><eid>2-s2.0-84929631110</eid><dc:title>Comparison of I-123 MIBG planar imaging and SPECT for the detection of decreased heart uptake in Parkinson disease</dc:title><dc:creator>Oh J.</dc:creator><prism:publicationName>Journal of Neural Transmission</prism:publicationName><prism:issn>03009564</prism:issn><prism:eIssn>14351463</prism:eIssn><prism:coverDate>2015-05-24</prism:coverDate><prism:coverDisplayDate>24 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00702-015-1409-1</prism:doi><dc:description>© 2015 Springer-Verlag Wien Decreased myocardial uptake of I-123 metaiodobenzylguanidine (MIBG) is an important finding for diagnosis of Parkinson’s disease (PD). This study compared I-123 MIBG SPECT and planar imaging with regard to their diagnostic yield for PD. 52 clinically diagnosed PD patients who also had decreased striatal uptake on FP-CIT PET/CT were enrolled. 16 normal controls were also included. All underwent cardiac MIBG planar scintigraphy and SPECT separately. Myocardial I-123 MIBG uptake was interpreted on planar and SPECT/CT images separately by visual and quantitative analysis. The final diagnosis was made by consensus between two readers. Kappa analyses were performed to determine inter-observer agreement for both methods. Sensitivity, specificity, and accuracy were compared with McNemar’s test. The sensitivity, specificity, and accuracy were 84.6, 100, and 88.2 % for planar images and 96.2, 100 and 97.1 % for SPECT, respectively, with a significant difference between the two imaging methods (p &lt; 0.031). All inter-observer agreements were almost perfect (planar scintigraphy: κ = 0.82; SPECT: κ = 0.93). Heart-to-mediastinum ratios from PD patients with negative planar and positive SPECT scans (group A) and patients with positive planar and positive SPECT scans (group B) were 1.69 ± 0.16 (1.59–1.85) and 1.41 ± 0.15 (1.20–1.53), respectively, and showed significant difference (p = 0.023). Lung-to-mediastinum ratios for groups A and B were 2.16 ± 0.20 (1.96–2.37) and 1.6 ± 0.19 (1.3–1.78), respectively, and were significantly higher in the former (p = 0.001). I-123 MIBG SPECT has a significantly higher diagnostic performance for PD than planar images. Increased lung uptake may cause false-negative results on planar imaging.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003087</affiliation-url><afid>60003087</afid><affilname>The Catholic University of Korea</affilname><name-variant>The Catholic University of Korea</name-variant><affiliation-city>Youngdeungpo</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003087</affiliation-url><afid>60003087</afid><affilname>The Catholic University of Korea</affilname><name-variant>The Catholic University of Korea</name-variant><affiliation-city>Youngdeungpo</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56648734500</author-url><authid>56648734500</authid><authname>Oh J.</authname><surname>Oh</surname><given-name>Jin Kyoung</given-name><initials>J.K.</initials><afid>60003087</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55568444500</author-url><authid>55568444500</authid><authname>Choi E.</authname><surname>Choi</surname><given-name>Eun Kyoung</given-name><initials>E.K.</initials><afid>60003087</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:15846670500</author-url><authid>15846670500</authid><authname>Song I.</authname><surname>Song</surname><given-name>In Uk</given-name><initials>I.U.</initials><afid>60003087</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56651745900</author-url><authid>56651745900</authid><authname>Kim J.</authname><surname>Kim</surname><given-name>Joong Seok</given-name><initials>J.S.</initials><afid>60003087</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:48661765900</author-url><authid>48661765900</authid><authname>Chung Y.</authname><surname>Chung</surname><given-name>Yong An</given-name><initials>Y.A.</initials><afid>60003087</afid></author><authkeywords>I-123 MIBG | Parkinson's disease | Planar scintigraphy | Sensitivity and specificity | SPECT</authkeywords><intid>1535989639</intid><source-id>15300154855</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929643584"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929643584?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929643584&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929643584&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929643584</prism:url><dc:identifier>SCOPUS_ID:84929643584</dc:identifier><eid>2-s2.0-84929643584</eid><dc:title>Diabetes, prediabetes and cardiovascular risk | Diabetes, Prädiabetes und kardiovaskuläres Risiko</dc:title><dc:creator>Stratmann B.</dc:creator><prism:publicationName>Internist</prism:publicationName><prism:issn>00209554</prism:issn><prism:eIssn>14321289</prism:eIssn><prism:coverDate>2015-05-24</prism:coverDate><prism:coverDisplayDate>24 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00108-015-3681-4</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg Cardiovascular diseases continue to be the mainstay in morbidity and mortality in modern society with diabetes mellitus being a known risk factor for coronary artery disease, heart failure and vascular events. Most patients present with a combination of hypertension, dyslipoproteinaemia and (pre)diabetic metabolism potentiating the risk. From the perspective of organ damage two of three patients with coronary artery disease present with impaired glucose metabolism. In case of myocardial infarction 25–28 % of patients do not present with impaired glucose metabolism. Women are more often affected than men and exhibit a more severe outcome, if diagnoses of vascular events and diabetes occur in parallel. Atrial fibrillation and heart failure are significantly associated with diabetes and significantly confer to the overall prognosis. Epidemiologically, the risk for vascular events is closely associated with the glucose burden of the affected patient.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005322</affiliation-url><afid>60005322</afid><affilname>Universitat Bochum</affilname><name-variant>Ruhr-Universität Bochum</name-variant><affiliation-city>Bochum</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35235411000</author-url><authid>35235411000</authid><authname>Stratmann B.</authname><surname>Stratmann</surname><given-name>B.</given-name><initials>B.</initials><afid>60005322</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004391906</author-url><authid>7004391906</authid><authname>Tschoepe D.</authname><surname>Tschoepe</surname><given-name>D.</given-name><initials>D.</initials><afid>60005322</afid></author><authkeywords>Atrial fibrillation | Coronary disease | Diabetes mellitus | Glucose metabolism disorders | Heart failure</authkeywords><intid>1785990844</intid><source-id>78004</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929630340"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929630340?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929630340&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929630340&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929630340</prism:url><dc:identifier>SCOPUS_ID:84929630340</dc:identifier><eid>2-s2.0-84929630340</eid><dc:title>Exercise intensity modulates the change in cerebral blood flow following aerobic exercise in chronic stroke</dc:title><dc:creator>Robertson A.</dc:creator><prism:publicationName>Experimental Brain Research</prism:publicationName><prism:issn>00144819</prism:issn><prism:eIssn>14321106</prism:eIssn><prism:coverDate>2015-05-24</prism:coverDate><prism:coverDisplayDate>24 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00221-015-4317-6</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg The mechanisms supporting functional improvement by aerobic exercise following stroke remain incompletely understood. This study investigated how cycling intensity and aerobic fitness influence cerebral blood flow (CBF) following a single exercise session. Thirteen community-living stroke survivors performed 20 min of semi-recumbent cycling at low and moderate intensities (40–50 and 60–70 % of heart rate reserve, respectively) as determined from an exercise stress test. CBF was quantified by arterial spin labeling MRI at baseline, as well as 30 and 50 min post-exercise. An intensity-dependent effect was observed in the right post-central and supramarginal gyri up to 50 min after exercise (uncorrected p &lt; 0.005, cluster size ≥10). Regional CBF was increased 18 ± 17 % and reduced 8 ± 12 % following moderate- and low-intensity cycling, respectively. In contrast, CBF changes were similar between sessions in the right lentiform nucleus and mid-frontal gyrus, as well as the left temporal and parietal gyri. Aerobic fitness was directly related to posterior cingulate and thalamic CBF, and inversely related to precuneal CBF at rest (R&lt;sup&gt;2&lt;/sup&gt; ≥ 0.75); however, no relationship between fitness and the post-exercise change in CBF was observed. Divergent changes in regional CBF were observed in the right parietal cortex following low- and moderate-intensity exercise, which suggests that intensity of prescribed exercise may be useful in optimizing rehabilitation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016849</affiliation-url><afid>60016849</afid><affilname>University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014468</affiliation-url><afid>60014468</afid><affilname>University Health Network University of Toronto</affilname><name-variant>University Health Network</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014171</affiliation-url><afid>60014171</afid><affilname>University of Waterloo</affilname><name-variant>Univ of Waterloo</name-variant><affiliation-city>Waterloo</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016849</affiliation-url><afid>60016849</afid><affilname>University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26640737200</author-url><authid>26640737200</authid><authname>Robertson A.</authname><surname>Robertson</surname><given-name>Andrew D.</given-name><initials>A.D.</initials><afid>60016849</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37092656700</author-url><authid>37092656700</authid><authname>Crane D.</authname><surname>Crane</surname><given-name>David E.</given-name><initials>D.E.</initials><afid>60016849</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56085451600</author-url><authid>56085451600</authid><authname>Rajab A.</authname><surname>Rajab</surname><given-name>A. Saeed</given-name><initials>A.S.</initials><afid>60016849</afid><afid>60016849</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56085451600</author-url><authid>56085451600</authid><authname>Rajab A.</authname><surname>Rajab</surname><given-name>A. Saeed</given-name><initials>A.S.</initials><afid>60016849</afid><afid>60016849</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:16043825600</author-url><authid>16043825600</authid><authname>Swardfager W.</authname><surname>Swardfager</surname><given-name>Walter</given-name><initials>W.</initials><afid>60016849</afid><afid>60014468</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:16043825600</author-url><authid>16043825600</authid><authname>Swardfager W.</authname><surname>Swardfager</surname><given-name>Walter</given-name><initials>W.</initials><afid>60016849</afid><afid>60014468</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:26434763900</author-url><authid>26434763900</authid><authname>Marzolini S.</authname><surname>Marzolini</surname><given-name>Susan</given-name><initials>S.</initials><afid>60016849</afid><afid>60014468</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:26434763900</author-url><authid>26434763900</authid><authname>Marzolini S.</authname><surname>Marzolini</surname><given-name>Susan</given-name><initials>S.</initials><afid>60016849</afid><afid>60014468</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55198955500</author-url><authid>55198955500</authid><authname>Shirzadi Z.</authname><surname>Shirzadi</surname><given-name>Zahra</given-name><initials>Z.</initials><afid>60016849</afid><afid>60016849</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55198955500</author-url><authid>55198955500</authid><authname>Shirzadi Z.</authname><surname>Shirzadi</surname><given-name>Zahra</given-name><initials>Z.</initials><afid>60016849</afid><afid>60016849</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:16203486700</author-url><authid>16203486700</authid><authname>Middleton L.</authname><surname>Middleton</surname><given-name>Laura E.</given-name><initials>L.E.</initials><afid>60016849</afid><afid>60014468</afid><afid>60014171</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:16203486700</author-url><authid>16203486700</authid><authname>Middleton L.</authname><surname>Middleton</surname><given-name>Laura E.</given-name><initials>L.E.</initials><afid>60016849</afid><afid>60014468</afid><afid>60014171</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:16203486700</author-url><authid>16203486700</authid><authname>Middleton L.</authname><surname>Middleton</surname><given-name>Laura E.</given-name><initials>L.E.</initials><afid>60016849</afid><afid>60014468</afid><afid>60014171</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56601786900</author-url><authid>56601786900</authid><authname>MacIntosh B.</authname><surname>MacIntosh</surname><given-name>Bradley J.</given-name><initials>B.J.</initials><afid>60016849</afid><afid>60016849</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56601786900</author-url><authid>56601786900</authid><authname>MacIntosh B.</authname><surname>MacIntosh</surname><given-name>Bradley J.</given-name><initials>B.J.</initials><afid>60016849</afid><afid>60016849</afid></author><authkeywords>Aerobic fitness | Arterial spin labeling | Basal ganglia | Exercise | Parietal cortex | Stroke</authkeywords><intid>535990330</intid><source-id>15585</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929646203"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929646203?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929646203&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929646203&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929646203</prism:url><dc:identifier>SCOPUS_ID:84929646203</dc:identifier><eid>2-s2.0-84929646203</eid><dc:title>Review and status report of pediatric left ventricular systolic strain and strain rate nomograms</dc:title><dc:creator>Cantinotti M.</dc:creator><prism:publicationName>Heart Failure Reviews</prism:publicationName><prism:issn>13824147</prism:issn><prism:eIssn>15737322</prism:eIssn><prism:coverDate>2015-05-24</prism:coverDate><prism:coverDisplayDate>24 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10741-015-9492-9</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Interest in strain (ε) and strain rate (SR) for the assessment of pediatric left ventricular (LV) myocardial function has increased. However, the strengths and limitations of published pediatric nomograms have not been critically evaluated. A literature search was conducted accessing the National Library of Medicine using the keywords myocardial velocity, strain, strain rate, pediatric, reference values, and nomograms. Adding the following keywords, the results were further refined: neonates, infants, adolescents, range/intervals, and speckle tracking. Ten published studies evaluating myocardial velocities, ε, or SR nomograms were analyzed. Sample sizes were limited in most of these studies, particularly in terms of neonates. Heterogeneous methods—tissue Doppler imaging, two- and three-dimensional speckle tracking—were used to perform and normalize measurements. Although most studies adjusted measurements for age, classification by specific age subgroups varied. Few studies addressed the relationships of ε and SR measurements to body size and heart rate. Data have been generally expressed by mean values and standard deviations; Z scores and percentiles that are commonly employed for pediatric echocardiographic quantification have been never used. Reference values for ε and SR were found to be reproducible in older children; however, they varied significantly in neonates and infants. Pediatric nomograms for LV ε and SR are limited by (a) small sample sizes, (b) inconsistent methodology used for derivation and normalization, and (c) scarcity of neonatal data. Some of the studies demonstrate reproducible patterns for systolic deformation in older children. There is need for comprehensive nomograms of myocardial ε and SR involving a large population of normal children obtained using standardized methodology.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112648166</affiliation-url><afid>112648166</afid><affilname>Ospedale Del Cuore G. Pasquinucci</affilname><name-variant>Ospedale Del Cuore G. Pasquinucci</name-variant><affiliation-city>Massa</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009071</affiliation-url><afid>60009071</afid><affilname>Istituto di Fisiologia Clinica del CNR</affilname><name-variant>CNR</name-variant><affiliation-city>Pisa</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016261</affiliation-url><afid>60016261</afid><affilname>University of Nebraska Medical Center</affilname><name-variant>University of Nebraska Medical Center</name-variant><affiliation-city>Omaha</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:16244162100</author-url><authid>16244162100</authid><authname>Cantinotti M.</authname><surname>Cantinotti</surname><given-name>Massimiliano</given-name><initials>M.</initials><afid>112648166</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56606394800</author-url><authid>56606394800</authid><authname>Kutty S.</authname><surname>Kutty</surname><given-name>Shelby</given-name><initials>S.</initials><afid>60016261</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36550305800</author-url><authid>36550305800</authid><authname>Giordano R.</authname><surname>Giordano</surname><given-name>Raffaele</given-name><initials>R.</initials><afid>112648166</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603329140</author-url><authid>6603329140</authid><authname>Assanta N.</authname><surname>Assanta</surname><given-name>Nadia</given-name><initials>N.</initials><afid>112648166</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701461576</author-url><authid>6701461576</authid><authname>Murzi B.</authname><surname>Murzi</surname><given-name>Bruno</given-name><initials>B.</initials><afid>112648166</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35867053500</author-url><authid>35867053500</authid><authname>Crocetti M.</authname><surname>Crocetti</surname><given-name>Maura</given-name><initials>M.</initials><afid>112648166</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55539769200</author-url><authid>55539769200</authid><authname>Marotta M.</authname><surname>Marotta</surname><given-name>Marco</given-name><initials>M.</initials><afid>112648166</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7004086794</author-url><authid>7004086794</authid><authname>Iervasi G.</authname><surname>Iervasi</surname><given-name>Giorgio</given-name><initials>G.</initials><afid>60009071</afid></author><authkeywords>Children | Echocardiography | Myocardial strain</authkeywords><intid>1535989773</intid><source-id>23234</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929629674"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929629674?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929629674&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929629674&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929629674</prism:url><dc:identifier>SCOPUS_ID:84929629674</dc:identifier><eid>2-s2.0-84929629674</eid><dc:title>Prenatally buprenorphine-exposed children: health to 3 years of age</dc:title><dc:creator>Kivistö K.</dc:creator><prism:publicationName>European Journal of Pediatrics</prism:publicationName><prism:issn>03406199</prism:issn><prism:eIssn>14321076</prism:eIssn><prism:coverDate>2015-05-24</prism:coverDate><prism:coverDisplayDate>24 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00431-015-2562-0</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg Our prospective study is among the first attempts to examine the health of prenatally buprenorphine-exposed children after neonatal age and to determine the types of child maltreatment in this patient group. The study population included 102 children (61/41 Caucasian males/females) who had a positive urine screen for buprenorphine as a newborn. In addition to buprenorphine, the children were also prenatally exposed to other substances. The data were collected by pediatricians in follow-up visits until 3 years of age and from medical records. Ten prenatally buprenorphine-exposed children (10 %) had some birth defect. The study children had slightly more major anomalies than newborns on average in Finland (3.4 %). Eye disorders (nystagmus, opticus atrophy, and strabismus) occurred in 11 % of children. One child was diagnosed with hepatitis C transmission. One female died of sudden infant death syndrome (SIDS), and one male died of congenital heart disease. Pediatricians submitted altogether 70 reports to child welfare services of suspected maltreatment. Of these reports, 45 (64 %) involved medical neglect. Physical abuse was suspected in four reports. Conclusion: We suggest that prenatally buprenorphine-exposed children have several types of problems with their health at toddler age and that they are susceptible to child maltreatment, especially to medical neglect.(Table presented.)</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016987</affiliation-url><afid>60016987</afid><affilname>Helsinki University Central Hospital</affilname><name-variant>Helsinki University Central Hospital</name-variant><affiliation-city>Helsinki</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002952</affiliation-url><afid>60002952</afid><affilname>Helsingin Yliopisto</affilname><name-variant>University of Helsinki</name-variant><affiliation-city>Helsinki</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:17340668300</author-url><authid>17340668300</authid><authname>Kivistö K.</authname><surname>Kivistö</surname><given-name>Kaisa</given-name><initials>K.</initials><afid>60016987</afid><afid>60002952</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:17340668300</author-url><authid>17340668300</authid><authname>Kivistö K.</authname><surname>Kivistö</surname><given-name>Kaisa</given-name><initials>K.</initials><afid>60016987</afid><afid>60002952</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602703499</author-url><authid>6602703499</authid><authname>Tupola S.</authname><surname>Tupola</surname><given-name>Sarimari</given-name><initials>S.</initials><afid>60016987</afid><afid>60002952</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602703499</author-url><authid>6602703499</authid><authname>Tupola S.</authname><surname>Tupola</surname><given-name>Sarimari</given-name><initials>S.</initials><afid>60016987</afid><afid>60002952</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6603632765</author-url><authid>6603632765</authid><authname>Kivitie-Kallio S.</authname><surname>Kivitie-Kallio</surname><given-name>Satu</given-name><initials>S.</initials><afid>60016987</afid><afid>60002952</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6603632765</author-url><authid>6603632765</authid><authname>Kivitie-Kallio S.</authname><surname>Kivitie-Kallio</surname><given-name>Satu</given-name><initials>S.</initials><afid>60016987</afid><afid>60002952</afid></author><authkeywords>Birth defects | Buprenorphine | Child maltreatment | Health | Prenatal opioid exposure | Preschool child</authkeywords><intid>535990241</intid><source-id>15006</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929650391"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929650391?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929650391&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929650391&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929650391</prism:url><dc:identifier>SCOPUS_ID:84929650391</dc:identifier><eid>2-s2.0-84929650391</eid><dc:title>Predicting factors of health-related quality of life in octogenarians: a 3-year follow-up longitudinal study</dc:title><dc:creator>Ferrer A.</dc:creator><prism:publicationName>Quality of Life Research</prism:publicationName><prism:issn>09629343</prism:issn><prism:coverDate>2015-05-24</prism:coverDate><prism:coverDisplayDate>24 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s11136-015-1004-9</prism:doi><dc:description>© 2015 Springer International Publishing Switzerland Purpose: The proportion of very old people is rising, and so, describing their health-related quality of life (HRQoL) is an important point of interest. The aim of this study was to analyse the predictive factors on HRQoL throughout a 3-year follow-up period, in a community-based cohort of octogenarian people. Methods: From 290 subjects aged 85 and over, sociodemographic and geriatric data, including levels of frailty phenotype assessment, and HRQoL using the EuroQol 5D3L (EQ-5D) instrument were collected. A longitudinal analysis was performed by generalized estimating equations (jointly testing the bivariate effect of variables and its time dependence) and regression mixed models to evaluate the adjusted effect of variables on HRQoL after a 3-year follow-up. Results: In the EQ-5D baseline assessment, the average visual analogue self-rating scale value was 63.82 (SD ± 19.45), the EQ-5D index was 0.67 (0.34) and the most significant issues were pain/discomfort (61.2 %), depression (45.3 %) and mobility (44.6 %). The third year index was 0.55 (0.38). Independent predictive factors of a lower HRQoL identified by the regression mixed models were female gender (marginal effect ME = −0.101; p = 0.003), being pre-frail (ME = −0.142; p = 0.011) or frail (ME = −0.071; p = 0.030), having heart failure (ME = −0.081; p = 0.037) and having a high social risk score (ME = −0.020; p = 0.015). In contrast, higher functional status (ME = 0.050; p &lt; 0.001) and nutritional score (ME = 0.013; p = 0.011) appeared to be predictive factors of an enhanced HRQoL. The adjusted effect of “time of follow-up” had no statistical significance.Conclusion: Frail individuals at baseline have a significant lower HRQoL, whereas a higher functional status and nutritional status are independent predicting factors of an enhanced HRQoL after 3 years of follow-up. These findings may encourage clinicians in order to asses HRQoL.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112566962</affiliation-url><afid>112566962</afid><affilname>Primary Healthcare Centre El Plà CAP-I</affilname><name-variant>Primary Healthcare Centre ‘El Plà’ CAP-I</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60080989</affiliation-url><afid>60080989</afid><affilname>Institut dInvestigacio en Atencio Primaria Jordi Go</affilname><name-variant>IDIAP Jordi Gol</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011805</affiliation-url><afid>60011805</afid><affilname>Hospital Universitari de Bellvitge</affilname><name-variant>Hospital Universitari de Bellvitge</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025847</affiliation-url><afid>60025847</afid><affilname>Institut d'Investigacio Biomedica de Bellvitge</affilname><name-variant>Bellvitge Biomedical Research Institute (IDIBELL)</name-variant><affiliation-city>Hospitalet de Llobregat</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Direcció d’Atencío Primària Costa de Ponent</affilname><name-variant>Unitat de Suport a la Recerca Metropolitana Sud</name-variant><affiliation-city>Cornellà de Llobregat</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115261720</affiliation-url><afid>115261720</afid><affilname>Primary Healthcare Centre Just Oliveres</affilname><name-variant>Primary Healthcare Centre Just Oliveres</name-variant><affiliation-city>Hospitalet de Llobregat</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068651</affiliation-url><afid>60068651</afid><affilname>Universitat Internacional de Catalunya</affilname><name-variant>Universitat Internacional de Catalunya</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60085099</affiliation-url><afid>60085099</afid><affilname>CIBER Epidemiologia Y Salud Publica</affilname><name-variant>CIBER Epidemiología y Salud Pública (CIBERESP)</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8345202500</author-url><authid>8345202500</authid><authname>Ferrer A.</authname><surname>Ferrer</surname><given-name>Assumpta</given-name><initials>A.</initials><afid>112566962</afid><afid>60080989</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8345202500</author-url><authid>8345202500</authid><authname>Ferrer A.</authname><surname>Ferrer</surname><given-name>Assumpta</given-name><initials>A.</initials><afid>112566962</afid><afid>60080989</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24474137200</author-url><authid>24474137200</authid><authname>Formiga F.</authname><surname>Formiga</surname><given-name>Francesc</given-name><initials>F.</initials><afid>60011805</afid><afid>60025847</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24474137200</author-url><authid>24474137200</authid><authname>Formiga F.</authname><surname>Formiga</surname><given-name>Francesc</given-name><initials>F.</initials><afid>60011805</afid><afid>60025847</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35762806900</author-url><authid>35762806900</authid><authname>Cunillera O.</authname><surname>Cunillera</surname><given-name>Oriol</given-name><initials>O.</initials><afid>60080989</afid><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35762806900</author-url><authid>35762806900</authid><authname>Cunillera O.</authname><surname>Cunillera</surname><given-name>Oriol</given-name><initials>O.</initials><afid>60080989</afid><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:54880215000</author-url><authid>54880215000</authid><authname>Megido M.</authname><surname>Megido</surname><given-name>M. Jesús</given-name><initials>M.J.</initials><afid>60080989</afid><afid>115261720</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:54880215000</author-url><authid>54880215000</authid><authname>Megido M.</authname><surname>Megido</surname><given-name>M. Jesús</given-name><initials>M.J.</initials><afid>60080989</afid><afid>115261720</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004014299</author-url><authid>7004014299</authid><authname>Corbella X.</authname><surname>Corbella</surname><given-name>Xavier</given-name><initials>X.</initials><afid>60011805</afid><afid>60025847</afid><afid>60068651</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004014299</author-url><authid>7004014299</authid><authname>Corbella X.</authname><surname>Corbella</surname><given-name>Xavier</given-name><initials>X.</initials><afid>60011805</afid><afid>60025847</afid><afid>60068651</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004014299</author-url><authid>7004014299</authid><authname>Corbella X.</authname><surname>Corbella</surname><given-name>Xavier</given-name><initials>X.</initials><afid>60011805</afid><afid>60025847</afid><afid>60068651</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36930578100</author-url><authid>36930578100</authid><authname>Almeda J.</authname><surname>Almeda</surname><given-name>Jesús</given-name><initials>J.</initials><afid>60080989</afid><afid/><afid>60085099</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36930578100</author-url><authid>36930578100</authid><authname>Almeda J.</authname><surname>Almeda</surname><given-name>Jesús</given-name><initials>J.</initials><afid>60080989</afid><afid/><afid>60085099</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36930578100</author-url><authid>36930578100</authid><authname>Almeda J.</authname><surname>Almeda</surname><given-name>Jesús</given-name><initials>J.</initials><afid>60080989</afid><afid/><afid>60085099</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56652301800</author-url><authid>56652301800</authid><authname>Octabaix Study Group </authname><surname>Octabaix Study Group</surname><given-name/><initials/><afid>112566962</afid><afid>60080989</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56652301800</author-url><authid>56652301800</authid><authname>Octabaix Study Group </authname><surname>Octabaix Study Group</surname><given-name/><initials/><afid>112566962</afid><afid>60080989</afid></author><authkeywords>Age 80 and older | Disability | Frailty | Health-related quality of life</authkeywords><intid>1535988623</intid><source-id>17732</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929646164"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929646164?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929646164&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929646164&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929646164</prism:url><dc:identifier>SCOPUS_ID:84929646164</dc:identifier><eid>2-s2.0-84929646164</eid><dc:title>Mesenchymal Stem Cells in IBD: unMaSCing Their Therapeutic Mechanisms</dc:title><dc:creator>Scaldaferri F.</dc:creator><prism:publicationName>Digestive Diseases and Sciences</prism:publicationName><prism:issn>01632116</prism:issn><prism:eIssn>15732568</prism:eIssn><prism:coverDate>2015-05-24</prism:coverDate><prism:coverDisplayDate>24 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10620-015-3724-7</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031984</affiliation-url><afid>60031984</afid><affilname>Universita Cattolica del Sacro Cuore, Rome</affilname><name-variant>Catholic University</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024876</affiliation-url><afid>60024876</afid><affilname>Istituto Clinico Humanitas</affilname><name-variant>Istituto Clinico Humanitas</name-variant><affiliation-city>Rozzano</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100528530</affiliation-url><afid>100528530</afid><affilname>Istituto Humanitas</affilname><name-variant>Humanitas University</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8222069100</author-url><authid>8222069100</authid><authname>Scaldaferri F.</authname><surname>Scaldaferri</surname><given-name>Franco</given-name><initials>F.</initials><afid>60031984</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602460425</author-url><authid>6602460425</authid><authname>Vetrano S.</authname><surname>Vetrano</surname><given-name>Stefania</given-name><initials>S.</initials><afid>60024876</afid><afid>100528530</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602460425</author-url><authid>6602460425</authid><authname>Vetrano S.</authname><surname>Vetrano</surname><given-name>Stefania</given-name><initials>S.</initials><afid>60024876</afid><afid>100528530</afid></author><intid>1535988461</intid><source-id>28300</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930078996"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930078996?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930078996&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930078996&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930078996</prism:url><dc:identifier>SCOPUS_ID:84930078996</dc:identifier><eid>2-s2.0-84930078996</eid><dc:title>Increased plasma BMP-2 levels are associated with atherosclerosis burden and coronary calcification in type 2 diabetic patients</dc:title><dc:creator>Zhang M.</dc:creator><prism:publicationName>Cardiovascular Diabetology</prism:publicationName><prism:eIssn>14752840</prism:eIssn><prism:coverDate>2015-05-24</prism:coverDate><prism:coverDisplayDate>May 24, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12933-015-0214-3</prism:doi><dc:description>© 2015 Zhang et al.; licensee BioMed Central. Background: Although Bone morphogenetic protein-2 (BMP-2) is a known mediator of bone regeneration and vascular calcification, to date no study has investigated the relationship between BMP-2 and type 2 diabetes mellitus (T2DM) and its possible role in coronary artery disease (CAD). The purpose of this study is to evaluate the relationship of BMP-2 with atherosclerosis and calcification in patients with T2DM. Methods: 124 subjects were enrolled in this study: 29 patients with T2DM and CAD; 26 patients with T2DM and without CAD; 36 patients with CAD and without T2DMand 34 without T2DM or CAD (control group). Severity of coronary lesions was assessed using coronary angiography and intravascular ultrasound (IVUS). Plasma BMP-2 levels were quantified using a commercially available ELISA kit. Results: Compared to the control group, the mean plasma BMP-2 level was significantly higher in T2DM patients with or without CAD (20.1 ± 1.7 or 19.3 ± 1.5 pg/ml, vs 17.2 ± 3.3 pg/ml, P &lt;0.001). In a multivariable linear regression analysis, both T2DM and CAD were significantly and positively associated with BMP-2 (Estimate, 0.249; standard error (SE), 0.063; p &lt;0.0001; Estimate, 0.400; SE, 0.06; p &lt;0.0001). Plasma BMP-2 was also strongly correlated with glycosylated hemoglobin A1c (HbA1c) (Spearman ρ = -0.31; p = 0.0005). SYNTAX score was also significantly associated with BMP-2 (Spearman ρ = 0.46; p = 0.0002). Using the results from IVUS, plasma BMP-2 levels were shown to positively correlate with plaque burden (Spearman ρ = 0.38, P = 0.002) and plaque calcification (Spearman ρ =0.44, P = 0.0003) and to negatively correlate with lumen volume (Spearman ρ =0.31, P = 0.01). Conclusions: Our study demonstrates that patients with T2DM had higher circulating levels of BMP-2 than normal controls. Plasma BMP-2 levels correlated positively with plaque burden and calcification in patients with T2DM.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026707</affiliation-url><afid>60026707</afid><affilname>Capital Medical University China</affilname><name-variant>Capital Medical University</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100823150</affiliation-url><afid>100823150</afid><affilname>Beijing Institute of Heart</affilname><name-variant>Institute of Heart</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026829</affiliation-url><afid>60026829</afid><affilname>Mayo Medical School</affilname><name-variant>Mayo Clinic College of Medicine</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025278</affiliation-url><afid>60025278</afid><affilname>Tsinghua University</affilname><name-variant>Tsinghua University</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030623</affiliation-url><afid>60030623</afid><affilname>Rutgers, The State University of New Jersey</affilname><name-variant>Rutgers University</name-variant><affiliation-city>New Brunswick</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032083</affiliation-url><afid>60032083</afid><affilname>University at Buffalo State University of New York</affilname><name-variant>State University of New York at Buffalo</name-variant><affiliation-city>Buffalo</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55595470600</author-url><authid>55595470600</authid><authname>Zhang M.</authname><surname>Zhang</surname><given-name>Ming</given-name><initials>M.</initials><afid>60026707</afid><afid>100823150</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55595470600</author-url><authid>55595470600</authid><authname>Zhang M.</authname><surname>Zhang</surname><given-name>Ming</given-name><initials>M.</initials><afid>60026707</afid><afid>100823150</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56458671800</author-url><authid>56458671800</authid><authname>Sara J.</authname><surname>Sara</surname><given-name>Jaskanwal Deep</given-name><initials>J.D.</initials><afid>60026829</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56660054600</author-url><authid>56660054600</authid><authname>Wang F.</authname><surname>Wang</surname><given-name>Fei long</given-name><initials>F.l.</initials><afid>60026829</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56096598600</author-url><authid>56096598600</authid><authname>Liu L.</authname><surname>Liu</surname><given-name>Li Ping</given-name><initials>L.P.</initials><afid>60025278</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56637558900</author-url><authid>56637558900</authid><authname>Su L.</authname><surname>Su</surname><given-name>Li Xiao</given-name><initials>L.X.</initials><afid>60030623</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56660470100</author-url><authid>56660470100</authid><authname>Zhe J.</authname><surname>Zhe</surname><given-name>Jing</given-name><initials>J.</initials><afid>60032083</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56070246300</author-url><authid>56070246300</authid><authname>Wu X.</authname><surname>Wu</surname><given-name>Xi</given-name><initials>X.</initials><afid>60026707</afid><afid>100823150</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56070246300</author-url><authid>56070246300</authid><authname>Wu X.</authname><surname>Wu</surname><given-name>Xi</given-name><initials>X.</initials><afid>60026707</afid><afid>100823150</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55705811000</author-url><authid>55705811000</authid><authname>Liu J.</authname><surname>Liu</surname><given-name>Jing hua</given-name><initials>J.h.</initials><afid>60026707</afid></author><authkeywords>Bone morphogenetic protein-2 | Coronary artery disease | Plaque burden and plaque calcification | Type 2 diabetes mellitus (T2DM)</authkeywords><intid>536061721</intid><source-id>25441</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930198133"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930198133?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930198133&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930198133&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930198133</prism:url><dc:identifier>SCOPUS_ID:84930198133</dc:identifier><eid>2-s2.0-84930198133</eid><dc:title>Frailty assessment based on trunk kinematic parameters during walking</dc:title><dc:creator>Martínez-Ramírez A.</dc:creator><prism:publicationName>Journal of NeuroEngineering and Rehabilitation</prism:publicationName><prism:eIssn>17430003</prism:eIssn><prism:volume>12</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-24</prism:coverDate><prism:coverDisplayDate>24 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s12984-015-0040-6</prism:doi><dc:description>© 2015 Martinez Ramirez et al.; licensee BioMed Central. Background: Physical frailty has become the center of attention of basic, clinical and demographic research due to its incidence level and gravity of adverse outcomes with age. Frailty syndrome is estimated to affect 20 % of the population older than 75 years. Thus, one of the greatest current challenges in this field is to identify parameters that can discriminate between vulnerable and robust subjects. Gait analysis has been widely used to predict frailty. The aim of the present study was to investigate whether a collection of parameters extracted from the trunk acceleration signals could provide additional accurate information about frailty syndrome. Methods: A total of 718 subjects from an elderly population (319 males, 399 females; age: 75.4±6.1 years, mass: 71.8±12.4 kg, height: 158±6 cm) volunteered to participate in this study. The subjects completed a 3-m walk test at their own gait velocity. Kinematic data were acquired from a tri-axial inertial orientation tracker. Findings: The spatio-temporal and frequency parameters measured in this study with an inertial sensor are related to gait disorders and showed significant differences among groups (frail, pre-frail and robust). A selection of those parameters improves frailty classification obtained to gait velocity, compared to classification model based on gait velocity solely. Interpretation: Gait parameters simultaneously used with gait velocity are able to provide useful information for a more accurate frailty classification. Moreover, this technique could improve the early detection of pre-frail status, allowing clinicians to perform measurements outside of a laboratory environment with the potential to prescribe a treatment for reversing their physical decline.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033019</affiliation-url><afid>60033019</afid><affilname>Universidad Publica de Navarra</affilname><name-variant>Univ. Pública de Navarra</name-variant><affiliation-city>Pamplona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004199</affiliation-url><afid>60004199</afid><affilname>Hospital Universitario de Getafe</affilname><name-variant>Hospital Universitario de Getafe</name-variant><affiliation-city>Getafe</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024133</affiliation-url><afid>60024133</afid><affilname>Complejo Hospitalario de Toledo</affilname><name-variant>Hospital Virgen de la Salud</name-variant><affiliation-city>Toledo</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033019</affiliation-url><afid>60033019</afid><affilname>Universidad Publica de Navarra</affilname><name-variant>Univ. Pública de Navarra</name-variant><affiliation-city>Pamplona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25222073500</author-url><authid>25222073500</authid><authname>Martínez-Ramírez A.</authname><surname>Martínez-Ramírez</surname><given-name>Alicia</given-name><initials>A.</initials><afid>60033019</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56655118600</author-url><authid>56655118600</authid><authname>Martinikorena I.</authname><surname>Martinikorena</surname><given-name>Ion</given-name><initials>I.</initials><afid>60033019</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7401734073</author-url><authid>7401734073</authid><authname>Gómez M.</authname><surname>Gómez</surname><given-name>Marisol</given-name><initials>M.</initials><afid>60033019</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6506853386</author-url><authid>6506853386</authid><authname>Lecumberri P.</authname><surname>Lecumberri</surname><given-name>Pablo</given-name><initials>P.</initials><afid>60033019</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55807235300</author-url><authid>55807235300</authid><authname>Millor N.</authname><surname>Millor</surname><given-name>Nora</given-name><initials>N.</initials><afid>60033019</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004685679</author-url><authid>7004685679</authid><authname>Rodríguez-Mañas L.</authname><surname>Rodríguez-Mañas</surname><given-name>Leocadio</given-name><initials>L.</initials><afid>60004199</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004052133</author-url><authid>7004052133</authid><authname>García García F.</authname><surname>García García</surname><given-name>Francisco José</given-name><initials>F.J.</initials><afid>60024133</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7103111881</author-url><authid>7103111881</authid><authname>Izquierdo M.</authname><surname>Izquierdo</surname><given-name>Mikel</given-name><initials>M.</initials><afid>60033019</afid></author><authkeywords>Frailty, Accelerometer | Gait Analysis | Gyroscope | Inertial Sensors</authkeywords><intid>1536087423</intid><article-number>40</article-number><source-id>130095</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930213062"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930213062?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930213062&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930213062&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930213062</prism:url><dc:identifier>SCOPUS_ID:84930213062</dc:identifier><eid>2-s2.0-84930213062</eid><dc:title>Tetrapleura tetraptera spice attenuates high-carbohydrate, high-fat diet-induced obese and type 2 diabetic rats with metabolic syndrome features</dc:title><dc:creator>Kuate D.</dc:creator><prism:publicationName>Lipids in Health and Disease</prism:publicationName><prism:eIssn>1476511X</prism:eIssn><prism:volume>14</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-24</prism:coverDate><prism:coverDisplayDate>24 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s12944-015-0051-0</prism:doi><dc:description>© 2015 Kuate et al.; licensee BioMed Central. Background: Tetrapleura tetraptera, a seasoning and nutritive spice is also used in western African folk medicine in the management of wide variety of diseases including diabetes, inflammation and hypertension. Flavonoids and saponins are some abundant secondary metabolic constituents in the fruits of this plant. This study aimed at evaluating the potential therapeutic action of the polyphenol-rich hydroethanolic extract (HET) of this fruit in experimentally induced obese and type 2 diabetic rats (T2DM) with characteristic metabolic syndrome (MetS). Methods: MetS was induced in rats by high-carbohydrate, high-fat diet and administration of low-dose streptozotocin. Then different oral doses of HET (200 and 400 mg/kg) were administered to T2DM rats for 28 days. A standard antidiabetic drug, metformin (300 mg/kg), was used for comparison. The body weight, systolic blood pressure, oxidative stress and metabolic parameters were then assessed to evaluate the effect of HET on MetS. Results: HET reduced weight gain, fasting blood glucose and plasma insulin levels as well as homeostasis model assessment of insulin resistance (HOMA-IR) and alleviated obesity and T2DM associated oxidative stress and hypertension in rats. Moreover, a significantly hypolipidemic property and an attenuation of liver injury and tissue steatosis was observed after HET administration. HET further demonstrated its anti-inflammation effect via down regulation of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP), leptin and an increase in adiponectin. The HET exhibited dose-dependent effects which were comparable to that of metformin. Conclusions: The present study thereby demonstrates the anti-insulin resistance, antilipidemic, anti-obesity, hypotensive and anti-inflammatory properties of HET; hence it has the potential to be further developed for the management of MetS such as obesity, T2DM and hypertension.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000906</affiliation-url><afid>60000906</afid><affilname>Universiti Sains Malaysia</affilname><name-variant>Universiti Sains Malaysia</name-variant><affiliation-city>Seri Ampangan</affiliation-city><affiliation-country>Malaysia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070932</affiliation-url><afid>60070932</afid><affilname>University of Dschang</affilname><name-variant>University of Dschang</name-variant><affiliation-city>Dschang</affiliation-city><affiliation-country>Cameroon</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070926</affiliation-url><afid>60070926</afid><affilname>University of Buea</affilname><name-variant>University of Buea</name-variant><affiliation-city>Buea</affiliation-city><affiliation-country>Cameroon</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14626252300</author-url><authid>14626252300</authid><authname>Kuate D.</authname><surname>Kuate</surname><given-name>Dieudonne</given-name><initials>D.</initials><afid>60000906</afid><afid>60070932</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14626252300</author-url><authid>14626252300</authid><authname>Kuate D.</authname><surname>Kuate</surname><given-name>Dieudonne</given-name><initials>D.</initials><afid>60000906</afid><afid>60070932</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662853000</author-url><authid>56662853000</authid><authname>Kengne A.</authname><surname>Kengne</surname><given-name>Anne Pascale Nouemsi</given-name><initials>A.P.N.</initials><afid>60070932</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56662193500</author-url><authid>56662193500</authid><authname>Biapa C.</authname><surname>Biapa</surname><given-name>Cabral Prosper Nya</given-name><initials>C.P.N.</initials><afid>60070932</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56663235100</author-url><authid>56663235100</authid><authname>Azantsa B.</authname><surname>Azantsa</surname><given-name>Boris Gabin Kingue</given-name><initials>B.G.K.</initials><afid>60070926</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6505511234</author-url><authid>6505511234</authid><authname>Wan Muda W.</authname><surname>Wan Muda</surname><given-name>Wan Abdul Manan Bin</given-name><initials>W.A.M.B.</initials><afid>60000906</afid></author><authkeywords>High-carbohydrate high-fat diet | Inflammation | Metabolic syndrome | Obesity | Tetrapleura tetraptera | Type 2 diabetes</authkeywords><intid>1786087537</intid><article-number>50</article-number><source-id>14126</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929649781"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929649781?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929649781&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929649781&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929649781</prism:url><dc:identifier>SCOPUS_ID:84929649781</dc:identifier><eid>2-s2.0-84929649781</eid><dc:title>The effects of remodeling with heart failure on mode of initiation of ventricular fibrillation and its spatiotemporal organization</dc:title><dc:creator>Everett T.</dc:creator><prism:publicationName>Journal of Interventional Cardiac Electrophysiology</prism:publicationName><prism:issn>1383875X</prism:issn><prism:eIssn>15728595</prism:eIssn><prism:coverDate>2015-05-23</prism:coverDate><prism:coverDisplayDate>23 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10840-015-0016-2</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Purpose: The effect of the heart failure substrate on the initiation of ventricular fibrillation (VF) and its resulting mechanism is not known. The objective of this study was to determine the effects of substrate on VF initiation and its spatiotemporal organization in the heart failure model. Methods: Optical action potentials were recorded from LV wedge preparations either from structurally normal hearts (control, n = 11) or from congestive heart failure (CHF; n = 7), at the epicardial surface, endocardial surface which included a papillary muscle, and a transmural cross section. Action potential duration (APD&lt;inf&gt;80&lt;/inf&gt;) was determined, and VF was initiated. A fast Fourier transform was calculated, and the dominant frequency (DF) was determined. Results: The CHF group showed increased VF vulnerability (69 vs 26 %, p &lt; 0.03), and every mapped surface showed an APD&lt;inf&gt;80&lt;/inf&gt; gradient which included islands of higher APDs on the transmural surface (M cells) which was not observed in controls. VF in the CHF group was characterized by stable, discrete, high-DF areas that correlated to either foci or spiral waves located on the transmural surface at the site of the papillary muscle. Overall, the top 10 % of DFs correlated to an APD of 101 ms while the bottom 10 % of DFs correlated to an APD of 126 ms (p &lt; 0.01). Conclusions: In the CHF model, APD gradients correlated with an increased vulnerability to VF, and the highest stable DFs were located on the transmural surface which was not seen in controls. This indicates that the CHF substrate creates unique APD and DF characteristics.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021947</affiliation-url><afid>60021947</afid><affilname>Indiana University School of Medicine Indianapolis</affilname><name-variant>Indiana University School of Medicine</name-variant><affiliation-city>Indianapolis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023691</affiliation-url><afid>60023691</afid><affilname>University of California, San Francisco</affilname><name-variant>University of California, San Francisco</name-variant><affiliation-city>San Francisco</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55666921500</author-url><authid>55666921500</authid><authname>Everett T.</authname><surname>Everett</surname><given-name>Thomas H.</given-name><initials>T.H.</initials><afid>60021947</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36022363100</author-url><authid>36022363100</authid><authname>Hulley G.</authname><surname>Hulley</surname><given-name>George S.</given-name><initials>G.S.</initials><afid>60023691</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56651222400</author-url><authid>56651222400</authid><authname>Lee K.</authname><surname>Lee</surname><given-name>Ken W.</given-name><initials>K.W.</initials><afid>60023691</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55987576800</author-url><authid>55987576800</authid><authname>Chang R.</authname><surname>Chang</surname><given-name>Roger</given-name><initials>R.</initials><afid>60023691</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35188019500</author-url><authid>35188019500</authid><authname>Wilson E.</authname><surname>Wilson</surname><given-name>Emily E.</given-name><initials>E.E.</initials><afid>60023691</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7006887967</author-url><authid>7006887967</authid><authname>Olgin J.</authname><surname>Olgin</surname><given-name>Jeffrey E.</given-name><initials>J.E.</initials><afid>60023691</afid></author><authkeywords>Alternans | Fourier analysis | Heart failure | Mapping | Ventricular fibrillation</authkeywords><intid>1035984983</intid><source-id>23879</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929688509"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929688509?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929688509&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929688509&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929688509</prism:url><dc:identifier>SCOPUS_ID:84929688509</dc:identifier><eid>2-s2.0-84929688509</eid><dc:title>Sex differences in heart rate variability: a longitudinal study in international elite cross-country skiers</dc:title><dc:creator>Schäfer D.</dc:creator><prism:publicationName>European Journal of Applied Physiology</prism:publicationName><prism:issn>14396319</prism:issn><prism:coverDate>2015-05-23</prism:coverDate><prism:coverDisplayDate>23 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00421-015-3190-0</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg Purpose: Exercise-related sudden cardiac deaths (SCD) occur with a striking male predominance. A higher sympathetic tone in men has been suggested as risk factor for SCD. Elite athletes have the highest risk for exercise-related SCD. We aimed to analyze the autonomic nervous system of elite cross-country skiers from Norway, Russia and Switzerland in supine position and after orthostatic challenge in various training periods (TP). Method: Measurements of heart rate variability (HRV) were performed on a weekly basis over 1 year using an orthostatic challenge test with controlled breathing. Main outcome parameters were the high-frequency power in supine position (HFsupine) as marker of cardiac parasympathetic activity and the low-frequency/high-frequency power ratio after orthostatic challenge (LF/HFstand) as marker of cardiac sympathetic activation. Training intensity and duration were recorded daily and expressed as training strain. The training year was divided into three TPs. An average of weekly HRV measurements was calculated for each TP. Result: Female (n = 19, VO&lt;inf&gt;2max&lt;/inf&gt; 62.0 ± 4.6 ml kg&lt;sup&gt;−1&lt;/sup&gt; min&lt;sup&gt;−1&lt;/sup&gt;, age 25.8 ± 4.3 years) and male (n = 16, VO&lt;inf&gt;2max&lt;/inf&gt; 74.3 ± 6.3 ml kg&lt;sup&gt;−1&lt;/sup&gt; min&lt;sup&gt;−1&lt;/sup&gt;, age 24.4 ± 4.2 years) athletes were included. Training strain was comparable between sexes (all p &gt; 0.05) and changed between TPs (all p &lt; 0.05) while no HRV parameters changed over time. There were no sex differences in HFsupine while the LF/HFstand was significantly higher in male athletes in all TPs. Conclusion: For a comparable amount of training, male athletes showed constantly higher markers of sympathetic activity after a provocation maneuver. This may explain part of the male predominance in sports-related SCD.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020486</affiliation-url><afid>60020486</afid><affilname>Universitat Bern</affilname><name-variant>University of Berne</name-variant><affiliation-city>Bern</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60105037</affiliation-url><afid>60105037</afid><affilname>Oslo University Hospital</affilname><name-variant>Oslo University Hospital</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069317</affiliation-url><afid>60069317</afid><affilname>Diakonhjemmet Sykehus</affilname><name-variant>Diakonhjemmet Hospital</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112821816</affiliation-url><afid>112821816</afid><affilname>Moscow Research and Practical Center</affilname><name-variant>Moscow Res. Pract. Ctr. Prev. D.A</name-variant><affiliation-city>Moscow</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113763193</affiliation-url><afid>113763193</afid><affilname>Swiss Olympic Medical Base</affilname><name-variant>Swiss Olympic Medical Base</name-variant><affiliation-city>Bern</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Polar Electro Oy</affilname><affiliation-city>Kempele</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56007783400</author-url><authid>56007783400</authid><authname>Schäfer D.</authname><surname>Schäfer</surname><given-name>Daniela</given-name><initials>D.</initials><afid>60020486</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55603922300</author-url><authid>55603922300</authid><authname>Gjerdalen G.</authname><surname>Gjerdalen</surname><given-name>Gard Filip</given-name><initials>G.F.</initials><afid>60105037</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005087052</author-url><authid>7005087052</authid><authname>Solberg E.</authname><surname>Solberg</surname><given-name>Erik Ekker</given-name><initials>E.E.</initials><afid>60069317</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56653303400</author-url><authid>56653303400</authid><authname>Khokhlova M.</authname><surname>Khokhlova</surname><given-name>Maria</given-name><initials>M.</initials><afid>112821816</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6506797694</author-url><authid>6506797694</authid><authname>Badtieva V.</authname><surname>Badtieva</surname><given-name>Victoria</given-name><initials>V.</initials><afid>112821816</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56606942400</author-url><authid>56606942400</authid><authname>Herzig D.</authname><surname>Herzig</surname><given-name>David</given-name><initials>D.</initials><afid>60020486</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56653334800</author-url><authid>56653334800</authid><authname>Trachsel L.</authname><surname>Trachsel</surname><given-name>Lukas Daniel</given-name><initials>L.D.</initials><afid>60020486</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56653308000</author-url><authid>56653308000</authid><authname>Noack P.</authname><surname>Noack</surname><given-name>Patrik</given-name><initials>P.</initials><afid>113763193</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56653378900</author-url><authid>56653378900</authid><authname>Karavirta L.</authname><surname>Karavirta</surname><given-name>Laura</given-name><initials>L.</initials><afid/></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55957598900</author-url><authid>55957598900</authid><authname>Eser P.</authname><surname>Eser</surname><given-name>Prisca</given-name><initials>P.</initials><afid>60020486</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:55835032800</author-url><authid>55835032800</authid><authname>Saner H.</authname><surname>Saner</surname><given-name>Hugo</given-name><initials>H.</initials><afid>60020486</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:24831282000</author-url><authid>24831282000</authid><authname>Wilhelm M.</authname><surname>Wilhelm</surname><given-name>Matthias</given-name><initials>M.</initials><afid>60020486</afid></author><authkeywords>Athletes | Autonomic nervous system | Endurance | Heart rate variability | Orthostatic test | Training</authkeywords><intid>1785998166</intid><source-id>23402</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929631261"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929631261?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929631261&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929631261&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929631261</prism:url><dc:identifier>SCOPUS_ID:84929631261</dc:identifier><eid>2-s2.0-84929631261</eid><dc:title>Knowledge on cardiac resynchronization therapy (CRT) | Sachkunde „Kardiale Resynchronisationstherapie (CRT)“</dc:title><dc:creator>Butter C.</dc:creator><prism:publicationName>Kardiologe</prism:publicationName><prism:issn>18649718</prism:issn><prism:eIssn>18649726</prism:eIssn><prism:coverDate>2015-05-23</prism:coverDate><prism:coverDisplayDate>23 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12181-015-0659-3</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg The listing of knowledge on cardiac resynchronization therapy (CRT) summarizes the theoretical knowledge required for the use of CRT in analogy to the listing of knowledge in pacemaker therapy and in implantable cardioverter defibrillator (ICD) therapy. Together with practical experience gained during in-house training and education, they form the prerequisites for a high quality utilization of CRT. Participation in courses on CRT require prior participation in courses on pacemaker therapy and ICD therapy. The listing includes specific knowledge of heart failure, bundle branch block in the ECG, echocardiography (including parameters of dyssynchrony), indications for CRT, coronary sinus anatomy, implantation, CRT device and electrode technology, and CRT follow-up, which are necessary to adequately apply CRT. Special emphasis lies on troubleshooting and translating theoretical knowledge into practice using clinical examples. Courses on pacemaker, ICD and CRT therapy complete the theoretical program to attain the certificate of special rhythmology.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:107653465</affiliation-url><afid>107653465</afid><affilname>Herzzentrum Brandenburg in Bernau</affilname><name-variant>Herzzentrum Bernau</name-variant><affiliation-city>Bernau</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003282</affiliation-url><afid>60003282</afid><affilname>Evangelisches Krankenhaus Bielefeld</affilname><name-variant>Evangelisches Krankenhaus Bielefeld</name-variant><affiliation-city>Bielefeld</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55866666600</author-url><authid>55866666600</authid><authname>Butter C.</authname><surname>Butter</surname><given-name>C.</given-name><initials>C.</initials><afid>107653465</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:17346496500</author-url><authid>17346496500</authid><authname>Seifert M.</authname><surname>Seifert</surname><given-name>M.</given-name><initials>M.</initials><afid>107653465</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005881304</author-url><authid>7005881304</authid><authname>Israel C.</authname><surname>Israel</surname><given-name>C. W.</given-name><initials>C.W.</initials><afid>60003282</afid></author><authkeywords>Device therapy | Further education | Heart failure | Special rhythmology | Troubleshooting</authkeywords><intid>1785989193</intid><source-id>19600157215</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929649167"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929649167?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929649167&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929649167&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929649167</prism:url><dc:identifier>SCOPUS_ID:84929649167</dc:identifier><eid>2-s2.0-84929649167</eid><dc:title>Long-term continuous positive airway pressure therapy improves cardiac autonomic tone during sleep in patients with obstructive sleep apnea</dc:title><dc:creator>Palma J.</dc:creator><prism:publicationName>Clinical Autonomic Research</prism:publicationName><prism:issn>09599851</prism:issn><prism:eIssn>16191560</prism:eIssn><prism:coverDate>2015-05-23</prism:coverDate><prism:coverDisplayDate>23 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10286-015-0297-7</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg Background: Cardiac autonomic tone after long-term continuous positive airway pressure therapy in patients with obstructive sleep apnea remains unexplored. Methods: Thirty patients with obstructive sleep apnea (14 with moderate and 16 with severe obstructive sleep apnea) were studied during a baseline polysomnographic study, after a full night of acute continuous positive airway pressure treatment, and after long-term (~2 years) chronic continuous positive airway pressure therapy. Twenty age- and gender-matched controls with baseline sleep study were selected for comparison purposes. Cross-spectral analysis and the low-frequency (LF) and high-frequency (HF) components of the heart rate variability were computed separately over 10-min ECG epochs during rapid eye movement sleep, non-rapid eye movement sleep, and wakefulness. Results: During the baseline study, obstructive sleep apnea patients exhibited increased LF, decreased HF, and increased LF/HF ratio during sleep when compared to controls. In a multiple regression model, the mean oxygen saturation explained the increased LF during rapid and non-rapid eye movement sleep in obstructive sleep apnea patients. Acute continuous positive airway pressure therapy decreased the LF modulations and the LF/HF ratio and increased the HF modulations during sleep in patients with severe obstructive sleep apnea. Long-term continuous positive airway pressure therapy decreased LF modulations and LF/HF ratio with increased HF modulations during sleep in patients with moderate and severe obstructive sleep apnea. Conclusions: Long-term continuous positive airway pressure reduces the sympathovagal imbalance in patients with moderate and severe obstructive sleep apnea, both during rapid and non-rapid eye movement sleep. Continuous positive airway pressure seems to exert its changes in cardiac autonomic modulation by decreasing the burden of nocturnal hypoxia.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020930</affiliation-url><afid>60020930</afid><affilname>Clinica Universitaria de Navarra</affilname><name-variant>Clinica Universitaria de Navarra</name-variant><affiliation-city>Pamplona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024541</affiliation-url><afid>60024541</afid><affilname>New York University School of Medicine</affilname><name-variant>New York Univ. School of Medicine</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020930</affiliation-url><afid>60020930</afid><affilname>Clinica Universitaria de Navarra</affilname><name-variant>Clinica Universitaria de Navarra</name-variant><affiliation-city>Pamplona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033320</affiliation-url><afid>60033320</afid><affilname>Universidad de Navarra</affilname><name-variant>Universidad de Navarra</name-variant><affiliation-city>Pamplona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35800102800</author-url><authid>35800102800</authid><authname>Palma J.</authname><surname>Palma</surname><given-name>Jose Alberto</given-name><initials>J.A.</initials><afid>60020930</afid><afid>60024541</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35800102800</author-url><authid>35800102800</authid><authname>Palma J.</authname><surname>Palma</surname><given-name>Jose Alberto</given-name><initials>J.A.</initials><afid>60020930</afid><afid>60024541</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:19635129100</author-url><authid>19635129100</authid><authname>Iriarte J.</authname><surname>Iriarte</surname><given-name>Jorge</given-name><initials>J.</initials><afid>60020930</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7202872787</author-url><authid>7202872787</authid><authname>Fernandez S.</authname><surname>Fernandez</surname><given-name>Secundino</given-name><initials>S.</initials><afid>60020930</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006326579</author-url><authid>7006326579</authid><authname>Alegre M.</authname><surname>Alegre</surname><given-name>Manuel</given-name><initials>M.</initials><afid>60020930</afid><afid>60033320</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006326579</author-url><authid>7006326579</authid><authname>Alegre M.</authname><surname>Alegre</surname><given-name>Manuel</given-name><initials>M.</initials><afid>60020930</afid><afid>60033320</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56128616200</author-url><authid>56128616200</authid><authname>Valencia M.</authname><surname>Valencia</surname><given-name>Miguel</given-name><initials>M.</initials><afid>60033320</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7006708505</author-url><authid>7006708505</authid><authname>Artieda J.</authname><surname>Artieda</surname><given-name>Julio</given-name><initials>J.</initials><afid>60020930</afid><afid>60033320</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7006708505</author-url><authid>7006708505</authid><authname>Artieda J.</authname><surname>Artieda</surname><given-name>Julio</given-name><initials>J.</initials><afid>60020930</afid><afid>60033320</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602313530</author-url><authid>6602313530</authid><authname>Urrestarazu E.</authname><surname>Urrestarazu</surname><given-name>Elena</given-name><initials>E.</initials><afid>60020930</afid></author><authkeywords>CPAP | Heart rate variability | Hypoxia | OSA | Sleep-disordered breathing</authkeywords><intid>2035984889</intid><source-id>29306</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929650563"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929650563?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929650563&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929650563&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929650563</prism:url><dc:identifier>SCOPUS_ID:84929650563</dc:identifier><eid>2-s2.0-84929650563</eid><dc:title>Short-Term Effects and Safety Analysis of Retrograde Autologous Blood Priming for Cardiopulmonary Bypass in Patients with Cardiac Valve Replacement Surgery</dc:title><dc:creator>Cheng M.</dc:creator><prism:publicationName>Cell Biochemistry and Biophysics</prism:publicationName><prism:issn>10859195</prism:issn><prism:coverDate>2015-05-23</prism:coverDate><prism:coverDisplayDate>23 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12013-015-0661-1</prism:doi><dc:description>© 2015 Springer Science+Business Media New York This randomized, double-blind study evaluated the short-term effects and safety of perioperative retrograde autologous priming (RAP) for cardiopulmonary bypass (CPB) in patients with cardiac replacement surgery to determine if this approach is a better substitute for crystal liquids priming in patients with valvular heart disease. We observed that RAP significantly decreased the actual priming volume, preserved the hematocrit and hemoglobin level during CPB to a certain degree, and decreased lactate accumulation in CPB period. Moreover, RAP lowered the volume of transfusion and dosage blood products. Thus, our results showed that RAP approach effectively improved tissue perfusion and lowered intraoperative Lac levels, by reducing the hemodilution, which safely and reliably improve the microcirculation perfusion.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073546</affiliation-url><afid>60073546</afid><affilname>Second Affiliated Hospital of Harbin Medical University</affilname><name-variant>The Second Affiliated Hospital of Harbin Medical University</name-variant><affiliation-city>Harbin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56651544200</author-url><authid>56651544200</authid><authname>Cheng M.</authname><surname>Cheng</surname><given-name>Ming</given-name><initials>M.</initials><afid>60073546</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56651876400</author-url><authid>56651876400</authid><authname>Li J.</authname><surname>Li</surname><given-name>Jun Quan</given-name><initials>J.Q.</initials><afid>60073546</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56651380000</author-url><authid>56651380000</authid><authname>Wu T.</authname><surname>Wu</surname><given-name>Tian Chi</given-name><initials>T.C.</initials><afid>60073546</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56651581300</author-url><authid>56651581300</authid><authname>Tian W.</authname><surname>Tian</surname><given-name>Wei Chen</given-name><initials>W.C.</initials><afid>60073546</afid></author><authkeywords>Cardiac valve replacement surgery | Cardiopulmonary bypass | Retrograde autologous blood priming | Valvular heart disease</authkeywords><intid>1785989446</intid><source-id>38819</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929649870"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929649870?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929649870&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929649870&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929649870</prism:url><dc:identifier>SCOPUS_ID:84929649870</dc:identifier><eid>2-s2.0-84929649870</eid><dc:title>Molecular diagnostics of cardiovascular diseases: Expert consensus statement by the German Cardiac Society (DGK) and the German Society of Pediatric Cardiology (DGPK) | Gendiagnostik bei kardiovaskulären Erkrankungen: Positionspapier der Deutschen Gesellschaft für Kardiologie (DGK) und der Deutschen Gesellschaft für Pädiatrische Kardiologie (DGPK)</dc:title><dc:creator>Schulze-Bahr E.</dc:creator><prism:publicationName>Kardiologe</prism:publicationName><prism:issn>18649718</prism:issn><prism:eIssn>18649726</prism:eIssn><prism:coverDate>2015-05-23</prism:coverDate><prism:coverDisplayDate>23 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12181-014-0636-2</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg Many cardiovascular disorders have a genetic background and occur in a familial setting. The majority belong to the group of rare diseases as their prevalence is low (&lt; 1:2000); only hypertrophic cardiomyopathy and familial hypercholesterolemia are more frequent. There is often a widespread genetic heterogeneity and complexity (5–15 specific genes causing the disease) and a private (family-specific) mutation associated with a variable phenotypic manifestation. Molecular diagnostics and genetic testing are helpful in cardiovascular diseases and may be useful for therapeutic and preventive decisions in addition to the diagnostic value. In particular, they allow early detection of disease development and better family counselling. This expert consensus statement provides useful information and recommendations on the importance of genetic testing in cardiac arrhythmia, cardiomyopathy, congenital heart and vessel diseases, rare cardiac syndromes as well as in familial hypercholesterolemia and for molecular autopsies, e.g. for sudden infant death syndrome (SIDS) and sudden unexpected death syndrome (SUDS).</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006490</affiliation-url><afid>60006490</afid><affilname>Universitatsklinikum Munster</affilname><name-variant>Universitätsklinikum Münster</name-variant><affiliation-city>Munster</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026245</affiliation-url><afid>60026245</afid><affilname>Charite - Universitatsmedizin Berlin</affilname><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023686</affiliation-url><afid>60023686</afid><affilname>Universitatsklinikum des Saarlandes Medizinische Fakultat der Universitat des Saarlandes</affilname><name-variant>University of Saarland</name-variant><affiliation-city>Homburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009113</affiliation-url><afid>60009113</afid><affilname>Deutsches Herzzentrum Berlin</affilname><name-variant>German Heart Institute</name-variant><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019722</affiliation-url><afid>60019722</afid><affilname>Technische Universitat Munchen</affilname><name-variant>Technische Universität München</name-variant><affiliation-city>Munich</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003988018</author-url><authid>7003988018</authid><authname>Schulze-Bahr E.</authname><surname>Schulze-Bahr</surname><given-name>E.</given-name><initials>E.</initials><afid>60006490</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56652111200</author-url><authid>56652111200</authid><authname>Klaassen S.</authname><surname>Klaassen</surname><given-name>S.</given-name><initials>S.</initials><afid>60026245</afid><afid>60009113</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56652111200</author-url><authid>56652111200</authid><authname>Klaassen S.</authname><surname>Klaassen</surname><given-name>S.</given-name><initials>S.</initials><afid>60026245</afid><afid>60009113</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56651990700</author-url><authid>56651990700</authid><authname>Abdul-Khaliq H.</authname><surname>Abdul-Khaliq</surname><given-name>H.</given-name><initials>H.</initials><afid>60023686</afid><afid>60009113</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56651990700</author-url><authid>56651990700</authid><authname>Abdul-Khaliq H.</authname><surname>Abdul-Khaliq</surname><given-name>H.</given-name><initials>H.</initials><afid>60023686</afid><afid>60009113</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006507139</author-url><authid>7006507139</authid><authname>Schunkert H.</authname><surname>Schunkert</surname><given-name>H.</given-name><initials>H.</initials><afid>60019722</afid></author><authkeywords>Arrhythmia | Cardiomyopathies | Genetics | Hypercholesterolemia | Mutation</authkeywords><intid>535990766</intid><source-id>19600157215</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929649523"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929649523?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929649523&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929649523&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929649523</prism:url><dc:identifier>SCOPUS_ID:84929649523</dc:identifier><eid>2-s2.0-84929649523</eid><dc:title>The Optimum Level of Sevoflurane in Pediatric Echocardiography</dc:title><dc:creator>Conghai F.</dc:creator><prism:publicationName>Cell Biochemistry and Biophysics</prism:publicationName><prism:issn>10859195</prism:issn><prism:coverDate>2015-05-23</prism:coverDate><prism:coverDisplayDate>23 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12013-015-0602-z</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Sevoflurane is shown to be safe and effective in pediatric echocardiography. This study explores the optimum level in pediatric echocardiography. One hundred and twenty children, with an age range of 35 days–3 years, were included in this study. The children with severe cyanotic congenital heart disease or severe pneumonia, which was Grade I or II according to the American College of Physicians Guideline Grading, were excluded. All children received the anesthesia with sevoflurane. The inhalation anesthesia level decreased from 2.5 to 1.0 %, with a decrement of 0.5 %. The induction time (T0), echocardiography time (T1), and time to awakening (T2) in each child were recorded, and the changes in the blood pressure, heart rate, breath, and oxygen saturation in each child were also monitored. The Ramsay scale scoring during anesthesia and the case number of failure in echocardiography in each group were also recorded. When the level of sevoflurane inhalation was maintained at 1.0 %, the childrens’ scores were low, including 8 incompliant children, and p &lt; 0.05 in comparison with other groups. The scores increased as the sevoflurane inhalation level increased. When the sevoflurane inhalation increased to 1.5 %, the children could sleep with stable blood pressure, and no dysphoria occurred during the echocardiography. When the sevoflurane inhalation level increased to 2.5 %, the Ramsay scores did not increase. However, the T2 significantly increased (p &lt; 0.05). The blood pressure and heart rate in each group did not change significantly. With the premise of safety and efficacy in children, the optimum level of sevoflurane in pediatric echocardiography was 1.5–2.0 %.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105148828</affiliation-url><afid>105148828</afid><affilname>Xuzhou Children's Hospital</affilname><name-variant>Xuzhou Children's Hospital</name-variant><affiliation-city>Xuzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56652254900</author-url><authid>56652254900</authid><authname>Conghai F.</authname><surname>Conghai</surname><given-name>Fan</given-name><initials>F.</initials><afid>105148828</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56652181300</author-url><authid>56652181300</authid><authname>Fengchao Z.</authname><surname>Fengchao</surname><given-name>Zhang</given-name><initials>Z.</initials><afid>105148828</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56652195900</author-url><authid>56652195900</authid><authname>Chengjing S.</authname><surname>Chengjing</surname><given-name>Shan</given-name><initials>S.</initials><afid>105148828</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56651502900</author-url><authid>56651502900</authid><authname>Cheng W.</authname><surname>Cheng</surname><given-name>Wen</given-name><initials>W.</initials><afid>105148828</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56652339400</author-url><authid>56652339400</authid><authname>Yunji W.</authname><surname>Yunji</surname><given-name>Wang</given-name><initials>W.</initials><afid>105148828</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56652096000</author-url><authid>56652096000</authid><authname>Xiaobo L.</authname><surname>Xiaobo</surname><given-name>Li</given-name><initials>L.</initials><afid>105148828</afid></author><authkeywords>Anesthesia | Echocardiography | Level | Sedation | Sevoflurane</authkeywords><intid>535989651</intid><source-id>38819</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929649735"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929649735?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929649735&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929649735&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929649735</prism:url><dc:identifier>SCOPUS_ID:84929649735</dc:identifier><eid>2-s2.0-84929649735</eid><dc:title>Embryogenic potential of immature zygotic embryos of Passiflora: a new advance for in vitro propagation without plant growth regulators</dc:title><dc:creator>Ferreira D.</dc:creator><prism:publicationName>Plant Cell, Tissue and Organ Culture</prism:publicationName><prism:issn>01676857</prism:issn><prism:coverDate>2015-05-23</prism:coverDate><prism:coverDisplayDate>23 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s11240-015-0796-1</prism:doi><dc:description>© 2015 Springer Science+Business Media Dordrecht In vitro strategies for Passiflora have been developed owing to its economic and ecological importance. However, plantlet regeneration through somatic embryogenesis has presented some problems, such as the reproducibility of the protocol and formation of abnormal embryos and plantlets. Thus, this study aimed to establish a protocol exploring the embryogenic potential of immature zygotic embryos (IZE) of the wild species Passiflora miniata Vanderpl. and Passiflora speciosa Gardn. Friable calli, which formed on the abaxial surface of the cotyledons, yielded globular, heart-shaped, torpedo and cotyledonary somatic embryos, characterising the embryogenic response as asynchronous. A high percentage of normal regenerants (90 %) was obtained from IZE in media lacking 2,4-dichlorophenoxyacetic acid (2,4-D) in comparison to the value of normal plantlets (60 %) regenerated from mature zygotic embryos inoculated in media with 2,4-D. This result demonstrates that IZE of P. miniata and P. speciosa possess sufficient levels of endogenous phytohormones to trigger a high rate of indirect somatic embryogenesis. All regenerated plantlets had the same genome size and chromosome number as the explant donor plants. Therefore, the indirect embryogenic pathway, employing IZE inoculated into media free of growth regulators, did not cause changes in the karyotype and morphology. Based on these results, IZE should be considered as explant for the establishment of somatic embryogenesis in other species. Besides, a new, reliable and relatively rapid protocol to recover plantlets of P. miniata and P. speciosa yielded several plants, which were acclimatised and used for ornamental purposes and breeding programs, and for reintroduction into biological reserves.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028426</affiliation-url><afid>60028426</afid><affilname>Universidade Federal do Espirito Santo</affilname><name-variant>Universidade Federal do Espírito Santo</name-variant><affiliation-city>Vitoria</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013918</affiliation-url><afid>60013918</afid><affilname>Universidade Federal de Vicosa</affilname><name-variant>Universidade Federal de Viçosa</name-variant><affiliation-city>Vicosa</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56651754300</author-url><authid>56651754300</authid><authname>Ferreira D.</authname><surname>Ferreira</surname><given-name>Darley Aparecido Tavares</given-name><initials>D.A.T.</initials><afid>60028426</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56651883100</author-url><authid>56651883100</authid><authname>Sattler M.</authname><surname>Sattler</surname><given-name>Mariana Cansian</given-name><initials>M.C.</initials><afid>60028426</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35616713800</author-url><authid>35616713800</authid><authname>Carvalho C.</authname><surname>Carvalho</surname><given-name>Carlos Roberto</given-name><initials>C.R.</initials><afid>60013918</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:54790533600</author-url><authid>54790533600</authid><authname>Clarindo W.</authname><surname>Clarindo</surname><given-name>Wellington Ronildo</given-name><initials>W.R.</initials><afid>60028426</afid></author><authkeywords>Auxin | Biotechnology | Conservation | Somatic embryogenesis</authkeywords><intid>2035983483</intid><source-id>19020</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929677964"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929677964?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929677964&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929677964&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929677964</prism:url><dc:identifier>SCOPUS_ID:84929677964</dc:identifier><eid>2-s2.0-84929677964</eid><dc:title>Predictors of morbidity and mortality among patients with cervical spondylotic myelopathy treated surgically</dc:title><dc:creator>David Kaye I.</dc:creator><prism:publicationName>European Spine Journal</prism:publicationName><prism:issn>09406719</prism:issn><prism:eIssn>14320932</prism:eIssn><prism:coverDate>2015-05-23</prism:coverDate><prism:coverDisplayDate>23 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00586-015-4010-2</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg Purpose: The aim of this study is to report and quantify the associated factors for morbidity and mortality following surgical management of cervical spondylotic myelopathy (CSM). Methods: The Nationwide Inpatient Sample (NIS) database was use to retrospectively review all patients over 25 years of age with a diagnosis of CSM who underwent anterior and/or posterior cervical fusion or laminoplasty between 2001 and 2010. The main outcome measures were total procedure-related complications and mortality. Multivariate regression analysis was used to identify demographic, comorbidity, and surgical parameters associated with increased morbidity and mortality risk [reported as: OR (95 % CI)]. Results: A total of 54,348 patients underwent surgical intervention for CSM with an overall morbidity rate of 9.83 % and mortality rate of 0.43 %. Comorbidities found to be associated with an increased complication rate included: pulmonary circulation disorders [6.92 (5.91–8.12)], pathologic weight loss [3.42 (3.00–3.90)], and electrolyte imbalance [2.82 (2.65–3.01)]. Comorbidities found to be associated with an increased mortality rate included: congestive heart failure [4.59 (3.62–5.82)], pulmonary circulation disorders [11.29 (8.24–15.47)], and pathologic weight loss [5.43 (4.07–7.26)]. Alternatively, hypertension [0.56 (0.46–0.67)] and obesity [0.36 (0.22–0.61)] were found to confer a decreased risk of mortality. Increased morbidity and mortality rates were also identified for fusions of 4–8 levels [morbidity: 1.55 (1.48–1.62), mortality: 1.80 (1.48–2.18)] and for age &gt;65 years [morbidity: 1.65 (1.57–1.72), mortality: 2.74 (2.25–3.34)]. An increased morbidity rate was found for posterior-only [1.55 (1.47–1.63)] and combined anterior and posterior fusions [3.20 (2.98–3.43)], and an increased mortality rate was identified for posterior-only fusions [1.87 (1.40–2.49)]. Although revision fusions were associated with an increased morbidity rate [1.81 (1.64–2.00)], they were associated with a decreased rate of mortality [0.24 (0.10–0.59)]. Conclusion: The NIS database was used to provide national estimates of morbidity and mortality following surgical management of CSM in the United States. Several comorbidities, as well as demographic and surgical parameters, were identified as associated factors.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002262</affiliation-url><afid>60002262</afid><affilname>NYU Hospital for Joint Diseases</affilname><name-variant>Hospital for Joint Diseases</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56653478300</author-url><authid>56653478300</authid><authname>David Kaye I.</authname><surname>David Kaye</surname><given-name>I.</given-name><initials>I.</initials><afid>60002262</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55642327700</author-url><authid>55642327700</authid><authname>Marascalchi B.</authname><surname>Marascalchi</surname><given-name>Bryan J.</given-name><initials>B.J.</initials><afid>60002262</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14422349100</author-url><authid>14422349100</authid><authname>Macagno A.</authname><surname>Macagno</surname><given-name>Angel E.</given-name><initials>A.E.</initials><afid>60002262</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56653263900</author-url><authid>56653263900</authid><authname>Lafage V.</authname><surname>Lafage</surname><given-name>Virginie A.</given-name><initials>V.A.</initials><afid>60002262</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6603639903</author-url><authid>6603639903</authid><authname>Bendo J.</authname><surname>Bendo</surname><given-name>John A.</given-name><initials>J.A.</initials><afid>60002262</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:24179090100</author-url><authid>24179090100</authid><authname>Passias P.</authname><surname>Passias</surname><given-name>Peter G.</given-name><initials>P.G.</initials><afid>60002262</afid></author><authkeywords>Cervical spondylotic myelopathy | Morbidity | Mortality | NIS database</authkeywords><intid>535999055</intid><source-id>21129</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929833799"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929833799?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929833799&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929833799&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929833799</prism:url><dc:identifier>SCOPUS_ID:84929833799</dc:identifier><eid>2-s2.0-84929833799</eid><dc:title>Knowledge of physical activity recommendations in adults employed in England: Associations with individual and workplace-related predictors</dc:title><dc:creator>Knox E.</dc:creator><prism:publicationName>International Journal of Behavioral Nutrition and Physical Activity</prism:publicationName><prism:eIssn>14795868</prism:eIssn><prism:coverDate>2015-05-23</prism:coverDate><prism:coverDisplayDate>May 23, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12966-015-0231-3</prism:doi><dc:description>© 2015 Knox et al.; licensee BioMed Central. Background: Physical activity guidelines state that adults should engage in at least 150 min of moderate to vigorous physical activity (MVPA) per week to benefit health. A high proportion of adults in England fail to reach this target. Accurate knowledge of MVPA guidelines could influence the amount and quality of MVPA engaged in by adults. This study aimed to determine knowledge of the MVPA guideline within a large sample of working adults in England and identify individual and workplace-related predictors of knowledge. Methods: 10,992 adults completed an online survey which included questions on demographics, knowledge of the MVPA guideline and workplace predictors for physical activity. Multinomial logistic regression identified predictors of underestimating, overestimating or not knowing the MVPA guideline relative to accurately reporting the guideline for males and females separately. Results: Respondents were 37 % male, 95 % White, 63 % with a degree or higher, and had a mean age of 38.9 ± 11 years. The MVPA guideline was accurately reported by 15 % of adults while 13.8 % overestimated, 8.9 % underestimated and 62.3 % failed to provide any estimate of the guideline. Low education predicted underestimation (females: OR = 0.36, 95 % CI 0.17, 0.80) and not knowing (males: OR = 0.37, 95 % CI 0.14, 0.96; females: OR = 0.36, 95 % CI 0.19, 0.69). Ethnicity was a significant predictor for females only (OR 3.55, 95 % CI 1.46, 8.63; OR 4.03, 95 % CI 1.58, 10.27; OR 3.73, 95 % CI 1.67, 8.33). Employer support for physical activity was a significant predictor of accurate knowledge of the MVPA guideline for both males (underestimation: OR = 0.63, 95 % CI 0.40, 1.00; 'don't know': OR = 0.71, 95 % CI 0.51, 1.00) and females (overestimation: OR = 0.72, 95 % CI 0.53, 0.97; underestimation: OR = 0.66, 95 % CI 0.47, 0.92; 'don't know': OR = 0.60, 95 % CI 0.47, 0.76). Conclusions: Knowledge of the MVPA guideline within working adults in England is low. Employers should play a role in using targeted strategies to increase knowledge as employer support-related factors may influence knowledge of the MVPA guideline. Employers who assert strategies to promote physical activity and encourage employees who have responsibility for promoting health to educate their colleagues may help improve the MVPA knowledge of their employees.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000891</affiliation-url><afid>60000891</afid><affilname>Loughborough University</affilname><name-variant>Loughborough University</name-variant><affiliation-city>Loughborough</affiliation-city><affiliation-country/></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56006890700</author-url><authid>56006890700</authid><authname>Knox E.</authname><surname>Knox</surname><given-name>Emily C L</given-name><initials>E.C.L.</initials><afid>60000891</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37051116500</author-url><authid>37051116500</authid><authname>Musson H.</authname><surname>Musson</surname><given-name>Hayley</given-name><initials>H.</initials><afid>60000891</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:11338865200</author-url><authid>11338865200</authid><authname>Adams E.</authname><surname>Adams</surname><given-name>Emma J.</given-name><initials>E.J.</initials><afid>60000891</afid></author><authkeywords>Employee | Guidelines | Health | Knowledge | Moderate-to-vigorous physical activity | Workplace</authkeywords><intid>1036014658</intid><source-id>14875</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929833288"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929833288?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929833288&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929833288&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929833288</prism:url><dc:identifier>SCOPUS_ID:84929833288</dc:identifier><eid>2-s2.0-84929833288</eid><dc:title>Impact of fast-track discharge from cardiothoracic intensive care on family satisfaction</dc:title><dc:creator>Omar A.</dc:creator><prism:publicationName>BMC Anesthesiology</prism:publicationName><prism:eIssn>14712253</prism:eIssn><prism:coverDate>2015-05-23</prism:coverDate><prism:coverDisplayDate>May 23, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12871-015-0060-6</prism:doi><dc:description>© 2015 Omar et al.; licensee BioMed Central. Background: Dissatisfaction with the intensive care unit may threaten medical care. Clarifying treatment preferences can be useful in these settings, where physician direction may influence decision making and therefore medical treatment. This study aimed to evaluate whether fast-track discharge from intensive care units affects the satisfaction of family members. Methods: We used a single-center non-randomized trial, with all eligible family members involved. To evaluate family satisfaction, we used the Society of Critical Care Family Needs Assessment questionnaire (SCCMFNAQ). We hypothesized that those discharged within 24 h of intensive care unit admission and their families would have higher levels of satisfaction. Patients were scored using the therapeutic interventions scoring system (TISS) and additive EuroSCORE. Results: Two-hundred fifty-five family members were enrolled. The mean patient age was 53 years, and 92 % were male. The median satisfaction level among family members was 17.9 (range 14-31). Patients were divided into two groups, one receiving fast-track discharge (116 patients), and one whose members stayed longer (139 patients). The overall satisfaction was affected significantly by quality of the delivered care and dissatisfaction increased by lack of comfort in hospital settings, including the waiting room. No significant differences were seen between the two groups for overall satisfaction (p = 0.546) and individual components of the questionnaire. Higher satisfaction was linked to higher levels of education among family members (p = 0.045) and information being relayed by a senior physician p = 0.03 (two-tailed test). Conclusions: Fast-track discharge from intensive care did not influence family satisfaction as hypothesized. Satisfaction relied on family members' level of education and the level of seniority of the physician relaying information.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072743</affiliation-url><afid>60072743</afid><affilname>Hamad Medical Corporation</affilname><name-variant>Hamad Medical Corporation</name-variant><affiliation-city>Doha</affiliation-city><affiliation-country>Qatar</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007948</affiliation-url><afid>60007948</afid><affilname>University of Beni Suef</affilname><name-variant>Beni Suef University</name-variant><affiliation-city>Beni Suef</affiliation-city><affiliation-country>Egypt</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072743</affiliation-url><afid>60072743</afid><affilname>Hamad Medical Corporation</affilname><name-variant>Hamad Medical Corporation</name-variant><affiliation-city>Doha</affiliation-city><affiliation-country>Qatar</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35092805800</author-url><authid>35092805800</authid><authname>Omar A.</authname><surname>Omar</surname><given-name>Amr S.</given-name><initials>A.S.</initials><afid>60072743</afid><afid>60007948</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35092805800</author-url><authid>35092805800</authid><authname>Omar A.</authname><surname>Omar</surname><given-name>Amr S.</given-name><initials>A.S.</initials><afid>60072743</afid><afid>60007948</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56625239500</author-url><authid>56625239500</authid><authname>Sivadasan P.</authname><surname>Sivadasan</surname><given-name>Praveen C.</given-name><initials>P.C.</initials><afid>60072743</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56654887800</author-url><authid>56654887800</authid><authname>Gul M.</authname><surname>Gul</surname><given-name>Mumi</given-name><initials>M.</initials><afid>60072743</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56654934900</author-url><authid>56654934900</authid><authname>Taha R.</authname><surname>Taha</surname><given-name>Rula</given-name><initials>R.</initials><afid>60072743</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56536408200</author-url><authid>56536408200</authid><authname>Tuli A.</authname><surname>Tuli</surname><given-name>Alejandro Kohn</given-name><initials>A.K.</initials><afid>60072743</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8713125400</author-url><authid>8713125400</authid><authname>Singh R.</authname><surname>Singh</surname><given-name>Rajvir</given-name><initials>R.</initials><afid>60072743</afid></author><authkeywords>Family satisfaction | Fast-track discharge | Intensive care unit</authkeywords><intid>1036014774</intid><source-id>21855</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929688180"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929688180?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929688180&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929688180&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929688180</prism:url><dc:identifier>SCOPUS_ID:84929688180</dc:identifier><eid>2-s2.0-84929688180</eid><dc:title>Chemokines and microRNAs in atherosclerosis</dc:title><dc:creator>Hartmann P.</dc:creator><prism:publicationName>Cellular and Molecular Life Sciences</prism:publicationName><prism:issn>1420682X</prism:issn><prism:eIssn>14209071</prism:eIssn><prism:coverDate>2015-05-23</prism:coverDate><prism:coverDisplayDate>23 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00018-015-1925-z</prism:doi><dc:description>© 2015 The Author(s) The crucial role of chemokines in the initiation and progression of atherosclerosis has been widely recognized. Through essential functions in leukocyte recruitment, chemokines govern the infiltration with mononuclear cells and macrophage accumulation in atherosclerotic lesions. Beyond recruitment, chemokines also provide homeostatic functions supporting cell survival and mediating the mobilization and homing of progenitor cells. As a new regulatory layer, several microRNAs (miRNAs) have been found to modulate the function of endothelial cells (ECs), smooth muscle cells and macrophages by controlling the expression levels of chemokines and thereby affecting different stages in the progression of atherosclerosis. For instance, the expression of CXCL1 can be down-regulated by miR-181b, which inhibits nuclear factor-κB activation in atherosclerotic endothelium, thus attenuating the adhesive properties of ECs and exerting early atheroprotective effects. Conversely, CXCL12 expression can be induced by miR-126 in ECs through an auto-amplifying feedback loop to facilitate endothelial regeneration, thus limiting atherosclerosis and mediating plaque stabilization. In contrast, miR-155 plays a pro-atherogenic role by promoting the expression of CCL2 in M1-type macrophages, thereby enhancing vascular inflammation. Herein, we will review novel aspects of chemokines and their regulation by miRNAs during atherogenesis. Understanding the complex cross-talk of miRNAs controlling chemokine expression may open novel therapeutic options to treat atherosclerosis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028717</affiliation-url><afid>60028717</afid><affilname>Ludwig-Maximilians-Universitat Munchen</affilname><name-variant>University of Munich</name-variant><affiliation-city>Munich</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114043235</affiliation-url><afid>114043235</afid><affilname>DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance</affilname><name-variant>DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance</name-variant><affiliation-city>Munich</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:16318984200</author-url><authid>16318984200</authid><authname>Hartmann P.</authname><surname>Hartmann</surname><given-name>Petra</given-name><initials>P.</initials><afid>60028717</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56107606100</author-url><authid>56107606100</authid><authname>Schober A.</authname><surname>Schober</surname><given-name>Andreas</given-name><initials>A.</initials><afid>60028717</afid><afid>114043235</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56107606100</author-url><authid>56107606100</authid><authname>Schober A.</authname><surname>Schober</surname><given-name>Andreas</given-name><initials>A.</initials><afid>60028717</afid><afid>114043235</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7402376914</author-url><authid>7402376914</authid><authname>Weber C.</authname><surname>Weber</surname><given-name>Christian</given-name><initials>C.</initials><afid>60028717</afid><afid>114043235</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7402376914</author-url><authid>7402376914</authid><authname>Weber C.</authname><surname>Weber</surname><given-name>Christian</given-name><initials>C.</initials><afid>60028717</afid><afid>114043235</afid></author><authkeywords>Atherosclerosis | Chemokines | Inflammation | MicroRNAs</authkeywords><intid>1785998461</intid><source-id>13903</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929692797"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929692797?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929692797&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929692797&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929692797</prism:url><dc:identifier>SCOPUS_ID:84929692797</dc:identifier><eid>2-s2.0-84929692797</eid><dc:title>Biochemical and clinical deficiency is uncommon in African immigrants despite a high prevalence of low vitamin D: the Africans in America study</dc:title><dc:creator>Thoreson C.</dc:creator><prism:publicationName>Osteoporosis International</prism:publicationName><prism:issn>0937941X</prism:issn><prism:eIssn>14332965</prism:eIssn><prism:coverDate>2015-05-23</prism:coverDate><prism:coverDisplayDate>23 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00198-015-3169-z</prism:doi><dc:description>© 2015 International Osteoporosis Foundation and National Osteoporosis Foundation Summary: African ancestry is associated with low vitamin D levels but high bone density. Fifty percent of African immigrants had low vitamin D levels, but &lt;10 % had evidence of deficiency. The value of providing vitamin D supplementation to African immigrants without evidence of deficiency needs to be determined. Introduction: The Endocrine Society and Institute of Medicine (IOM) have concluded from studies in largely white populations that 25(OH)D is necessary for bone health. However, their definition of vitamin D insufficiency differs. The Endocrine Society recommends a 25(OH)D threshold of &lt;30 ng/mL. The IOM uses a lower threshold of 25(OH)D of &lt;20 ng/mL. As African ancestry is associated with decreased 25(OH)D but increased bone mineral density (BMD), the applicability of these thresholds to Africans is unknown. Therefore, we examined in African immigrants the relationship of 25(OH)D to parathyroid hormone (PTH) and BMD. Methods: One hundred eighty-six African immigrants(69 % male, age 38 ± 10 (mean ± SD), range 20–64 years) living in metropolitan Washington, DC, were enrolled. BMD was determined from whole-body dual-energy X-ray absorptiometry (DXA) scans. Decreased BMD required T-scores ≤−1.0. The threshold for low 25(OH)D was the concentration of 25(OH)D at which PTH became suppressed. This is known as the inflection point. Biochemical deficiency required low 25(OH)D and PTH of &gt;65 pg/mL. Clinical deficiency required low 25(OH)D and T-scores ≤−1.0. Results: 25(OH)D &lt;30 and &lt;20 ng/mL occurred in 83 and 46 % of African immigrants, respectively. PTH inversely correlated with 25(OH)D (r = −0.31, P = 0.002). The inflection point occurred at a 25(OH)D concentration of 20 ng/mL. Biochemical and clinical deficiency occurred in only 8 and 3 % of immigrants, respectively. Conclusion: As PTH became suppressed at 25(OH)D of 20 ng/mL, the 25(OH)D &lt;20 ng/mL threshold for insufficiency may apply to African immigrants. However, ~50 % of African immigrants have 25(OH)D &lt;20 ng/mL, but only &lt;10 % had evidence of deficiency. The value of providing vitamin D supplementation to the large number of African immigrants with 25(OH)D &lt;20 ng/mL and no detectable evidence of deficiency needs to be determined.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006577</affiliation-url><afid>60006577</afid><affilname>National Institutes of Health, Bethesda</affilname><name-variant>National Institute of Health</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106028742</affiliation-url><afid>106028742</afid><affilname>Clinical Center</affilname><name-variant>Clinical Center</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:109465477</affiliation-url><afid>109465477</afid><affilname>National Heart Lung Blood Institute</affilname><name-variant>National Heart Lung Blood Institute</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:107323332</affiliation-url><afid>107323332</afid><affilname>NIDDK</affilname><name-variant>NIDDK</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55932626300</author-url><authid>55932626300</authid><authname>Thoreson C.</authname><surname>Thoreson</surname><given-name>C. K.</given-name><initials>C.K.</initials><afid>60006577</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56497361700</author-url><authid>56497361700</authid><authname>Chung S.</authname><surname>Chung</surname><given-name>S. T.</given-name><initials>S.T.</initials><afid>60006577</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:22135985500</author-url><authid>22135985500</authid><authname>Ricks M.</authname><surname>Ricks</surname><given-name>M.</given-name><initials>M.</initials><afid>60006577</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56652956800</author-url><authid>56652956800</authid><authname>Reynolds J.</authname><surname>Reynolds</surname><given-name>J. C.</given-name><initials>J.C.</initials><afid>106028742</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006511029</author-url><authid>7006511029</authid><authname>Remaley A.</authname><surname>Remaley</surname><given-name>A. T.</given-name><initials>A.T.</initials><afid>109465477</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004074950</author-url><authid>7004074950</authid><authname>Periwal V.</authname><surname>Periwal</surname><given-name>V.</given-name><initials>V.</initials><afid>107323332</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56653555200</author-url><authid>56653555200</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Y.</given-name><initials>Y.</initials><afid>107323332</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7102846091</author-url><authid>7102846091</authid><authname>Sumner A.</authname><surname>Sumner</surname><given-name>A. E.</given-name><initials>A.E.</initials><afid>60006577</afid></author><authkeywords>African immigrants | Bone mineral density | Parathyroid hormone | Vitamin D</authkeywords><intid>35997193</intid><source-id>16453</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930207602"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930207602?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930207602&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930207602&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930207602</prism:url><dc:identifier>SCOPUS_ID:84930207602</dc:identifier><eid>2-s2.0-84930207602</eid><dc:title>Mitochondrial dihydrolipoamide dehydrogenase is upregulated in response to intermittent hypoxic preconditioning</dc:title><dc:creator>Li R.</dc:creator><prism:publicationName>International Journal of Medical Sciences</prism:publicationName><prism:issn>14491907</prism:issn><prism:volume>12</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>432-440</prism:pageRange><prism:coverDate>2015-05-23</prism:coverDate><prism:coverDisplayDate>23 May 2015</prism:coverDisplayDate><prism:doi>10.7150/ijms.11402</prism:doi><dc:description>© 2015 Ivyspring International Publisher. Intermittent hypoxia preconditioning (IHP) has been shown to protect neurons against ischemic stroke injury. Studying how proteins respond to IHP may identify targets that can help fight stroke. The objective of the present study was to investigate whether mitochondrial dihydrolipoamide dehydrogenase (DLDH) would respond to IHP and if so, whether such a response could be linked to neuroprotection in ischemic stroke injury. To do this, we subjected male rats to IHP for 20 days and measured the content and activity of DLDH as well as the three α-keto acid dehydrogenase complexes that contain DLDH. We also measured mitochondrial electron transport chain enzyme activities. Results show that DLDH content was indeed upregulated by IHP and this upregulation did not alter the activities of the three α-keto acid dehydrogenase complexes. Results also show that the activities of the five mitochondrial complexes (I-V) were not altered either by IHP. To investigate whether IHP-induced DLDH upregulation is linked to neuroprotection against ischemic stroke injury, we subjected both DLDH deficient mouse and DLDH transgenic mouse to stroke surgery followed by measurement of brain infarction volume. Results indicate that while mouse deficient in DLDH had exacerbated brain injury after stroke, mouse overexpressing human DLDH also showed increased brain injury after stroke. Therefore, the physiological significance of IHP-induced DLDH upregulation remains to be further investigated.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010544</affiliation-url><afid>60010544</afid><affilname>University of North Texas Health Science Center</affilname><name-variant>University of North Texas Health Science Center at Fort Worth</name-variant><affiliation-city>Fort Worth</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033100</affiliation-url><afid>60033100</afid><affilname>Nanjing University</affilname><name-variant>Nanjing University</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101600838</affiliation-url><afid>101600838</afid><affilname>Gannan Medical University</affilname><name-variant>Gannan Medical University</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010544</affiliation-url><afid>60010544</afid><affilname>University of North Texas Health Science Center</affilname><name-variant>University of North Texas Health Science Center at Fort Worth</name-variant><affiliation-city>Fort Worth</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015780</affiliation-url><afid>60015780</afid><affilname>Xinjiang University</affilname><name-variant>Xinjiang University</name-variant><affiliation-city>Urumqi</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033100</affiliation-url><afid>60033100</afid><affilname>Nanjing University</affilname><name-variant>Nanjing University</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662607100</author-url><authid>56662607100</authid><authname>Li R.</authname><surname>Li</surname><given-name>Rongrong</given-name><initials>R.</initials><afid>60010544</afid><afid>60033100</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662607100</author-url><authid>56662607100</authid><authname>Li R.</authname><surname>Li</surname><given-name>Rongrong</given-name><initials>R.</initials><afid>60010544</afid><afid>60033100</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56583063800</author-url><authid>56583063800</authid><authname>Luo X.</authname><surname>Luo</surname><given-name>Xiaoting</given-name><initials>X.</initials><afid>60010544</afid><afid>101600838</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56583063800</author-url><authid>56583063800</authid><authname>Luo X.</authname><surname>Luo</surname><given-name>Xiaoting</given-name><initials>X.</initials><afid>60010544</afid><afid>101600838</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56583082900</author-url><authid>56583082900</authid><authname>Wu J.</authname><surname>Wu</surname><given-name>Jinzi</given-name><initials>J.</initials><afid>60010544</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15754840800</author-url><authid>15754840800</authid><authname>Thangthaeng N.</authname><surname>Thangthaeng</surname><given-name>Nopporn</given-name><initials>N.</initials><afid>60010544</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56662672800</author-url><authid>56662672800</authid><authname>Jung M.</authname><surname>Jung</surname><given-name>Marianna E.</given-name><initials>M.E.</initials><afid>60010544</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56662775200</author-url><authid>56662775200</authid><authname>Jing S.</authname><surname>Jing</surname><given-name>Siqun</given-name><initials>S.</initials><afid>60010544</afid><afid>60015780</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56662775200</author-url><authid>56662775200</authid><authname>Jing S.</authname><surname>Jing</surname><given-name>Siqun</given-name><initials>S.</initials><afid>60010544</afid><afid>60015780</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56662533400</author-url><authid>56662533400</authid><authname>Li L.</authname><surname>Li</surname><given-name>Linya</given-name><initials>L.</initials><afid>60010544</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7402567071</author-url><authid>7402567071</authid><authname>Ellis D.</authname><surname>Ellis</surname><given-name>Dorette Z.</given-name><initials>D.Z.</initials><afid>60010544</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56486600800</author-url><authid>56486600800</authid><authname>Liu L.</authname><surname>Liu</surname><given-name>Li</given-name><initials>L.</initials><afid>60033100</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56662662800</author-url><authid>56662662800</authid><authname>Ding Z.</authname><surname>Ding</surname><given-name>Zhengnian</given-name><initials>Z.</initials><afid>60033100</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7102341202</author-url><authid>7102341202</authid><authname>Forster M.</authname><surname>Forster</surname><given-name>Michael J.</given-name><initials>M.J.</initials><afid>60010544</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7402670855</author-url><authid>7402670855</authid><authname>Yan L.</authname><surname>Yan</surname><given-name>Liang Jun</given-name><initials>L.J.</initials><afid>60010544</afid></author><authkeywords>Dihydrolipoamide dehydrogenase | Intermittent hypoxic preconditioning | Ischemic stroke | Mitochondria | Neuroprotection</authkeywords><intid>1786088189</intid><source-id>130020</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929192560"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929192560?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929192560&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929192560&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929192560</prism:url><dc:identifier>SCOPUS_ID:84929192560</dc:identifier><eid>2-s2.0-84929192560</eid><dc:title>Physical activity as a protective factor against depressive symptoms in older chinese veterans in the community: Result from a national cross-sectional study</dc:title><dc:creator>Du W.</dc:creator><prism:publicationName>Neuropsychiatric Disease and Treatment</prism:publicationName><prism:issn>11766328</prism:issn><prism:eIssn>11782021</prism:eIssn><prism:volume>11</prism:volume><prism:pageRange>803-813</prism:pageRange><prism:coverDate>2015-05-23</prism:coverDate><prism:coverDisplayDate>23 May 2015</prism:coverDisplayDate><prism:doi>10.2147/NDT.S80295</prism:doi><dc:description>© 2015 Du et al. Background: Physical activity is generally considered to be effective in reducing the prevalence of depression and promoting remission of its symptoms. However, large-scale epidemiological research on this issue is lacking in older Chinese adults. We performed a nationwide epidemiological survey to determine the relationship between physical activity and depressive symptoms in older Chinese veterans in the community, with adjustment for potential confounders. Methods: A cross-sectional study was conducted in a representative sample of 9,676 community-dwelling older Chinese veterans. Depressive symptoms were identified using the Center for Epidemiological Studies Depression Scale. Physical activity was self-reported using a one-year physical activity questionnaire. Information about covariates was obtained by questionnaire-based interview. Relationships between study variables and symptoms of depression were estimated using unadjusted and adjusted analyses. Results: The median age was 82.29 (interquartile range 80.25–84.60) years. In total, 81.84% of the study participants engaged in physical activity that was predominantly light in intensity. In unadjusted analyses, physical activity was associated with a significantly decreased likelihood of depressive symptoms (5.43% versus 18.83%, P,0.0001). Multivariate logistic regression with adjustment and controlling for confounders, physical activity was still inversely associated with depressive symptoms and was the only independent protective factor (odds ratio 0.57, 95% confidence interval 0.44–0.72, P,0.0001) among the associated factors in this study. In a univariate general linear model, there was a significant difference in Center for Epidemiological Studies Depression Scale score between subjects participating in active physical activity and those who did not (F=59.07, P,0.0001). Conclusion: This study found an inverse relationship between physical activity and symptoms of depression in older Chinese veterans in the community. It was also indicated that the antidepressant effect of physical activity probably extended to the oldest-old, and the light-intensity physical activity was probably available for the same protective effect. This information could be used to devise further interventions to prevent or ameliorate symptoms of depression.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106771917</affiliation-url><afid>106771917</afid><affilname>General Hospital of Chinese PLA</affilname><name-variant>Chinese P.L.A. General Hospital</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014966</affiliation-url><afid>60014966</afid><affilname>Peking University</affilname><name-variant>Peking University</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35363998200</author-url><authid>35363998200</authid><authname>Du W.</authname><surname>Du</surname><given-name>Wen Jin</given-name><initials>W.J.</initials><afid>106771917</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56461848900</author-url><authid>56461848900</authid><authname>Tan J.</authname><surname>Tan</surname><given-name>Ji Ping</given-name><initials>J.P.</initials><afid>106771917</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56017216200</author-url><authid>56017216200</authid><authname>Yi F.</authname><surname>Yi</surname><given-name>Fang</given-name><initials>F.</initials><afid>106771917</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56640382200</author-url><authid>56640382200</authid><authname>Zou Y.</authname><surname>Zou</surname><given-name>Yong Ming</given-name><initials>Y.M.</initials><afid>106771917</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56537178100</author-url><authid>56537178100</authid><authname>Gao Y.</authname><surname>Gao</surname><given-name>Ya</given-name><initials>Y.</initials><afid>106771917</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56461738400</author-url><authid>56461738400</authid><authname>Zhao Y.</authname><surname>Zhao</surname><given-name>Yi Ming</given-name><initials>Y.M.</initials><afid>60014966</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56537814200</author-url><authid>56537814200</authid><authname>Wang L.</authname><surname>Wang</surname><given-name>Lu Ning</given-name><initials>L.N.</initials><afid>106771917</afid></author><authkeywords>Chinese veteran | Depression | Older adults | Physical activity | Protective factor</authkeywords><intid>1535915768</intid><source-id>4100151703</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930002941"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930002941?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930002941&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930002941&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930002941</prism:url><dc:identifier>SCOPUS_ID:84930002941</dc:identifier><eid>2-s2.0-84930002941</eid><dc:title>Free breathing contrast-enhanced time-resolved magnetic resonance angiography in pediatric and adult congenital heart disease</dc:title><dc:creator>Steeden J.</dc:creator><prism:publicationName>Journal of Cardiovascular Magnetic Resonance</prism:publicationName><prism:issn>10976647</prism:issn><prism:eIssn>1532429X</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s12968-015-0138-9</prism:doi><dc:description>© 2015 Steeden et al.; licensee BioMed Central. Background: Contrast enhanced magnetic resonance angiography (MRA) is generally performed during a long breath-hold (BH), limiting its utility in infants and small children. This study proposes a free-breathing (FB) time resolved MRA (TRA) technique for use in pediatric and adult congenital heart disease (CHD). Methods: A TRA sequence was developed by combining spiral trajectories with sensitivity encoding (SENSE, x4 kx-ky and x2 kz) and partial Fourier (75% in kz). As no temporal data sharing is used, an independent 3D data set was acquired every ∼1.3s, with acceptable spatial resolution (∼2.3x2.3x2.3mm). The technique was tested during FB over 50 consecutive volumes. Conventional BH-MRA and FB-TRA data was acquired in 45 adults and children with CHD. We calculated quantitative image quality for both sequences. Diagnostic accuracy was assessed in all patients from both sequences. Additionally, vessel measurements were made at the sinotubular junction (N = 43), proximal descending aorta (N = 43), descending aorta at the level of the diaphragm (N = 43), main pulmonary artery (N = 35), left pulmonary artery (N = 35) and the right pulmonary artery (N = 35). Intra and inter observer variability was assessed in a subset of 10 patients. Results: BH-MRA had significantly higher homogeneity in non-contrast enhancing tissue (coefficient of variance, P &lt;0.0001), signal-to-noise ratio (P &lt;0.0001), contrast-to-noise ratio (P &lt;0.0001) and relative contrast (P = 0.02) compared to the FB-TRA images. However, homogeneity in the vessels was similar in both techniques (P = 0.52) and edge sharpness was significantly (P &lt;0.0001) higher in FB-TRA compared to BH-MRA. BH-MRA provided overall diagnostic accuracy of 82%, and FB-TRA of 87%, with no statistical difference between the two sequences (P = 0.77). Vessel diameter measurements showed excellent agreement between the two techniques (r = 0.98, P &lt;0.05), with no bias (0.0mm, P = 0.71), and clinically acceptable limits of agreement (-2.7 to +2.8mm). Inter and intra observer reproducibility showed good agreement of vessel diameters (r&gt;0.988, P&lt;0.0001), with negligible biases (between -0.2 and +0.1mm) and small limits of agreement (between -2.4 and +2.5mm). Conclusions: We have described a FB-TRA technique that is shown to enable accurate diagnosis and vessel measures compared to conventional BH-MRA. This simplifies the MRA technique and will enable angiography to be performed in children and adults whom find breath-holding difficult.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022148</affiliation-url><afid>60022148</afid><affilname>UCL</affilname><name-variant>University College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022148</affiliation-url><afid>60022148</afid><affilname>UCL</affilname><name-variant>University College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:107898031</affiliation-url><afid>107898031</afid><affilname>Cardiorespiratory Unit</affilname><name-variant>Cardiorespiratory Unit</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36605240600</author-url><authid>36605240600</authid><authname>Steeden J.</authname><surname>Steeden</surname><given-name>Jennifer A.</given-name><initials>J.A.</initials><afid>60022148</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:12545915200</author-url><authid>12545915200</authid><authname>Pandya B.</authname><surname>Pandya</surname><given-name>Bejal</given-name><initials>B.</initials><afid>60022148</afid><afid>60022148</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:12545915200</author-url><authid>12545915200</authid><authname>Pandya B.</authname><surname>Pandya</surname><given-name>Bejal</given-name><initials>B.</initials><afid>60022148</afid><afid>60022148</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24339325500</author-url><authid>24339325500</authid><authname>Tann O.</authname><surname>Tann</surname><given-name>Oliver</given-name><initials>O.</initials><afid>107898031</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7801671480</author-url><authid>7801671480</authid><authname>Muthurangu V.</authname><surname>Muthurangu</surname><given-name>Vivek</given-name><initials>V.</initials><afid>60022148</afid><afid>107898031</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7801671480</author-url><authid>7801671480</authid><authname>Muthurangu V.</authname><surname>Muthurangu</surname><given-name>Vivek</given-name><initials>V.</initials><afid>60022148</afid><afid>107898031</afid></author><authkeywords>3D stack-of-spirals | Congenital heart disease | Free-breathing | Time-resolved MR angiography</authkeywords><intid>36048630</intid><article-number>38</article-number><source-id>23845</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929400117"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929400117?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929400117&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929400117&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929400117</prism:url><dc:identifier>SCOPUS_ID:84929400117</dc:identifier><eid>2-s2.0-84929400117</eid><dc:title>Free breathing contrast-enhanced time-resolved magnetic resonance angiography in pediatric and adult congenital heart disease</dc:title><dc:creator>Steeden J.</dc:creator><prism:publicationName>Journal of Cardiovascular Magnetic Resonance</prism:publicationName><prism:issn>10976647</prism:issn><prism:eIssn>1532429X</prism:eIssn><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>May 22, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12968-015-0138-9</prism:doi><dc:description>© 2015 Steeden et al.; licensee BioMed Central. Background: Contrast enhanced magnetic resonance angiography (MRA) is generally performed during a long breath-hold (BH), limiting its utility in infants and small children. This study proposes a free-breathing (FB) time resolved MRA (TRA) technique for use in pediatric and adult congenital heart disease (CHD). Methods: A TRA sequence was developed by combining spiral trajectories with sensitivity encoding (SENSE, x4 kx-ky and x2 kz) and partial Fourier (75% in kz). As no temporal data sharing is used, an independent 3D data set was acquired every ~1.3s, with acceptable spatial resolution (~2.3x2.3x2.3mm). The technique was tested during FB over 50 consecutive volumes. Conventional BH-MRA and FB-TRA data was acquired in 45 adults and children with CHD. We calculated quantitative image quality for both sequences. Diagnostic accuracy was assessed in all patients from both sequences. Additionally, vessel measurements were made at the sinotubular junction (N = 43), proximal descending aorta (N = 43), descending aorta at the level of the diaphragm (N = 43), main pulmonary artery (N = 35), left pulmonary artery (N = 35) and the right pulmonary artery (N = 35). Intra and inter observer variability was assessed in a subset of 10 patients. Results: BH-MRA had significantly higher homogeneity in non-contrast enhancing tissue (coefficient of variance, P &lt;0.0001), signal-to-noise ratio (P &lt;0.0001), contrast-to-noise ratio (P &lt;0.0001) and relative contrast (P = 0.02) compared to the FB-TRA images. However, homogeneity in the vessels was similar in both techniques (P = 0.52) and edge sharpness was significantly (P &lt;0.0001) higher in FB-TRA compared to BH-MRA. BH-MRA provided overall diagnostic accuracy of 82%, and FB-TRA of 87%, with no statistical difference between the two sequences (P = 0.77). Vessel diameter measurements showed excellent agreement between the two techniques (r = 0.98, P &lt;0.05), with no bias (0.0mm, P = 0.71), and clinically acceptable limits of agreement (-2.7 to +2.8mm). Inter and intra observer reproducibility showed good agreement of vessel diameters (r&gt;0.988, P&lt;0.0001), with negligible biases (between -0.2 and +0.1mm) and small limits of agreement (between -2.4 and +2.5mm). Conclusions: We have described a FB-TRA technique that is shown to enable accurate diagnosis and vessel measures compared to conventional BH-MRA. This simplifies the MRA technique and will enable angiography to be performed in children and adults whom find breath-holding difficult.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022148</affiliation-url><afid>60022148</afid><affilname>UCL</affilname><name-variant>University College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022148</affiliation-url><afid>60022148</afid><affilname>UCL</affilname><name-variant>University College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:107898031</affiliation-url><afid>107898031</afid><affilname>Cardiorespiratory Unit</affilname><name-variant>Cardiorespiratory Unit</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36605240600</author-url><authid>36605240600</authid><authname>Steeden J.</authname><surname>Steeden</surname><given-name>Jennifer A.</given-name><initials>J.A.</initials><afid>60022148</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:12545915200</author-url><authid>12545915200</authid><authname>Pandya B.</authname><surname>Pandya</surname><given-name>Bejal</given-name><initials>B.</initials><afid>60022148</afid><afid>60022148</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:12545915200</author-url><authid>12545915200</authid><authname>Pandya B.</authname><surname>Pandya</surname><given-name>Bejal</given-name><initials>B.</initials><afid>60022148</afid><afid>60022148</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24339325500</author-url><authid>24339325500</authid><authname>Tann O.</authname><surname>Tann</surname><given-name>Oliver</given-name><initials>O.</initials><afid>107898031</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7801671480</author-url><authid>7801671480</authid><authname>Muthurangu V.</authname><surname>Muthurangu</surname><given-name>Vivek</given-name><initials>V.</initials><afid>60022148</afid><afid>107898031</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7801671480</author-url><authid>7801671480</authid><authname>Muthurangu V.</authname><surname>Muthurangu</surname><given-name>Vivek</given-name><initials>V.</initials><afid>60022148</afid><afid>107898031</afid></author><authkeywords>3D stack-of-spirals | Congenital heart disease | Free-breathing | Time-resolved MR angiography</authkeywords><intid>1035951368</intid><source-id>23845</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929427868"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929427868?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929427868&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929427868&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115002676"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929427868</prism:url><dc:identifier>SCOPUS_ID:84929427868</dc:identifier><eid>2-s2.0-84929427868</eid><dc:title>Shenfu decoction as adjuvant therapy for improving quality of life and hepatic dysfunction in patients with symptomatic chronic heart failure</dc:title><dc:creator>Wei H.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>169</prism:volume><prism:pageRange>347-355</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.04.016</prism:doi><pii>S0378874115002676</pii><dc:description>© 2015 Elsevier Ireland Ltd. All rights reserved. Ethnopharmacological relevance Shenfu decoction (SFD) is a water extract of the dried root or root stalk of Panax ginseng C. A. Mey (Asian ginseng) and the lateral root of Aconitum carmichaeli Debx (prepared by Fuzi, Heishunpian in Chinese). It has been used to treat heart failure for over a thousand years. The main active components of SFD, ginsenosides and higenamine, enhance heart contractility, increase the coronary blood supply, improve ischemic myocardial metabolism, scavenge free radicals and protect myocardial ultrastructure. Aim of the study To investigate the effect of SFD on quality of life (QOL) and hepatic function in symptomatic chronic heart failure (CHF) patients. Materials and methods Forty patients enrolled in the study were randomized into two groups: an SFD group (18 cases) and a control group (22 cases). All the patients received standard heart failure therapy, and the SFD group patients were also treated with Shenfu granules for 14 days as an adjunctive therapy. The effects of SFD on QOL, plasma alanine aminotransferase (ALT) level, cardiac function, left ventricular ejection fraction (LVEF) and tumor necrosis factor-α (TNF-α) level were studied. ALT threshold in hepatic injury are 21 U/L for men and 17 U/L for women. Results Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores were improved by 35.27±10.72 vs. 23.87±11.96 in the SFD and control groups respectively (p&lt;0.01). Subgroup analysis of the MLHFQ results demonstrated that both physical and emotional scores were significantly higher in the SFD group (21.00±5.66 vs. 16.75±6.25, p&lt;0.05; 4.64±4.84 vs. 1.13±2.85, p&lt;0.05). Circulating ALT was significantly decreased by SFD (13.3 IU/L vs. 0.6 IU/L, p&lt;0.01). The grading of cardiac function and LVEF were increased by 1.6±0.5 vs. 1.1±0.3 and 18%±13% vs. 8%±8% in the SFD and control groups respectively (p&lt;0.05 and p&lt;0.05). The level of TNF-α declined more in SFD than control group (64.8±5.0 to 57.6±4.1, p&lt;0.05; vs. 61.6±5.9 vs. 57.7±3.2. p&gt;0.05). Conclusion Compared with standard heart failure treatment, oral SFD as an adjuvant therapy significantly improved QOL and hepatic injury in CHF patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014966</affiliation-url><afid>60014966</afid><affilname>Peking University</affilname><name-variant>Peking University</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103284</affiliation-url><afid>60103284</afid><affilname>China Academy of Chinese Medical Sciences</affilname><name-variant>China Academy of Chinese Medical Sciences</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101480784</affiliation-url><afid>101480784</afid><affilname>Beijing Hospital of Integrated Traditional and Western Medicine</affilname><name-variant>Beijing Hospital of Integrated Traditional and Western Medicine</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Postdoctoral Workstation of the Zhongguancun Haidian Science Park</affilname><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56645424600</author-url><authid>56645424600</authid><authname>Wei H.</authname><surname>Wei</surname><given-name>Huamin</given-name><initials>H.</initials><afid>60014966</afid><afid>60103284</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56645424600</author-url><authid>56645424600</authid><authname>Wei H.</authname><surname>Wei</surname><given-name>Huamin</given-name><initials>H.</initials><afid>60014966</afid><afid>60103284</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56288858200</author-url><authid>56288858200</authid><authname>Wu H.</authname><surname>Wu</surname><given-name>Hongjin</given-name><initials>H.</initials><afid>60014966</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56645320800</author-url><authid>56645320800</authid><authname>Yu W.</authname><surname>Yu</surname><given-name>Wen</given-name><initials>W.</initials><afid>101480784</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56645357700</author-url><authid>56645357700</authid><authname>Yan X.</authname><surname>Yan</surname><given-name>Xu</given-name><initials>X.</initials><afid>101480784</afid><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56645357700</author-url><authid>56645357700</authid><authname>Yan X.</authname><surname>Yan</surname><given-name>Xu</given-name><initials>X.</initials><afid>101480784</afid><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56645140200</author-url><authid>56645140200</authid><authname>Zhang X.</authname><surname>Zhang</surname><given-name>Xiaoyu</given-name><initials>X.</initials><afid>101480784</afid></author><authkeywords>Clinical trials | Heart failure | Liver | Shenfu decoction | Traditional Chinese medicine</authkeywords><intid>535956093</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929687887"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929687887?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929687887&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929687887&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929687887</prism:url><dc:identifier>SCOPUS_ID:84929687887</dc:identifier><eid>2-s2.0-84929687887</eid><dc:title>Mathematical Modeling of Hemodynamic Characteristics of Pumps for Pulsatile Circulatory Support Systems</dc:title><dc:creator>Belyaev L.</dc:creator><prism:publicationName>Biomedical Engineering</prism:publicationName><prism:issn>00063398</prism:issn><prism:eIssn>15738256</prism:eIssn><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10527-015-9489-7</prism:doi><dc:description>© 2015 Springer Science+Business Media New York An approach to designing blood pumps for pulsatile circulatory support systems based on numerical modeling of hemodynamic processes is presented. Additionally, the influence of the geometry of artificial heart valves and connecting sockets on hemodynamic processes occurring during the blood pump operation is studied. This approach to design of blood pumps of circulatory support systems is justified taking into account hemodynamic characteristics.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020886</affiliation-url><afid>60020886</afid><affilname>Vladimirskij Gosudarstvennyj Universitet</affilname><name-variant>Vladimir State University</name-variant><affiliation-city>Vladimir</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56653324800</author-url><authid>56653324800</authid><authname>Belyaev L.</authname><surname>Belyaev</surname><given-name>L. V.</given-name><initials>L.V.</initials><afid>60020886</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56653314000</author-url><authid>56653314000</authid><authname>Ivanchenko A.</authname><surname>Ivanchenko</surname><given-name>A. B.</given-name><initials>A.B.</initials><afid>60020886</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35875963500</author-url><authid>35875963500</authid><authname>Zhdanov A.</authname><surname>Zhdanov</surname><given-name>A. V.</given-name><initials>A.V.</initials><afid>60020886</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:19234988900</author-url><authid>19234988900</authid><authname>Morozov V.</authname><surname>Morozov</surname><given-name>V. V.</given-name><initials>V.V.</initials><afid>60020886</afid></author><intid>535999283</intid><source-id>28203</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929692708"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929692708?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929692708&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929692708&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929692708</prism:url><dc:identifier>SCOPUS_ID:84929692708</dc:identifier><eid>2-s2.0-84929692708</eid><dc:title>Severe vitamin D deficiency in patients with Kawasaki disease: a potential role in the risk to develop heart vascular abnormalities?</dc:title><dc:creator>Stagi S.</dc:creator><prism:publicationName>Clinical Rheumatology</prism:publicationName><prism:issn>07703198</prism:issn><prism:eIssn>14349949</prism:eIssn><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10067-015-2970-6</prism:doi><dc:description>© 2015 International League of Associations for Rheumatology (ILAR) Twenty-five-hydroxyvitamin D (25(OH)-vitamin D) is crucial in the regulation of immunologic processes, but—although its deficiency has been reported in patients with different rheumatological disorders—no data are available for Kawasaki disease (KD). The goals of this study were to assess the serum levels of 25(OH)-vitamin D in children with KD and evaluate the relationship with the eventual occurrence of KD-related vascular abnormalities. We evaluated serum 25(OH)-vitamin D levels in 79 children with KD (21 females, 58 males, median age 4.9 years, range 1.4–7.5 years) in comparison with healthy sex-/age-matched controls. A significantly higher percentage of KD patients (98.7 %) were shown to have reduced 25(OH)-vitamin D levels (&lt;30 ng/mL) in comparison with controls (78.6 %, p &lt; 0.0001). Furthermore, KD patients had severely low levels of 25(OH)-vitamin D than controls (9.17 ± 4.94 vs 23.3 ± 10.6 ng/mL, p &lt; 0.0001), especially the subgroup who developed coronary artery abnormalities (4.92 ± 1.36 vs 9.41 ± 4.95 ng/mL, p &lt; 0.0001). In addition, serum 25(OH)-vitamin D levels correlated not only with erythrosedimentation rate (p &lt; 0.0001), C-reactive protein (p &lt; 0.0001), hemoglobin level at KD diagnosis (p &lt; 0.0001) but also with both coronary artery aneurysms (p = 0.005) and non-aneurysmatic cardiovascular lesions (p &lt; 0.05). Low serum concentrations of 25(OH)-vitamin D might have a contributive role in the development of coronary artery complications observed in children with KD.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021859</affiliation-url><afid>60021859</afid><affilname>Universita degli Studi di Firenze</affilname><name-variant>Università di Firenze</name-variant><affiliation-city>Florence</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073799</affiliation-url><afid>60073799</afid><affilname>Policlinico Universitario Agostino Gemelli</affilname><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021859</affiliation-url><afid>60021859</afid><affilname>Universita degli Studi di Firenze</affilname><name-variant>Università di Firenze</name-variant><affiliation-city>Florence</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6506305399</author-url><authid>6506305399</authid><authname>Stagi S.</authname><surname>Stagi</surname><given-name>Stefano</given-name><initials>S.</initials><afid>60021859</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56283401600</author-url><authid>56283401600</authid><authname>Rigante D.</authname><surname>Rigante</surname><given-name>Donato</given-name><initials>D.</initials><afid>60073799</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55588064900</author-url><authid>55588064900</authid><authname>Lepri G.</authname><surname>Lepri</surname><given-name>Gemma</given-name><initials>G.</initials><afid>60021859</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005642558</author-url><authid>7005642558</authid><authname>Matucci Cerinic M.</authname><surname>Matucci Cerinic</surname><given-name>Marco</given-name><initials>M.</initials><afid>60021859</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005441458</author-url><authid>7005441458</authid><authname>Falcini F.</authname><surname>Falcini</surname><given-name>Fernanda</given-name><initials>F.</initials><afid>60021859</afid></author><authkeywords>25(OH)-vitamin D | Coronary artery aneurysms | Kawasaki disease</authkeywords><intid>2035992271</intid><source-id>19187</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930197682"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930197682?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930197682&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930197682&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930197682</prism:url><dc:identifier>SCOPUS_ID:84930197682</dc:identifier><eid>2-s2.0-84930197682</eid><dc:title>Increased gastrointestinal blood flow: An essential circulatory modification for euryhaline rainbow trout (Oncorhynchus mykiss) migrating to sea</dc:title><dc:creator>Brijs J.</dc:creator><prism:publicationName>Scientific Reports</prism:publicationName><prism:eIssn>20452322</prism:eIssn><prism:volume>5</prism:volume><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1038/srep10430</prism:doi><pii>srep10430</pii><dc:description>The large-scale migrations of anadromous fish species from freshwater to seawater have long been considered particularly enigmatic, as this life history necessitates potentially energetically costly changes in behaviour and physiology. A significant knowledge gap concerns the integral role of cardiovascular responses, which directly link many of the well-documented adaptations (i.e. through oxygen delivery, water and ion transport) allowing fish to maintain osmotic homeostasis in the sea. Using long-term recordings of cardiorespiratory variables and a novel method for examining drinking dynamics, we show that euryhaline rainbow trout (Oncorhynchus mykiss) initiate drinking long before the surrounding environment reaches full seawater salinity (30-33ppt), suggesting the presence of an external osmo-sensing mechanism. Onset of drinking was followed by a delayed, yet substantial increase in gastrointestinal blood flow through increased pulse volume exclusively, as heart rate remained unchanged. While seawater entry did not affect whole animal energy expenditure, enhanced gastrointestinal perfusion represents a mechanism crucial for ion and water absorption, as well as possibly increasing local gastrointestinal oxygen supply. Collectively, these modifications are essential for anadromous fish to maintain homeostasis at sea, whilst conserving cardiac and metabolic scope for activities directly contributing to fitness and reproductive success.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016437</affiliation-url><afid>60016437</afid><affilname>Goteborgs Universitet</affilname><name-variant>Göteborg University</name-variant><affiliation-city>Goteborg</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027152</affiliation-url><afid>60027152</afid><affilname>Sveriges lantbruksuniversitet</affilname><name-variant>Swedish University of Agricultural Sciences</name-variant><affiliation-city>Uppsala</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56531948700</author-url><authid>56531948700</authid><authname>Brijs J.</authname><surname>Brijs</surname><given-name>Jeroen</given-name><initials>J.</initials><afid>60016437</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8668720400</author-url><authid>8668720400</authid><authname>Axelsson M.</authname><surname>Axelsson</surname><given-name>Michael</given-name><initials>M.</initials><afid>60016437</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24773121600</author-url><authid>24773121600</authid><authname>Gräns A.</authname><surname>Gräns</surname><given-name>Albin</given-name><initials>A.</initials><afid>60027152</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56663084500</author-url><authid>56663084500</authid><authname>Pichaud N.</authname><surname>Pichaud</surname><given-name>Nicolas</given-name><initials>N.</initials><afid>60016437</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7103312827</author-url><authid>7103312827</authid><authname>Olsson C.</authname><surname>Olsson</surname><given-name>Catharina</given-name><initials>C.</initials><afid>60016437</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8618536200</author-url><authid>8618536200</authid><authname>Sandblom E.</authname><surname>Sandblom</surname><given-name>Erik</given-name><initials>E.</initials><afid>60016437</afid></author><intid>1536087453</intid><article-number>10430</article-number><source-id>21100200805</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929698667"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929698667?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929698667&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929698667&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929698667</prism:url><dc:identifier>SCOPUS_ID:84929698667</dc:identifier><eid>2-s2.0-84929698667</eid><dc:title>New Sources for Comparative Social Science: Historical Population Panel Data From East Asia</dc:title><dc:creator>Dong H.</dc:creator><prism:publicationName>Demography</prism:publicationName><prism:issn>00703370</prism:issn><prism:eIssn>15337790</prism:eIssn><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s13524-015-0397-y</prism:doi><dc:description>© 2015 The Author(s) Comparison and comparability lie at the heart of any comparative social science. Still, precise comparison is virtually impossible without using similar methods and similar data. In recent decades, social demographers, historians, and economic historians have compiled and made available a large number of micro-level data sets of historical populations for North America and Europe. Studies using these data have already made important contributions to many academic disciplines. In a similar spirit, we introduce five new micro-level historical panel data sets from East Asia, including the China Multi-Generational Panel Dataset–Liaoning (CMGPD-LN) 1749–1909, the China Multi-Generational Panel Dataset–Shuangcheng (CMGPD-SC) 1866–1913, the Japanese Ninbetsu-Aratame-Cho Population Register Database–Shimomoriya and Niita (NAC-SN) 1716–1870, the Korea Multi-Generational Panel Dataset–Tansung (KMGPD-TS) 1678–1888, and the Colonial Taiwan Household Registration Database (CTHRD) 1906–1945. These data sets in total contain more than 3.7 million linked observations of 610,000 individuals and are the first such Asian data to be made available online or by application. We discuss the key features and historical institutions that originally collected these data; the subsequent processes by which the data were reconstructed into individual-level panels; their particular data limitations and strengths; and their potential for comparative social scientific research.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008592</affiliation-url><afid>60008592</afid><affilname>Hong Kong University of Science and Technology</affilname><name-variant>Hong Kong Univ. of Sci. and Technol.</name-variant><affiliation-city>Hong Kong</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008592</affiliation-url><afid>60008592</afid><affilname>Hong Kong University of Science and Technology</affilname><name-variant>Hong Kong Univ. of Sci. and Technol.</name-variant><affiliation-city>Hong Kong</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006195</affiliation-url><afid>60006195</afid><affilname>Reitaku University</affilname><name-variant>Reitaku University</name-variant><affiliation-city>Kashiwa</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103514</affiliation-url><afid>60103514</afid><affilname>Institute of Sociology, Academia Sinica</affilname><name-variant>Academia Sinica</name-variant><affiliation-city>Nankang</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008592</affiliation-url><afid>60008592</afid><affilname>Hong Kong University of Science and Technology</affilname><name-variant>Hong Kong Univ. of Sci. and Technol.</name-variant><affiliation-city>Hong Kong</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56652892000</author-url><authid>56652892000</authid><authname>Dong H.</authname><surname>Dong</surname><given-name>Hao</given-name><initials>H.</initials><afid>60008592</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7403368487</author-url><authid>7403368487</authid><authname>Campbell C.</authname><surname>Campbell</surname><given-name>Cameron</given-name><initials>C.</initials><afid>60008592</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56653267700</author-url><authid>56653267700</authid><authname>Kurosu S.</authname><surname>Kurosu</surname><given-name>Satomi</given-name><initials>S.</initials><afid>60006195</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56652781100</author-url><authid>56652781100</authid><authname>Yang W.</authname><surname>Yang</surname><given-name>Wenshan</given-name><initials>W.</initials><afid>60103514</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56653543700</author-url><authid>56653543700</authid><authname>Lee J.</authname><surname>Lee</surname><given-name>James Z.</given-name><initials>J.Z.</initials><afid>60008592</afid></author><authkeywords>Comparison | East Asia | Historical demography | Longitudinal data | Population registers</authkeywords><intid>1785998692</intid><source-id>26365</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929693083"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929693083?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929693083&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929693083&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929693083</prism:url><dc:identifier>SCOPUS_ID:84929693083</dc:identifier><eid>2-s2.0-84929693083</eid><dc:title>Mobile System for Automated Remote Monitoring of Cardiac Activity</dc:title><dc:creator>Bessmeltsev V.</dc:creator><prism:publicationName>Biomedical Engineering</prism:publicationName><prism:issn>00063398</prism:issn><prism:eIssn>15738256</prism:eIssn><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10527-015-9485-y</prism:doi><dc:description>© 2015 Springer Science+Business Media New York A prototype of a diagnostic complex for continuous monitoring of patient’s cardiac activity (electrocardiography, heart rate) is described. The complex contains an intelligent-sensor data acquisition system, a processing system based on a Bluetooth piconet-microserver, and a communicator for transmitting data from the data acquisition and processing system to a medical server. The algorithms of preprocessing of the sensor signals and the structure of the mobile application of the communicator and medical server are also presented. Structural, hardware, and software solutions presented demonstrate the feasibility of a complex with sensors that allow patients to perform their usual daily functions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033230</affiliation-url><afid>60033230</afid><affilname>Institute of Automation and Electrometry of SB RAS</affilname><name-variant>Russian Academy of Sciences</name-variant><affiliation-city>Novosibirsk</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60076721</affiliation-url><afid>60076721</afid><affilname>Institute of Chemical Biology and Fundamental Medicine, SB RAS</affilname><name-variant>Russian Academy of Sciences</name-variant><affiliation-city>Novosibirsk</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6507927698</author-url><authid>6507927698</authid><authname>Bessmeltsev V.</authname><surname>Bessmeltsev</surname><given-name>V. P.</given-name><initials>V.P.</initials><afid>60033230</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56653479400</author-url><authid>56653479400</authid><authname>Katasonov D.</authname><surname>Katasonov</surname><given-name>D. N.</given-name><initials>D.N.</initials><afid>60033230</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6507879005</author-url><authid>6507879005</authid><authname>Mazurok B.</authname><surname>Mazurok</surname><given-name>B. S.</given-name><initials>B.S.</initials><afid>60033230</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56653420700</author-url><authid>56653420700</authid><authname>Makeev I.</authname><surname>Makeev</surname><given-name>I. V.</given-name><initials>I.V.</initials><afid>60033230</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6506335878</author-url><authid>6506335878</authid><authname>Sluev V.</authname><surname>Sluev</surname><given-name>V. A.</given-name><initials>V.A.</initials><afid>60033230</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7402759603</author-url><authid>7402759603</authid><authname>Morozov V.</authname><surname>Morozov</surname><given-name>V. V.</given-name><initials>V.V.</initials><afid>60076721</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6506600077</author-url><authid>6506600077</authid><authname>Shevela A.</authname><surname>Shevela</surname><given-name>A. I.</given-name><initials>A.I.</initials><afid>60076721</afid></author><intid>1535997454</intid><source-id>28203</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930146515"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930146515?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930146515&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930146515&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930146515</prism:url><dc:identifier>SCOPUS_ID:84930146515</dc:identifier><eid>2-s2.0-84930146515</eid><dc:title>Mente Activa® improves impaired spatial memory in aging rats</dc:title><dc:creator>López-Avalos M.</dc:creator><prism:publicationName>Journal of Nutrition, Health and Aging</prism:publicationName><prism:issn>12797707</prism:issn><prism:eIssn>17604788</prism:eIssn><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12603-015-0546-4</prism:doi><dc:description>© 2015 Serdi and Springer-Verlag France Objectives: Aging is accompanied by a decline in several aspects of the cognitive function, having negative personal and socioeconomic impacts. Dietary supplements could be beneficial for preventing age-related cognitive decline. In this context, we examined whether the nutritional supplement Mente Activa® has beneficial effects on aging-related cognitive deficits without inducing side effects. Methods: Mente Activa® was administered to old rats (n= 30 treated rats and n= 30 control rats) during 5 months, and the Morris water maze was used to test the learning capacities of the animals. The first assessment was conducted before the nutritional intervention (age of 18-19 months), to determine the baseline of the performance of animals on this test, and the second assessment was performed at the end of the treatment (23-24 moths). In order to examine possible secondary effects of this nutritional supplement, plasma, heart anatomy and liver parameters were evaluated. Results: Our data indicate that supplemented rats showed less escape latency, distance swum, higher use of spatial search strategies, and crossed the former platform location with higher frequency than control rats. These effects were specific of the treatment, indicating that this nutritional supplement has a beneficial effect on spatial memory. On the other hand, the regular intake of Mente Activa® did not induce any negative effects in plasma parameters and heart size. Conclusions: Aged rats under a sustained dietary intake of the nutritional supplement Mente Activa® displayed improved learning and memory abilities compared to the non-treated rats. These results suggest the therapeutic potential and safety of use of Mente Activa® for age-related cognitive deficits, particularly, in the onset of the first cognitive dysfunction symptoms.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003662</affiliation-url><afid>60003662</afid><affilname>Universidad de Malaga</affilname><name-variant>University of Málaga</name-variant><affiliation-city>Malaga</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003662</affiliation-url><afid>60003662</afid><affilname>Universidad de Malaga</affilname><name-variant>University of Málaga</name-variant><affiliation-city>Malaga</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003662</affiliation-url><afid>60003662</afid><affilname>Universidad de Malaga</affilname><name-variant>University of Málaga</name-variant><affiliation-city>Malaga</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112832108</affiliation-url><afid>112832108</afid><affilname>Instituto de Investigación Biomédica de Málaga (IBIMA)</affilname><name-variant>Instituto de Investigación Biomédica de Málaga (IBIMA)</name-variant><affiliation-city>Malaga</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003662</affiliation-url><afid>60003662</afid><affilname>Universidad de Malaga</affilname><name-variant>University of Málaga</name-variant><affiliation-city>Malaga</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603236931</author-url><authid>6603236931</authid><authname>López-Avalos M.</authname><surname>López-Avalos</surname><given-name>M. D.</given-name><initials>M.D.</initials><afid>60003662</afid><afid>112832108</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603236931</author-url><authid>6603236931</authid><authname>López-Avalos M.</authname><surname>López-Avalos</surname><given-name>M. D.</given-name><initials>M.D.</initials><afid>60003662</afid><afid>112832108</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662164400</author-url><authid>56662164400</authid><authname>Fernández-Llebrez Zayas R.</authname><surname>Fernández-Llebrez Zayas</surname><given-name>R.</given-name><initials>R.</initials><afid>60003662</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7007166028</author-url><authid>7007166028</authid><authname>Cifuentes M.</authname><surname>Cifuentes</surname><given-name>M.</given-name><initials>M.</initials><afid>60003662</afid><afid>112832108</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7007166028</author-url><authid>7007166028</authid><authname>Cifuentes M.</authname><surname>Cifuentes</surname><given-name>M.</given-name><initials>M.</initials><afid>60003662</afid><afid>112832108</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56661982400</author-url><authid>56661982400</authid><authname>de Andrés M.</authname><surname>de Andrés</surname><given-name>M. V.</given-name><initials>M.V.</initials><afid>60003662</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56662185000</author-url><authid>56662185000</authid><authname>Fernández-Llebrez Del Rey P.</authname><surname>Fernández-Llebrez Del Rey</surname><given-name>P.</given-name><initials>P.</initials><afid>60003662</afid><afid>112832108</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56662185000</author-url><authid>56662185000</authid><authname>Fernández-Llebrez Del Rey P.</authname><surname>Fernández-Llebrez Del Rey</surname><given-name>P.</given-name><initials>P.</initials><afid>60003662</afid><afid>112832108</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6701528065</author-url><authid>6701528065</authid><authname>Grondona J.</authname><surname>Grondona</surname><given-name>J. M.</given-name><initials>J.M.</initials><afid>60003662</afid><afid>112832108</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6701528065</author-url><authid>6701528065</authid><authname>Grondona J.</authname><surname>Grondona</surname><given-name>J. M.</given-name><initials>J.M.</initials><afid>60003662</afid><afid>112832108</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6701763710</author-url><authid>6701763710</authid><authname>Pérez-Martín M.</authname><surname>Pérez-Martín</surname><given-name>M.</given-name><initials>M.</initials><afid>60003662</afid><afid>112832108</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6701763710</author-url><authid>6701763710</authid><authname>Pérez-Martín M.</authname><surname>Pérez-Martín</surname><given-name>M.</given-name><initials>M.</initials><afid>60003662</afid><afid>112832108</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6701723078</author-url><authid>6701723078</authid><authname>Pedraza C.</authname><surname>Pedraza</surname><given-name>C.</given-name><initials>C.</initials><afid>60003662</afid><afid>112832108</afid><afid>60003662</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6701723078</author-url><authid>6701723078</authid><authname>Pedraza C.</authname><surname>Pedraza</surname><given-name>C.</given-name><initials>C.</initials><afid>60003662</afid><afid>112832108</afid><afid>60003662</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6701723078</author-url><authid>6701723078</authid><authname>Pedraza C.</authname><surname>Pedraza</surname><given-name>C.</given-name><initials>C.</initials><afid>60003662</afid><afid>112832108</afid><afid>60003662</afid></author><intid>1786078024</intid><source-id>26661</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929600580"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929600580?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929600580&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929600580&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929600580</prism:url><dc:identifier>SCOPUS_ID:84929600580</dc:identifier><eid>2-s2.0-84929600580</eid><dc:title>From social movements to cloud protesting: the evolution of collective identity</dc:title><dc:creator>Milan S.</dc:creator><prism:publicationName>Information Communication and Society</prism:publicationName><prism:issn>1369118X</prism:issn><prism:eIssn>14684462</prism:eIssn><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1080/1369118X.2015.1043135</prism:doi><dc:description>© 2015 Taylor &amp; Francis This article develops a conceptual framework for understanding collective action in the age of social media, focusing on the role of collective identity and the process of its making. It is grounded on an interactionist approach that considers organized collective action as a social construct with communicative action at its core [Melucci, A. 1996. Challenging codes: Collective action in the information age. Cambridge, MA: Cambridge University Press]. It explains how micromobilization is mediated by social media, and argues that social media play a novel broker role in the activists' meaning construction processes. Social media impose precise material constraints on their social affordances, which have profound implications in both the symbolic production and organizational dynamics of social action. The materiality of social media deeply affects identity building, in two ways: firstly, it amplifies the ‘interactive and shared’ elements of collective identity (Melucci, 1996), and secondly, it sets in motion a politics of visibility characterized by individuality, performance, visibility, and juxtaposition. The politics of visibility, at the heart of what I call ‘cloud protesting’, exacerbates the centrality of the subjective and private experience of the individual in contemporary mobilizations, and has partially replaced the politics of identity typical of social movements. The politics of visibility creates individuals-in-the-group, whereby the ‘collective’ is experienced through the ‘individual’ and the group is the means of collective action, rather than its end.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002483</affiliation-url><afid>60002483</afid><affilname>University of Amsterdam</affilname><name-variant>University of Amsterdam</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56650728300</author-url><authid>56650728300</authid><authname>Milan S.</authname><surname>Milan</surname><given-name>Stefania</given-name><initials>S.</initials><afid>60002483</afid></author><authkeywords>collective identity | computer-mediated-communication | politics of visibility | social media | social movements</authkeywords><intid>2035976189</intid><source-id>200147110</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929692570"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929692570?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929692570&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929692570&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929692570</prism:url><dc:identifier>SCOPUS_ID:84929692570</dc:identifier><eid>2-s2.0-84929692570</eid><dc:title>Prediction of coronary artery stenosis by measurement of total plaque area and thickness versus intima media thickness of the carotid artery | Vorhersage einer stenosierenden KHK durch Bestimmung von Plaque-Fläche und -Dicke vs. IMT an der A. carotis</dc:title><dc:creator>Adams A.</dc:creator><prism:publicationName>Herz</prism:publicationName><prism:issn>03409937</prism:issn><prism:eIssn>16156692</prism:eIssn><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00059-015-4312-5</prism:doi><dc:description>© 2015 Urban &amp; Vogel Total plaque area (TPA), maximum plaque thickness and intima media thickness (IMT) in the carotid arteries of 431 patients aged 27–88 years were measured 1 day before a planned coronary artery angiography without any clinical knowledge about the patient. Age-related cut-off values of the TPA for the presence of coronary stenosis were evaluated. Using ultrasound four types of carotid artery atherosclerosis were identified. The accuracy of detection of cardiovascular coronary stenosis was 87 % for types III and IVb. No type I patient had coronary stenosis. The IMT was significantly less predictive: the area under the curve (AUC) for TPA by age and plaque thickness was 0.82 (95 % CI: 0.78–0.85) versus IMT 0.59 (95 % CI: 0.54–0.64, p = 0.001). Prediction with TPA measurement by age and plaque thickness was better than TPA alone: AUC 0.82 (95 % CI: 0.78–0.85) versus 0.77 (95 % CI: 0.73–0.81, p = 0.0028), respectively. In a second cohort of 2566 healthy men and 1216 healthy women aged between 20 and 64 years who were examined in an occupational screening program, 11.2 % of the men and 3.4 % of the women showed a type III or IVb result. In the mean follow-up of period of 23.4 ± 14.4 months, 14 heart attacks, 7 bypass operations and 3 stent implantations occurred and 6 subjects showed coronary stenosis between 50 % and 95 % in coronary angiography. In the baseline examination 26 out of 30 patients showed a type III or IVb result. In the case of men and women with types III and IVb diagnosis by ultrasound, pharmaceutical treatment could be indicated in order to reduce the risk of cardiovascular events. Type I patients do not need preventive medication or coronary catheterization.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:104840595</affiliation-url><afid>104840595</afid><affilname>Sicherheitstechnik GmbH</affilname><name-variant>BAD Gesundheitsvorsorge und Sicherheitstechnik GmbH Zentrum Koblenz</name-variant><affiliation-city>Koblenz</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115264621</affiliation-url><afid>115264621</afid><affilname>Medizinische Klinik Kardiologie Koblenz</affilname><name-variant>Medizinische Klinik Kardiologie Koblenz</name-variant><affiliation-city>Koblenz</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56652989700</author-url><authid>56652989700</authid><authname>Adams A.</authname><surname>Adams</surname><given-name>Ansgar</given-name><initials>A.</initials><afid>104840595</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56653355700</author-url><authid>56653355700</authid><authname>Bojara W.</authname><surname>Bojara</surname><given-name>Waldemar</given-name><initials>W.</initials><afid>115264621</afid></author><authkeywords>Cardiovascular risk | Carotid ultrasound | Coronary disease | Intima media thickness | Total plaque area</authkeywords><intid>2035992331</intid><source-id>23251</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930011882"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930011882?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930011882&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930011882&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930011882</prism:url><dc:identifier>SCOPUS_ID:84930011882</dc:identifier><eid>2-s2.0-84930011882</eid><dc:title>Characteristic cardiac phenotypes are detected by cardiovascular magnetic resonance in patients with different clinical phenotypes and genotypes of mitochondrial myopathy</dc:title><dc:creator>Florian A.</dc:creator><prism:publicationName>Journal of Cardiovascular Magnetic Resonance</prism:publicationName><prism:issn>10976647</prism:issn><prism:eIssn>1532429X</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s12968-015-0145-x</prism:doi><dc:description>© 2015 Florian et al.; licensee BioMed Central. Background: Mitochondrial myopathies (MM) are a heterogeneous group of inherited conditions resulting from a primary defect in the mitochondrial respiratory chain with consecutively impaired cellular energy metabolism. Small sized studies using mainly electrocardiography (ECG) and echocardiography have revealed cardiac abnormalities ranging from conduction abnormalities and arrhythmias to hypertrophic or dilated cardiomyopathy in these patients. Recently, characteristic patterns of cardiac involvement were documented by cardiovascular magnetic resonance (CMR) in patients with chronic progressive external ophthalmoplegia (CPEO)/Kearns-Sayre syndrome (KSS) and with mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS). The present study aimed to characterize the prevalence and pattern of cardiac abnormalities and to test the additional diagnostic value of CMR in this patient population. The hypothesis that different neuromuscular MM syndromes present with different cardiac disease phenotypes was evaluated. Methods: Sixty-four MM patients (50±15 years, 44 % male) and 25 matched controls (52±14 years, 36 % male) prospectively underwent cardiac evaluations including CMR (comprising cine- and late-gadolinium-enhancement (LGE) imaging). Based on the neuromuscular phenotype and genotype, the patients were grouped: a) CPEO/KSS (N=33); b) MELAS/-like (N=11); c) myoclonic epilepsy with ragged-red fibers (MERRF) (N=3) and d) other non-specific MM forms (N=17). Results: Among the 64 MM patients, 34 (53 %) had at least one abnormal CMR finding: 18 (28 %) demonstrated an impaired left ventricular ejection-fraction (LV-EF &lt;60 %), 14 (22 %) had unexplained LV hypertrophy and 21 (33 %) were LGE-positive. Compared to controls, MM patients showed significantly higher maximal wall thickness (10±3 vs. 8±2 mm, p=0.005) and concentricity (LV mass to end-diastolic volume: 0.84±0.27 vs. 0.67±0.11, p&lt;0.0001) with frequent presence of non-ischemic LGE (30 % vs. 0 %, p=0.001). CPEO/KSS showed a predominantly intramural pattern of LGE mostly confined to the basal LV inferolateral wall (8/10; 80 %) in addition to a tendency toward concentric remodelling. MELAS/-like patients showed the highest frequency of cardiac disease (in 10/11 (91 %)), a mostly concentric LV hypertrophy (6/9; 67 %) with or without LV systolic dysfunction and a predominantly focal, patchy LGE equally distributed among LV segments (8/11; 73 %). Patients with MERRF and non-specific MM had no particular findings. Pathological CMR findings indicating cardiac involvement were detected significantly more often than pathological ECG results or elevated cardiac serum biomarkers (34 (53 %) vs. 18 (28 %) vs. 21 (33 %); p=0.008). Conclusion: Cardiac involvement is a frequent finding in MM patients - and particularly present in KSS/CPEO as well as MELAS/-like patients. Despite a high variability in clinical presentation, CPEO/KSS patients typically show an intramural pattern of LGE in the basal inferolateral wall whereas MELAS patients are characterized by overt concentric hypertrophy and a rather unique, focally accentuated and diffusely distributed LGE.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006490</affiliation-url><afid>60006490</afid><affilname>Universitatsklinikum Munster</affilname><name-variant>Universitätsklinikum Münster</name-variant><affiliation-city>Munster</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60078337</affiliation-url><afid>60078337</afid><affilname>Robert Bosch Krankenhaus Stuttgart</affilname><name-variant>Robert-Bosch-Krankenhaus</name-variant><affiliation-city>Stuttgart</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006490</affiliation-url><afid>60006490</afid><affilname>Universitatsklinikum Munster</affilname><name-variant>Universitätsklinikum Münster</name-variant><affiliation-city>Munster</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36100122200</author-url><authid>36100122200</authid><authname>Florian A.</authname><surname>Florian</surname><given-name>Anca</given-name><initials>A.</initials><afid>60006490</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55758933600</author-url><authid>55758933600</authid><authname>Ludwig A.</authname><surname>Ludwig</surname><given-name>Anna</given-name><initials>A.</initials><afid>60078337</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56431036700</author-url><authid>56431036700</authid><authname>Stubbe-Dräger B.</authname><surname>Stubbe-Dräger</surname><given-name>Bianca</given-name><initials>B.</initials><afid>60006490</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:23003594100</author-url><authid>23003594100</authid><authname>Boentert M.</authname><surname>Boentert</surname><given-name>Matthias</given-name><initials>M.</initials><afid>60006490</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35367367500</author-url><authid>35367367500</authid><authname>Young P.</authname><surname>Young</surname><given-name>Peter</given-name><initials>P.</initials><afid>60006490</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56268040600</author-url><authid>56268040600</authid><authname>Waltenberger J.</authname><surname>Waltenberger</surname><given-name>Johannes</given-name><initials>J.</initials><afid>60006490</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:36946351900</author-url><authid>36946351900</authid><authname>Rösch S.</authname><surname>Rösch</surname><given-name>Sabine</given-name><initials>S.</initials><afid>60078337</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006098975</author-url><authid>7006098975</authid><authname>Sechtem U.</authname><surname>Sechtem</surname><given-name>Udo</given-name><initials>U.</initials><afid>60078337</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35265413600</author-url><authid>35265413600</authid><authname>Yilmaz A.</authname><surname>Yilmaz</surname><given-name>Ali</given-name><initials>A.</initials><afid>60006490</afid></author><authkeywords>Cardiomyopathy | Cardiovascular magnetic resonance | CPEO | MELAS | Mitochondrial myopathy</authkeywords><intid>1036044741</intid><article-number>40</article-number><source-id>23845</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929698479"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929698479?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929698479&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929698479&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929698479</prism:url><dc:identifier>SCOPUS_ID:84929698479</dc:identifier><eid>2-s2.0-84929698479</eid><dc:title>Early goal-directed therapy: from discovery through enthusiasm to equipoise?</dc:title><dc:creator>Russell J.</dc:creator><prism:publicationName>Intensive Care Medicine</prism:publicationName><prism:issn>03424642</prism:issn><prism:eIssn>14321238</prism:eIssn><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00134-015-3857-3</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015670</affiliation-url><afid>60015670</afid><affilname>St. Paul's Hospital</affilname><name-variant>St Paul's Hospital</name-variant><affiliation-city>Vancouver</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006564</affiliation-url><afid>60006564</afid><affilname>Rigshospitalet</affilname><name-variant>Copenhagen University Hospital</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000905</affiliation-url><afid>60000905</afid><affilname>Inserm</affilname><name-variant>INSERM</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7404208893</author-url><authid>7404208893</authid><authname>Russell J.</authname><surname>Russell</surname><given-name>James A.</given-name><initials>J.A.</initials><afid>60015670</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56211718600</author-url><authid>56211718600</authid><authname>Møller M.</authname><surname>Møller</surname><given-name>Morten Hylander</given-name><initials>M.H.</initials><afid>60006564</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006490729</author-url><authid>7006490729</authid><authname>Annane D.</authname><surname>Annane</surname><given-name>Djillali</given-name><initials>D.</initials><afid>60000905</afid></author><intid>535998753</intid><source-id>14719</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930200490"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930200490?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930200490&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930200490&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930200490</prism:url><dc:identifier>SCOPUS_ID:84930200490</dc:identifier><eid>2-s2.0-84930200490</eid><dc:title>Real world research: A complementary method to establish the effectiveness of acupuncture</dc:title><dc:creator>Luo J.</dc:creator><prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName><prism:eIssn>14726882</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>May 22, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12906-015-0676-6</prism:doi><dc:description>© 2015 Luo et al. Acupuncture has been widely used in the management of a variety of diseases for thousands of years, and many relevant randomized controlled trials have been published. In recent years, many randomized controlled trials have provided controversial or less-than-convincing evidence that supports the efficacy of acupuncture. The clinical effectiveness of acupuncture in Western countries remains controversial. Discussion: Acupuncture is a complex intervention involving needling components, specific non-needling components, and generic components. Common problems that have contributed to the equivocal findings in acupuncture randomized controlled trials were imperfections regarding acupuncture treatment and inappropriate placebo/sham controls. In addition, some inherent limitations were also present in the design and implementation of current acupuncture randomized controlled trials such as weak external validity. The current designs of randomized controlled trials of acupuncture need to be further developed. In contrast to examining efficacy and adverse reaction in a "sterilized" environment in a narrowly defined population, real world research assesses the effectiveness and safety of an intervention in a much wider population in real world practice. For this reason, real world research might be a feasible and meaningful method for acupuncture assessment. Summary: Randomized controlled trials are important in verifying the efficacy of acupuncture treatment, but the authors believe that real world research, if designed and conducted appropriately, can complement randomized controlled trials to establish the effectiveness of acupuncture. Furthermore, the integrative model that can incorporate randomized controlled trial and real world research which can complement each other and potentially provide more objective and persuasive evidence.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013449</affiliation-url><afid>60013449</afid><affilname>China-Japan Friendship Hospital</affilname><name-variant>China-Japan Friendship Hospital</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069729</affiliation-url><afid>60069729</afid><affilname>Xiyuan Hospital</affilname><name-variant>Xiyuan Hospital</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103284</affiliation-url><afid>60103284</afid><affilname>China Academy of Chinese Medical Sciences</affilname><name-variant>China Academy of Chinese Medical Sciences</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55482669400</author-url><authid>55482669400</authid><authname>Luo J.</authname><surname>Luo</surname><given-name>Jing</given-name><initials>J.</initials><afid>60013449</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8578751100</author-url><authid>8578751100</authid><authname>Xu H.</authname><surname>Xu</surname><given-name>Hao</given-name><initials>H.</initials><afid>60069729</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56215510000</author-url><authid>56215510000</authid><authname>Liu B.</authname><surname>Liu</surname><given-name>Baoyan</given-name><initials>B.</initials><afid>60103284</afid></author><authkeywords>Acupuncture | Effectiveness | Randomized controlled trials | Real world research</authkeywords><intid>36086697</intid><article-number>153</article-number><source-id>34441</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929631121"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929631121?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929631121&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929631121&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929631121</prism:url><dc:identifier>SCOPUS_ID:84929631121</dc:identifier><eid>2-s2.0-84929631121</eid><dc:title>Assessment of left ventricular ejection fraction using low radiation dose computed tomography</dc:title><dc:creator>Yang Y.</dc:creator><prism:publicationName>Journal of Nuclear Cardiology</prism:publicationName><prism:issn>10713581</prism:issn><prism:eIssn>15326551</prism:eIssn><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12350-015-0123-6</prism:doi><dc:description>© 2015 American Society of Nuclear Cardiology Background: Cardiac CT is a non-invasive modality with the ability to estimate LVEF. However, given its limited temporal resolution and radiation, there has been initial resistance to use CT to measure LVEF. Developing an accurate, fast, low radiation dose protocol is desirable. Objective: The objective of this study is to demonstrate that a ‘low radiation dose’ 64 slice cardiac computed tomography (CT) protocol is feasible and can accurately measure left ventricular ejection fraction (LVEF) while delivering a radiation dose lower than radionuclide angiography (RNA). Methods: Patients undergoing RNA were prospectively screened and enrolled to undergo a ‘low-dose’ 64 slice CT LVEF protocol. LVEF measures, duration of each study and radiation dose between CT and RNA were compared. Results: A total of 77 patients (mean age = 61.8 ± 12.2 years and 58 men) were analyzed. The mean LVEF measured by CT and RNA were 41.9 ± 15.2% and 39.4 ± 13.9%, respectively, (P = 0.154) with a good correlation (r = 0.863). Bland-Altman plot revealed a good agreement between the CT and RNA LVEF (mean difference of −2.4). There was good agreement between CT LVEF and RNA for identifying patients with LVEF ≤30% (kappa = 0.693) and LVEF ≥50% (kappa = 0.749). The mean dose estimated effective dose for CT and RNA were 4.7 ± 1.6 and 9.5 ± 1.0 mSv, respectively. The mean CT LVEF imaging duration (4:32 ± 3:05 minutes) was significantly shorter than the RNA image acquisition time (9:05 ± 2:36 minutes; p &lt; 0.001). Conclusion: The results of our study suggest that low-dose CT LVEF protocol is feasible, accurate, and fast while delivering a lower radiation dose than traditional RNA.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011635</affiliation-url><afid>60011635</afid><affilname>University of Ottawa Heart Institute</affilname><name-variant>University of Ottawa Heart Institute</name-variant><affiliation-city>Ottawa</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028897</affiliation-url><afid>60028897</afid><affilname>University of Ottawa, Canada</affilname><name-variant>University of Ottawa</name-variant><affiliation-city>Ottawa</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011635</affiliation-url><afid>60011635</afid><affilname>University of Ottawa Heart Institute</affilname><name-variant>University of Ottawa Heart Institute</name-variant><affiliation-city>Ottawa</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56651739400</author-url><authid>56651739400</authid><authname>Yang Y.</authname><surname>Yang</surname><given-name>YiQi</given-name><initials>Y.</initials><afid>60011635</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35097026400</author-url><authid>35097026400</authid><authname>Yam Y.</authname><surname>Yam</surname><given-name>Yeung</given-name><initials>Y.</initials><afid>60011635</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55574216035</author-url><authid>55574216035</authid><authname>Chen L.</authname><surname>Chen</surname><given-name>Li</given-name><initials>L.</initials><afid>60011635</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55573420700</author-url><authid>55573420700</authid><authname>Aljizeeri A.</authname><surname>Aljizeeri</surname><given-name>Ahmed</given-name><initials>A.</initials><afid>60011635</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56652246700</author-url><authid>56652246700</authid><authname>Aliyary Ghraboghly S.</authname><surname>Aliyary Ghraboghly</surname><given-name>Siamak</given-name><initials>S.</initials><afid>60011635</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56359203100</author-url><authid>56359203100</authid><authname>Al-Harbi I.</authname><surname>Al-Harbi</surname><given-name>Ibraheem</given-name><initials>I.</initials><afid>60011635</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6507272152</author-url><authid>6507272152</authid><authname>Pen A.</authname><surname>Pen</surname><given-name>Ally</given-name><initials>A.</initials><afid>60011635</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35379224300</author-url><authid>35379224300</authid><authname>Ruddy T.</authname><surname>Ruddy</surname><given-name>Terrence D.</given-name><initials>T.D.</initials><afid>60011635</afid><afid>60028897</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35379224300</author-url><authid>35379224300</authid><authname>Ruddy T.</authname><surname>Ruddy</surname><given-name>Terrence D.</given-name><initials>T.D.</initials><afid>60011635</afid><afid>60028897</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:8286955100</author-url><authid>8286955100</authid><authname>Chow B.</authname><surname>Chow</surname><given-name>Benjamin J W</given-name><initials>B.J.W.</initials><afid>60011635</afid><afid>60028897</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:8286955100</author-url><authid>8286955100</authid><authname>Chow B.</authname><surname>Chow</surname><given-name>Benjamin J W</given-name><initials>B.J.W.</initials><afid>60011635</afid><afid>60028897</afid></author><authkeywords>Computed tomography | ejection fraction | radionuclide angiography</authkeywords><intid>1035985464</intid><source-id>17229</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929691993"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929691993?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929691993&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929691993&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929691993</prism:url><dc:identifier>SCOPUS_ID:84929691993</dc:identifier><eid>2-s2.0-84929691993</eid><dc:title>Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens</dc:title><dc:creator>Childs R.</dc:creator><prism:publicationName>Nature Reviews Drug Discovery</prism:publicationName><prism:issn>14741776</prism:issn><prism:eIssn>14741784</prism:eIssn><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1038/nrd4506</prism:doi><dc:description>© 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. Scientific insights into the human immune system have recently led to unprecedented breakthroughs in immunotherapy. In the twenty-first century, drugs and cell-based therapies developed to bolster humoral and T cell immunity represent an established and growing component of cancer therapeutics. Although natural killer (NK) cells have long been known to have advantages over T cells in terms of their capacity to induce antigen-independent host immune responses against malignancies, their therapeutic potential in the clinic has been largely unexplored. A growing number of scientific discoveries into pathways that both activate and suppress NK cell function, as well as methods to sensitize tumours to NK cell cytotoxicity, have led to the development of numerous pharmacological and genetic methods to enhance NK cell antitumour immunity. These findings, as well as advances in our ability to expand NK cells ex vivo and manipulate their capacity to home to the tumour, have now provided investigators with a variety of new methods and strategies to harness the full potential of NK cell-based cancer immunotherapy in the clinic.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005281</affiliation-url><afid>60005281</afid><affilname>National Heart, Lung, and Blood Institute</affilname><name-variant>NIH</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36449904100</author-url><authid>36449904100</authid><authname>Childs R.</authname><surname>Childs</surname><given-name>Richard W.</given-name><initials>R.W.</initials><afid>60005281</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507135383</author-url><authid>6507135383</authid><authname>Carlsten M.</authname><surname>Carlsten</surname><given-name>Mattias</given-name><initials>M.</initials><afid>60005281</afid></author><intid>1035993618</intid><source-id>20425</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929687811"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929687811?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929687811&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929687811&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929687811</prism:url><dc:identifier>SCOPUS_ID:84929687811</dc:identifier><eid>2-s2.0-84929687811</eid><dc:title>Transcutaneous carbon dioxide monitoring to avoid hypercapnia during complex catheter ablations: a feasibility study</dc:title><dc:creator>Cantillon D.</dc:creator><prism:publicationName>Journal of Interventional Cardiac Electrophysiology</prism:publicationName><prism:issn>1383875X</prism:issn><prism:eIssn>15728595</prism:eIssn><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10840-015-0013-5</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Purpose: The aim of this study was to determine if transcutaneous CO&lt;inf&gt;2&lt;/inf&gt; monitoring (TCO&lt;inf&gt;2&lt;/inf&gt;) is feasible to avoid hypercapnia during complex catheter ablation. Cumulative analgesic and anxiolytic effects during complex catheter ablation can rarely provoke hypoventilation and respiratory complications. End tidal CO&lt;inf&gt;2&lt;/inf&gt; monitors have limitations in non-ventilated patients, and frequent arterial blood gas sampling is impractical. Methods: Consecutive patients undergoing catheter ablation for atrial fibrillation (AF) or ventricular tachycardia (VT) received continuous TCO&lt;inf&gt;2&lt;/inf&gt; monitoring. Procedural evaluation of TCO&lt;inf&gt;2&lt;/inf&gt; was performed concomitantly with point-of-care arterial blood gas testing. Endpoints included PCO&lt;inf&gt;2&lt;/inf&gt; protocol feasibility, TCO&lt;inf&gt;2&lt;/inf&gt;/PCO&lt;inf&gt;2&lt;/inf&gt; agreement, and avoidance of hypercapnia-related procedural complications. Results: Fifty patients [AF n = 36 (72 %), VT n = 14 (28 %)] underwent catheter ablation (mean 221.7 ± 57.0 min duration, median 41.4 ± 21.1 min fluoroscopy) in which 6.0 ± 2.6 mg midazolam and 449 ± 225.5 mcg of fentanyl were administered. Monitoring protocol implementation was feasible in 50/50 (100 %) cases. Protocol-driven anesthesia consultation avoided an unplanned intubation in 1 case (2 %) and there was only 1 unplanned intubation (2 %) for oxygen desaturation due to heart failure without hypercapnia during a VT ablation (TCO&lt;inf&gt;2&lt;/inf&gt;/PCO&lt;inf&gt;2&lt;/inf&gt; agreement &lt;5 mmHg). There were no respiratory or pulseless electrical arrests (0 %) in the study. TCO&lt;inf&gt;2&lt;/inf&gt; and PCO&lt;inf&gt;2&lt;/inf&gt; correlated well (baseline: r = 0.75, p &lt; 0.001; 1 h:r= 0.72, p &lt; 0.001; 2 h: r = 0.55, p = 0.003; 3 h: r = 0.79, p = 0.02). However, desired agreement was lower than expected [baseline: 33/50 (66 %) &lt; 5 mmHg, 48/50 (96 %) &lt;10 mmHg; 1 h: 29/45 (64 %) &lt; 5 mmHg, 39/45 (87 %) &lt; 10 mmHg; 2 h: 14/26 (54 %) &lt; 5 mmHg, 22/26 (85 %) &lt; 10 mmHg; 3 h: 7/11 (64 %) &lt; 5 mmHg, 10/11 (91 %) &lt; 10 mmHg; &gt;3 h: 1/3 (33 %) &lt; 5 mmHg, 2/3 (66 %) &lt; 10 mmHg]. Conclusion: Transcutaneous CO&lt;inf&gt;2&lt;/inf&gt; monitoring is feasible during complex catheter ablation and correlates with invasively obtained data. However, further development is needed to achieve the desired level of agreement.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021160</affiliation-url><afid>60021160</afid><affilname>Cleveland Clinic Foundation</affilname><name-variant>Cleveland Clinic Foundation</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14621596000</author-url><authid>14621596000</authid><authname>Cantillon D.</authname><surname>Cantillon</surname><given-name>Daniel J.</given-name><initials>D.J.</initials><afid>60021160</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56653321000</author-url><authid>56653321000</authid><authname>Keene L.</authname><surname>Keene</surname><given-name>Lisa M.</given-name><initials>L.M.</initials><afid>60021160</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56653138500</author-url><authid>56653138500</authid><authname>Hakim A.</authname><surname>Hakim</surname><given-name>Ali</given-name><initials>A.</initials><afid>60021160</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56653069000</author-url><authid>56653069000</authid><authname>Spencer S.</authname><surname>Spencer</surname><given-name>Stephanie</given-name><initials>S.</initials><afid>60021160</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56653261100</author-url><authid>56653261100</authid><authname>Petro J.</authname><surname>Petro</surname><given-name>Jennifer</given-name><initials>J.</initials><afid>60021160</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56653486300</author-url><authid>56653486300</authid><authname>Ludvik M.</authname><surname>Ludvik</surname><given-name>Mary</given-name><initials>M.</initials><afid>60021160</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56653224000</author-url><authid>56653224000</authid><authname>Schell D.</authname><surname>Schell</surname><given-name>Dawn</given-name><initials>D.</initials><afid>60021160</afid></author><authkeywords>Catheter ablation | Hypercapnia | Transcutaneous carbon dioxide</authkeywords><intid>1785998725</intid><source-id>23879</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929650593"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929650593?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929650593&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929650593&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929650593</prism:url><dc:identifier>SCOPUS_ID:84929650593</dc:identifier><eid>2-s2.0-84929650593</eid><dc:title>Pancreatic Epithelial Cells Form Islet-Like Clusters in the Absence of Directed Migration</dc:title><dc:creator>Holfinger S.</dc:creator><prism:publicationName>Cellular and Molecular Bioengineering</prism:publicationName><prism:issn>18655025</prism:issn><prism:eIssn>18655033</prism:eIssn><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12195-015-0396-5</prism:doi><dc:description>© 2015 Biomedical Engineering Society The endocrine differentiation of pancreatic ductal epithelial cells is dependent upon their transition from a two-dimensional monolayer to three-dimensional islet-like clusters. Although clustering of these cells is commonly observed in vitro, it is not yet known whether clustering results from long-range signaling (e.g., chemotaxis) or short-range interactions (e.g., differential adhesion). To determine the mechanism behind clustering, we used experimental and computational modeling to determine the individual contributions of long-range and short-range interactions. Experimentally, the migration of PANC-1 cells on tissue culture treated plastic was tracked by time-lapse microscopy with or without a central cluster of cells that could act as a concentrated source of some long-range signal. Cell migration data was analyzed in terms of distance, number of steps, and migration rate in each direction, as well as migration rate as a function of distance from the cluster. Results did not indicate directed migration toward a central cluster (p &gt; 0.05). Computationally, an agent-based model was used to demonstrate the plausibility of clustering by short-range interactions only. In the presence of random cell migration, this model showed that a high, but not maximal, cell–cell adhesion probability and minimal cell–substrate adhesion probability supported the greatest islet-like cluster formation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003500</affiliation-url><afid>60003500</afid><affilname>Ohio State University</affilname><name-variant>The Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003500</affiliation-url><afid>60003500</afid><affilname>Ohio State University</affilname><name-variant>The Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003500</affiliation-url><afid>60003500</afid><affilname>Ohio State University</affilname><name-variant>The Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025778</affiliation-url><afid>60025778</afid><affilname>University Michigan Ann Arbor</affilname><name-variant>University of Michigan</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60090016</affiliation-url><afid>60090016</afid><affilname>Dorothy M. Davis Heart and Lung Research Institute</affilname><name-variant>Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55815568700</author-url><authid>55815568700</authid><authname>Holfinger S.</authname><surname>Holfinger</surname><given-name>Steven J.</given-name><initials>S.J.</initials><afid>60003500</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56004931000</author-url><authid>56004931000</authid><authname>Reinhardt J.</authname><surname>Reinhardt</surname><given-name>James W.</given-name><initials>J.W.</initials><afid>60003500</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602621252</author-url><authid>6602621252</authid><authname>Reen R.</authname><surname>Reen</surname><given-name>Rashmeet</given-name><initials>R.</initials><afid>60003500</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36867292100</author-url><authid>36867292100</authid><authname>Schultz K.</authname><surname>Schultz</surname><given-name>Kevin M.</given-name><initials>K.M.</initials><afid>60003500</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004430823</author-url><authid>7004430823</authid><authname>Passino K.</authname><surname>Passino</surname><given-name>Kevin M.</given-name><initials>K.M.</initials><afid>60003500</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56651972200</author-url><authid>56651972200</authid><authname>Ackerman W.</authname><surname>Ackerman</surname><given-name>William E.</given-name><initials>W.E.</initials><afid>60003500</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7005506173</author-url><authid>7005506173</authid><authname>Kniss D.</authname><surname>Kniss</surname><given-name>Douglas A.</given-name><initials>D.A.</initials><afid>60003500</afid><afid>60003500</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7005506173</author-url><authid>7005506173</authid><authname>Kniss D.</authname><surname>Kniss</surname><given-name>Douglas A.</given-name><initials>D.A.</initials><afid>60003500</afid><afid>60003500</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56651880700</author-url><authid>56651880700</authid><authname>Sander L.</authname><surname>Sander</surname><given-name>Leonard M.</given-name><initials>L.M.</initials><afid>60025778</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:26633841500</author-url><authid>26633841500</authid><authname>Gallego-Perez D.</authname><surname>Gallego-Perez</surname><given-name>Daniel</given-name><initials>D.</initials><afid>60003500</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7003314532</author-url><authid>7003314532</authid><authname>Gooch K.</authname><surname>Gooch</surname><given-name>Keith J.</given-name><initials>K.J.</initials><afid>60003500</afid><afid>60090016</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7003314532</author-url><authid>7003314532</authid><authname>Gooch K.</authname><surname>Gooch</surname><given-name>Keith J.</given-name><initials>K.J.</initials><afid>60003500</afid><afid>60090016</afid></author><authkeywords>Agent-based modeling | Diabetes | Differential adhesion | Islet cells | Time-lapse microscopy</authkeywords><intid>1535988733</intid><source-id>15500154705</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929792026"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929792026?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929792026&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929792026&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929792026</prism:url><dc:identifier>SCOPUS_ID:84929792026</dc:identifier><eid>2-s2.0-84929792026</eid><dc:title>The effect of a new communication template on anticipated willingness to initiate or resume allergen immunotherapy: An internet-based patient survey</dc:title><dc:creator>Calderon M.</dc:creator><prism:publicationName>Allergy, Asthma and Clinical Immunology</prism:publicationName><prism:issn>17101484</prism:issn><prism:eIssn>17101492</prism:eIssn><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>May 22, 2015</prism:coverDisplayDate><prism:doi>10.1186/s13223-015-0083-z</prism:doi><dc:description>© 2015 Calderon et al.; licensee BioMed Central. Background: A patient's knowledge of his/her allergic condition and treatment is a key factor in adherence and effectiveness. Methods: To assess patients' understanding of allergy and acceptance of allergen immunotherapy on the basis of (i) information given by their physician at the time of prescription and (ii) a new communication template viewed some months later, we performed an Internet-based survey of patient panels in France, Germany, Spain, the USA and Russia. The survey participants were either recent "early abandoners" (having discontinued allergen immunotherapy before the end of the prescribed course) or "non-starters" (having decided not to initiate a course of allergen immunotherapy recommended by their physician). All participants completed an on-line questionnaire immediately before and immediately after viewing the new communication template. The study's main objectives were to validate the new communication template and to assess its impact on anticipated willingness to initiate or resume allergen immunotherapy. Results: We surveyed a total of 261 patients (France: 57; Germany: 51; Spain: 52; USA: 51; Russia: 50), comprising 127 "early abandoners" and 134 "non-starters". The mean time since symptom onset and selection for the study was 14.5 years. Subcutaneous allergen immunotherapy had been prescribed in 60 % of cases. Twenty-eight percent of the participants did not know for which allergy they were being treated. Early abandoners reported a perception of low effectiveness (39 %) and complained about expense (39 %) and practical constraints (32 %). Twenty-two percent of the non-starters feared side effects. The communication template was considered to be clear (by 92 % of the patients), convincing (by 75 %) and reassuring (by 89 %); 80 % of the participants felt better informed afterwards, and 67 % stated that viewing the communication template would have made them more likely to continue or initiate allergen immunotherapy (overall willingness score: 5.65 out of 10 before viewing and 7.1 out of 10 afterwards). Conclusions: After viewing a new communication template on allergy and allergen immunotherapy, patients participating in the survey felt better informed and more likely to initiate or complete this therapy. It now remains to investigate the communication template's effect on actual acceptance of and adherence to allergen immunotherapy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009009</affiliation-url><afid>60009009</afid><affilname>Royal Brompton Hospital</affilname><name-variant>Brompton Hospital</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019600</affiliation-url><afid>60019600</afid><affilname>Nova Southeastern University</affilname><name-variant>Nova Southeastern University</name-variant><affiliation-city>Fort Lauderdale</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007740</affiliation-url><afid>60007740</afid><affilname>University of South Florida Tampa</affilname><name-variant>University of South Florida</name-variant><affiliation-city>Tampa</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008658</affiliation-url><afid>60008658</afid><affilname>Uniklinik Koln</affilname><affiliation-city>Koln</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112607885</affiliation-url><afid>112607885</afid><affilname>Center for Rhinology and Allergology</affilname><name-variant>Center for Rhinology and Allergology</name-variant><affiliation-city>Wiesbaden</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001972</affiliation-url><afid>60001972</afid><affilname>Universitatsklinikum Mannheim</affilname><name-variant>University of Heidelberg</name-variant><affiliation-city>Mannheim</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014959</affiliation-url><afid>60014959</afid><affilname>Amtssygehuset i Gentofte</affilname><name-variant>Gentofte Hospital</name-variant><affiliation-city>Hellerup</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019290</affiliation-url><afid>60019290</afid><affilname>Fundacion Jimenez Diaz</affilname><name-variant>Fundacion Jimenez Diaz</name-variant><affiliation-city>Madrid</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:109030947</affiliation-url><afid>109030947</afid><affilname>NRC Institute of Immunology FMBA</affilname><name-variant>Institute of Immunology FMBA of Russia</name-variant><affiliation-city>Moscow</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017438</affiliation-url><afid>60017438</afid><affilname>Hopital Arnaud de Villeneuve</affilname><name-variant>Hôpital Arnaud de Villeneuve</name-variant><affiliation-city>Montpellier</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018733</affiliation-url><afid>60018733</afid><affilname>Universite Paris Sorbonne - Paris IV</affilname><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005161322</author-url><authid>7005161322</authid><authname>Calderon M.</authname><surname>Calderon</surname><given-name>Moises A.</given-name><initials>M.A.</initials><afid>60009009</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35607150600</author-url><authid>35607150600</authid><authname>Cox L.</authname><surname>Cox</surname><given-name>Linda</given-name><initials>L.</initials><afid>60019600</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005524902</author-url><authid>7005524902</authid><authname>Casale T.</authname><surname>Casale</surname><given-name>Thomas B.</given-name><initials>T.B.</initials><afid>60007740</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55617900200</author-url><authid>55617900200</authid><authname>Mösges R.</authname><surname>Mösges</surname><given-name>Ralph</given-name><initials>R.</initials><afid>60008658</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:9744229500</author-url><authid>9744229500</authid><authname>Pfaar O.</authname><surname>Pfaar</surname><given-name>Oliver</given-name><initials>O.</initials><afid>112607885</afid><afid>60001972</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:9744229500</author-url><authid>9744229500</authid><authname>Pfaar O.</authname><surname>Pfaar</surname><given-name>Oliver</given-name><initials>O.</initials><afid>112607885</afid><afid>60001972</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35416427800</author-url><authid>35416427800</authid><authname>Malling H.</authname><surname>Malling</surname><given-name>Hans Jørgen</given-name><initials>H.J.</initials><afid>60014959</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7102442750</author-url><authid>7102442750</authid><authname>Sastre J.</authname><surname>Sastre</surname><given-name>Joaquin</given-name><initials>J.</initials><afid>60019290</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56655052300</author-url><authid>56655052300</authid><authname>Khaitov M.</authname><surname>Khaitov</surname><given-name>Musa</given-name><initials>M.</initials><afid>109030947</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7103273891</author-url><authid>7103273891</authid><authname>Demoly P.</authname><surname>Demoly</surname><given-name>Pascal</given-name><initials>P.</initials><afid>60017438</afid><afid>60018733</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7103273891</author-url><authid>7103273891</authid><authname>Demoly P.</authname><surname>Demoly</surname><given-name>Pascal</given-name><initials>P.</initials><afid>60017438</afid><afid>60018733</afid></author><authkeywords>Adherence | Allergen immunotherapy | Allergy | Information | Patient-physician communication</authkeywords><intid>36018564</intid><source-id>4800153203</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929688453"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929688453?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929688453&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929688453&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929688453</prism:url><dc:identifier>SCOPUS_ID:84929688453</dc:identifier><eid>2-s2.0-84929688453</eid><dc:title>Application of Gas chromatography–mass spectrometry for Assessment of the Condition of Intestinal Microflora</dc:title><dc:creator>Gurova M.</dc:creator><prism:publicationName>Biomedical Engineering</prism:publicationName><prism:issn>00063398</prism:issn><prism:eIssn>15738256</prism:eIssn><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10527-015-9486-x</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Using gas chromatography–mass spectrometer for studying and evaluating the intestinal microflora in humans with chronic gastroduodenitis compared to traditional methods of diagnosis and microbiological analysis can significantly extend the range of the defined microbiota and its possible changes at different phases of the disease, thus enabling successful correction of microflora and suggesting prospective targeted treatment, followed by evaluation of its effectiveness. The composition and quantity of microorganisms in the intestinal wall of 340 patients aged 12 to 18 years were analyzed using gas chromatography–mass spectrometer in the acute phase, in remission, and at the end of treatment.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114542262</affiliation-url><afid>114542262</afid><affilname>Belgorod National Research University</affilname><name-variant>Belgorod National Research University</name-variant><affiliation-city>Belgorod</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106002708</affiliation-url><afid>106002708</afid><affilname>V.A. Almazov Federal Center for Heart Blood and Endocrinology</affilname><name-variant>Almazov Federal Heart Blood and Endocrinology Centre</name-variant><affiliation-city>Saint Petersburg (ex Leningrad)</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60071000</affiliation-url><afid>60071000</afid><affilname>Southwest State University</affilname><name-variant>Southwest State University</name-variant><affiliation-city>Kursk</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56653377100</author-url><authid>56653377100</authid><authname>Gurova M.</authname><surname>Gurova</surname><given-name>M. M.</given-name><initials>M.M.</initials><afid>114542262</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56653220700</author-url><authid>56653220700</authid><authname>Romanova T.</authname><surname>Romanova</surname><given-name>T. A.</given-name><initials>T.A.</initials><afid>114542262</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56653237800</author-url><authid>56653237800</authid><authname>Novikova V.</authname><surname>Novikova</surname><given-name>V. P.</given-name><initials>V.P.</initials><afid>106002708</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56294388600</author-url><authid>56294388600</authid><authname>Avilova I.</authname><surname>Avilova</surname><given-name>I. A.</given-name><initials>I.A.</initials><afid>60071000</afid></author><intid>1035993482</intid><source-id>28203</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929993079"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929993079?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929993079&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929993079&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929993079</prism:url><dc:identifier>SCOPUS_ID:84929993079</dc:identifier><eid>2-s2.0-84929993079</eid><dc:title>Organization of subunits in the membrane domain of the bovine F-ATPase revealed by covalent cross-linking</dc:title><dc:creator>Lee J.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>21</prism:issueIdentifier><prism:pageRange>13308-13320</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M115.645283</prism:doi><dc:description>© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. The F-ATPase in bovine mitochondria is a membrane-bound complex of about 30 subunits of 18 different kinds. Currently, ∼85% of its structure is known. The enzyme has a membrane extrinsic catalytic domain, and a membrane intrinsic domain where the turning of the enzyme's rotor is generated from the transmembrane proton-motive force. The domains are linked by central and peripheral stalks. The central stalk and a hydrophobic ring of c-subunits in the membrane domain constitute the enzyme's rotor. The external surface of the catalytic domain and membrane subunit a are linked by the peripheral stalk, holding them static relative to the rotor. The membrane domain contains six additional subunits named ATP8, e, f, g, DAPIT (diabetes-associated protein in insulin-sensitive tissues), and 6.8PL (6.8-kDa proteolipid), each with a single predicted transmembrane α-helix, but their orientation and topography are unknown. Mutations in ATP8 uncouple the enzyme and interfere with its assembly, but its roles and the roles of the other five subunits are largely unknown. We have reacted accessible amino groups in the enzyme with bifunctional cross-linking agents and identified the linked residues. Cross-links involving the supernumerary subunits, where the structures are not known, show that the C terminus of ATP8 extends ∼70 Å from the membrane into the peripheral stalk and that the N termini of the other supernumerary subunits are on the same side of the membrane, probably in the mitochondrial matrix. These experiments contribute significantly toward building up a complete structural picture of the F-ATPase.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000368</affiliation-url><afid>60000368</afid><affilname>MRC Mitochondrial Biology Unit</affilname><name-variant>MRC Dunn Human Nutrition Unit</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010269</affiliation-url><afid>60010269</afid><affilname>The Medical Research Council Laboratory of Molecular Biology</affilname><name-variant>Medical Research Council</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56658071200</author-url><authid>56658071200</authid><authname>Lee J.</authname><surname>Lee</surname><given-name>Jennifer</given-name><initials>J.</initials><afid>60000368</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56583278000</author-url><authid>56583278000</authid><authname>Ding S.</authname><surname>Ding</surname><given-name>ShuJing</given-name><initials>S.</initials><afid>60000368</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56584384200</author-url><authid>56584384200</authid><authname>Walpole T.</authname><surname>Walpole</surname><given-name>Thomas B.</given-name><initials>T.B.</initials><afid>60000368</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:13613970200</author-url><authid>13613970200</authid><authname>Holding A.</authname><surname>Holding</surname><given-name>Andrew N.</given-name><initials>A.N.</initials><afid>60010269</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7102101173</author-url><authid>7102101173</authid><authname>Montgomery M.</authname><surname>Montgomery</surname><given-name>Martin G.</given-name><initials>M.G.</initials><afid>60000368</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004282077</author-url><authid>7004282077</authid><authname>Fearnley I.</authname><surname>Fearnley</surname><given-name>Ian M.</given-name><initials>I.M.</initials><afid>60000368</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35513086500</author-url><authid>35513086500</authid><authname>Walker J.</authname><surname>Walker</surname><given-name>John E.</given-name><initials>J.E.</initials><afid>60000368</afid></author><intid>536050733</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929619222"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929619222?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929619222&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929619222&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929619222</prism:url><dc:identifier>SCOPUS_ID:84929619222</dc:identifier><eid>2-s2.0-84929619222</eid><dc:title>Effect of apolipoprotein C3 genetic polymorphisms on serum lipid levels and the risk of intracerebral hemorrhage</dc:title><dc:creator>Jiang Y.</dc:creator><prism:publicationName>Lipids in Health and Disease</prism:publicationName><prism:eIssn>1476511X</prism:eIssn><prism:volume>14</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s12944-015-0047-9</prism:doi><dc:description>© 2015 Jiang et al.; licensee BioMed Central. Background: Serum lipid levels are associated with the risk of intracerebral hemorrhage (ICH). Genetic variants in the apolipoprotein C3 (APOC3) gene were associated with plasma triglyceride (TG) and very-low-density lipoprotein (VLDL) levels. The aim of this study was to evaluate the effect of two genetic variants (1100 C/T and 3238 C/G) of APOC3 on serum lipid levels and risk of ICH. Methods: A prospective hospital-based case-control design and logistic regression analysis were utilized. We enrolled 150 ICH patients and 150 age- and gender-matched controls. The APOC3 gene polymorphisms were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results: ICH patients had a significantly higher frequency of APOC3 3238 GG genotype [odds ratio (OR) =2.97, 95 % confidence interval (CI) = 1.20, 7.38; P = 0.02] and APOC3 3238 G allele (OR =1.53, 95 % CI = 1.03, 2.27; P = 0.04) than controls. The APOC3 3238 G allele was significantly associated with increasing plasma TG levels and VLDL levels both in ICH cases (P = 0.01) and controls (P = 0.02). No association was found between APOC3 1100 C/T polymorphisms and ICH. Conclusion: To the best of our knowledge, this is the first report in the literature that the APOC3 3238 GG genotype and G allele might contribute to an increased risk of ICH as a result of its effect on serum lipid levels.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016521</affiliation-url><afid>60016521</afid><affilname>Sichuan University</affilname><name-variant>Sichuan University</name-variant><affiliation-city>Chengdu</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56645172100</author-url><authid>56645172100</authid><authname>Jiang Y.</authname><surname>Jiang</surname><given-name>Yan</given-name><initials>Y.</initials><afid>60016521</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56278773900</author-url><authid>56278773900</authid><authname>Ma J.</authname><surname>Ma</surname><given-name>Junpeng</given-name><initials>J.</initials><afid>60016521</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56178827000</author-url><authid>56178827000</authid><authname>Li H.</authname><surname>Li</surname><given-name>Hao</given-name><initials>H.</initials><afid>60016521</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55924861000</author-url><authid>55924861000</authid><authname>Liu Y.</authname><surname>Liu</surname><given-name>Yi</given-name><initials>Y.</initials><afid>60016521</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56596156900</author-url><authid>56596156900</authid><authname>You C.</authname><surname>You</surname><given-name>Chao</given-name><initials>C.</initials><afid>60016521</afid></author><authkeywords>Apolipoprotein C3 | Gene polymorphism | Intracerebral hemorrhage | Lipid</authkeywords><intid>2035984722</intid><article-number>48</article-number><source-id>14126</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929408013"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929408013?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929408013&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929408013&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929408013</prism:url><dc:identifier>SCOPUS_ID:84929408013</dc:identifier><eid>2-s2.0-84929408013</eid><dc:title>Risk of mortality and vascular events in men and women with type 1 diabetes | Risiko für Mortalität und vaskuläre Ereignisse bei Frauen und Männern mit Typ-1-Diabetes</dc:title><dc:creator>Jecht M.</dc:creator><prism:publicationName>Urologe</prism:publicationName><prism:issn>03402592</prism:issn><prism:eIssn>14330563</prism:eIssn><prism:volume>54</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>721-722</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00120-015-3851-y</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>GK Havelhöhe – Diabetologie</affilname><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14625178600</author-url><authid>14625178600</authid><authname>Jecht M.</authname><surname>Jecht</surname><given-name>M.</given-name><initials>M.</initials><afid/></author><intid>1035952014</intid><article-number>17</article-number><source-id>20535</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929463979"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929463979?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929463979&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929463979&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929463979</prism:url><dc:identifier>SCOPUS_ID:84929463979</dc:identifier><eid>2-s2.0-84929463979</eid><dc:title>Holidays, celebrations, and commiserations: Measuring drinking during feasting and fasting to improve national and individual estimates of alcohol consumption</dc:title><dc:creator>Bellis M.</dc:creator><prism:publicationName>BMC Medicine</prism:publicationName><prism:eIssn>17417015</prism:eIssn><prism:volume>13</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>May 22, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12916-015-0337-0</prism:doi><dc:description>© Bellis et al.; licensee BioMed Central. Background: Accurate measures of alcohol consumption are critical in assessing health harms caused by alcohol. In many countries, there are large discrepancies between survey-based measures of consumption and those based on alcohol sales. In England, surveys measuring typical alcohol consumption account for only around 60% of alcohol sold. Here, using a national survey, we measure both typical drinking and atypical/special occasion drinking (i.e., feasting and fasting) in order to develop more complete measures of alcohol consumption. Methods: A national random probability telephone survey was implemented (May 2013 to April 2014). Inclusion criteria were resident in England and aged 16years or over. Respondents (n=6,085) provided information on typical drinking (amounts per day, drinking frequency) and changes in consumption associated with routine atypical days (e.g., Friday nights) and special dinking periods (e.g., holidays) and events (e.g., weddings). Generalized linear modelling was used to identify additional alcohol consumption associated with atypical/special occasion drinking by age, sex, and typical drinking level. Results: Accounting for atypical/special occasion drinking added more than 120 million UK units of alcohol/week (~12 million bottles of wine) to population alcohol consumption in England. The greatest impact was seen among 25- to 34-year-olds with the highest typical consumption, where atypical/special occasions added approximately 18 units/week (144g) for both sexes. Those reporting the lowest typical consumption (≤1 unit/week) showed large relative increases in consumption (209.3%) with most drinking associated with special occasions. In some demographics, adjusting for special occasions resulted in overall reductions in annual consumption (e.g., females, 65 to 74 years in the highest typical drinking category). Conclusions: Typical drinking alone can be a poor proxy for actual alcohol consumption. Accounting for atypical/special occasion drinking fills 41.6% of the gap between surveyed consumption and national sales in England. These additional units are inevitably linked to increases in lifetime risk of alcohol-related disease and injury, particularly as special occasions often constitute heavy drinking episodes. Better population measures of celebratory, festival, and holiday drinking are required in national surveys in order to adequately measure both alcohol consumption and the health harms associated with special occasion drinking.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025779</affiliation-url><afid>60025779</afid><affilname>Bangor University</affilname><name-variant>Bangor University</name-variant><affiliation-city>Bangor</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023998</affiliation-url><afid>60023998</afid><affilname>Cardiff University</affilname><name-variant>University of Wales</name-variant><affiliation-city>Cardiff</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028355</affiliation-url><afid>60028355</afid><affilname>Liverpool John Moores University</affilname><name-variant>Liverpool John Moores University</name-variant><affiliation-city>Liverpool</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031331</affiliation-url><afid>60031331</afid><affilname>London School of Hygiene &amp; Tropical Medicine</affilname><name-variant>London School of Hygiene and Tropical Medicine</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26643418800</author-url><authid>26643418800</authid><authname>Bellis M.</authname><surname>Bellis</surname><given-name>Mark A.</given-name><initials>M.A.</initials><afid>60025779</afid><afid>60023998</afid><afid>60028355</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26643418800</author-url><authid>26643418800</authid><authname>Bellis M.</authname><surname>Bellis</surname><given-name>Mark A.</given-name><initials>M.A.</initials><afid>60025779</afid><afid>60023998</afid><afid>60028355</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26643418800</author-url><authid>26643418800</authid><authname>Bellis M.</authname><surname>Bellis</surname><given-name>Mark A.</given-name><initials>M.A.</initials><afid>60025779</afid><afid>60023998</afid><afid>60028355</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7202448813</author-url><authid>7202448813</authid><authname>Hughes K.</authname><surname>Hughes</surname><given-name>Karen</given-name><initials>K.</initials><afid>60028355</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:34770238900</author-url><authid>34770238900</authid><authname>Jones L.</authname><surname>Jones</surname><given-name>Lisa</given-name><initials>L.</initials><afid>60028355</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:16426028900</author-url><authid>16426028900</authid><authname>Morleo M.</authname><surname>Morleo</surname><given-name>Michela</given-name><initials>M.</initials><afid>60028355</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56645807900</author-url><authid>56645807900</authid><authname>Nicholls J.</authname><surname>Nicholls</surname><given-name>James</given-name><initials>J.</initials><afid>60031331</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55023192200</author-url><authid>55023192200</authid><authname>McCoy E.</authname><surname>McCoy</surname><given-name>Ellie</given-name><initials>E.</initials><afid>60028355</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56645635600</author-url><authid>56645635600</authid><authname>Webster J.</authname><surname>Webster</surname><given-name>Jane</given-name><initials>J.</initials><afid>60028355</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603085104</author-url><authid>6603085104</authid><authname>Sumnall H.</authname><surname>Sumnall</surname><given-name>Harry</given-name><initials>H.</initials><afid>60028355</afid></author><authkeywords>Abstinence | Alcohol | Binge drinking | Holidays | Sales | Surveys</authkeywords><intid>535964954</intid><article-number>113</article-number><source-id>28111</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929456362"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929456362?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929456362&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929456362&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0367326X15001008"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929456362</prism:url><dc:identifier>SCOPUS_ID:84929456362</dc:identifier><eid>2-s2.0-84929456362</eid><dc:title>Isolation and quantification of oligomeric and polymeric procyanidins in leaves and flowers of Hawthorn (Crataegus spp.)</dc:title><dc:creator>Hellenbrand N.</dc:creator><prism:publicationName>Fitoterapia</prism:publicationName><prism:issn>0367326X</prism:issn><prism:eIssn>18736971</prism:eIssn><prism:volume>104</prism:volume><prism:pageRange>14-22</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.fitote.2015.04.010</prism:doi><pii>S0367326X15001008</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Proanthocyanidins (PAs) constitute a class of polyphenols with flavan-3-ols as monomeric building blocks. These polyphenols are mostly quantified by colorimetric methods or by chromatographic determination of monomeric flavan-3-ols or low molecular oligomers as lead compounds. No reliable analytical methods are available for unambiguous identification of the homologues series of oligo- and polymeric PAs. For Hawthorn leaf and flower (Crataegi folium cum flore) from Crataegus spp. (Rosaceae) a protocol for preparative isolation of oligomeric and polymeric PAs from an acetone-water extract was developed, yielding procyanidin reference clusters with defined degree of polymerization (DP) from 2 to 10 besides a procyanidin-polymer. Identity and purity of these clusters were proven by HPLC, MS and in part NMR studies. For identification and quantification from Hawthorn an ICH-Q2 validated UHPLC method with fluorimetric detection and less than 10 min runtime was developed. The method enabled quantification of procyanidin clusters with DP from 2 to 10 besides the polymer fraction. Batch analysis revealed procyanidin contents of about 20 to 45 mg/g from a homologues series of oligomeric PAs and about 50% of polymer fraction. Monitoring of procyanidin distribution during seasonal growth of fresh plants of Crataegus monogyna showed more or less constant contents between 20 and 55 mg/g dry weight of oligomeric procyanidins during the growing season in the different plant organs with strong accumulation in the flowers and fruits (55 mg/g dry weight). From these data it can be speculated that procyanidins serve as part of the plants defense system in the reproductive organs of the plant.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000401</affiliation-url><afid>60000401</afid><affilname>Westfalische Wilhelms-Universitat Munster</affilname><name-variant>University of Münster</name-variant><affiliation-city>Munster</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24401320000</author-url><authid>24401320000</authid><authname>Hellenbrand N.</authname><surname>Hellenbrand</surname><given-name>N.</given-name><initials>N.</initials><afid>60000401</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26538018800</author-url><authid>26538018800</authid><authname>Sendker J.</authname><surname>Sendker</surname><given-name>J.</given-name><initials>J.</initials><afid>60000401</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6507867540</author-url><authid>6507867540</authid><authname>Lechtenberg M.</authname><surname>Lechtenberg</surname><given-name>M.</given-name><initials>M.</initials><afid>60000401</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603603148</author-url><authid>6603603148</authid><authname>Petereit F.</authname><surname>Petereit</surname><given-name>F.</given-name><initials>F.</initials><afid>60000401</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005032220</author-url><authid>7005032220</authid><authname>Hensel A.</authname><surname>Hensel</surname><given-name>A.</given-name><initials>A.</initials><afid>60000401</afid></author><authkeywords>Crataegus | Diol-phase | Hawthorn | Oligomeric and polymeric procyanidins | UHPLC</authkeywords><intid>2035959378</intid><source-id>18077</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929453192"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929453192?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929453192&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929453192&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S037887411500255X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929453192</prism:url><dc:identifier>SCOPUS_ID:84929453192</dc:identifier><eid>2-s2.0-84929453192</eid><dc:title>Past, present and perspectives of Manipur traditional medicine: A major health care system available for rural population in the North-East India</dc:title><dc:creator>Deb L.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>169</prism:volume><prism:pageRange>387-400</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2014.12.074</prism:doi><pii>S037887411500255X</pii><dc:description>© 2015 Elsevier Ireland Ltd.All rights reserved. Background Traditional health care practices are still being followed extensively in Manipur, North-East India. This is the major or the only medical facility available in some rural areas of Manipur. Cross cultural ethno-pharmacological survey was conducted to document traditional health care practices by Maiba-Maibi (male-female traditional health care practitioners of Manipur). Materials and methods All together 59 traditional practitioners belonging to 12 ethnic communities in nine districts of the Manipur state were interviewed. A predesigned questionnaire was used for interviews, which included queries for type of ailments treating, symptoms, bioresources used, method of preparation, dosage forms, formulation, unit doses. The entire interviews were done in the residence of respective Maiba-Maibi, their patient handing and preparation of medicinal formulations were documented in written and audio-visual format. Results The survey recorded traditional knowledge on 949 formulations used for 66 human ailments. Five hundred forty six plant products, 42 animal products and 22 organic/inorganic materials were found to be used in these 949 formulations. Five plant species - Zingiber officinale (Zingiberaceae), Cocos nucifera (Arecaceae), Oroxylum indicum (Bignonaceae), Curcuma longa (Zingiberaceae) and Allium sativum (Liliaceae) used by maximum number of Maiba and Maibi in maximum number of formulations. Recommendation This particular method of documentation keeps traditional knowledge alive. The WHO estimated perspective of traditional medicine across the world. These observations support therapeutic worth of Manipur Traditional medicines (MTM). Having generated a large database in course of this survey, next focus targeted for the scientific justification of MTM with an aim to develop commercially viable products.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112604049</affiliation-url><afid>112604049</afid><affilname>Institute of Bioresources and Sustainable Development (IBSD)</affilname><name-variant>Institute of Bioresources and Sustainable Development (IBSD)</name-variant><affiliation-city>Imphal</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115250055</affiliation-url><afid>115250055</afid><affilname>Apunba Manipur Maiba Maibi Phurup (AMMMP)</affilname><name-variant>Apunba Manipur Maiba Maibi Phurup (AMMMP)</name-variant><affiliation-city>Imphal</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112604049</affiliation-url><afid>112604049</afid><affilname>Institute of Bioresources and Sustainable Development (IBSD)</affilname><name-variant>Institute of Bioresources and Sustainable Development (IBSD)</name-variant><affiliation-city>Imphal</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:34167756200</author-url><authid>34167756200</authid><authname>Deb L.</authname><surname>Deb</surname><given-name>Lokesh</given-name><initials>L.</initials><afid>112604049</afid><afid>112604049</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:34167756200</author-url><authid>34167756200</authid><authname>Deb L.</authname><surname>Deb</surname><given-name>Lokesh</given-name><initials>L.</initials><afid>112604049</afid><afid>112604049</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56133464700</author-url><authid>56133464700</authid><authname>Laishram S.</authname><surname>Laishram</surname><given-name>Surbala</given-name><initials>S.</initials><afid>112604049</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56648041100</author-url><authid>56648041100</authid><authname>Khumukcham N.</authname><surname>Khumukcham</surname><given-name>Nongalleima</given-name><initials>N.</initials><afid>112604049</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56648130000</author-url><authid>56648130000</authid><authname>Ningthoukhongjam D.</authname><surname>Ningthoukhongjam</surname><given-name>Dhaneshwor</given-name><initials>D.</initials><afid>112604049</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56648148500</author-url><authid>56648148500</authid><authname>Nameirakpam S.</authname><surname>Nameirakpam</surname><given-name>Surjit Singh</given-name><initials>S.S.</initials><afid>112604049</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55623683500</author-url><authid>55623683500</authid><authname>Dey A.</authname><surname>Dey</surname><given-name>Amitabha</given-name><initials>A.</initials><afid>112604049</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55235949400</author-url><authid>55235949400</authid><authname>Moirangthem D.</authname><surname>Moirangthem</surname><given-name>Dinesh Singh</given-name><initials>D.S.</initials><afid>112604049</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603003793</author-url><authid>6603003793</authid><authname>Talukdar N.</authname><surname>Talukdar</surname><given-name>Narayan Chandra</given-name><initials>N.C.</initials><afid>112604049</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56648037400</author-url><authid>56648037400</authid><authname>Ningthoukhongjam T.</authname><surname>Ningthoukhongjam</surname><given-name>Tombi Raj</given-name><initials>T.R.</initials><afid>115250055</afid></author><authkeywords>Maiba and Maibi | Manipur | North-East India | Traditional health care practice | Traditional knowledge</authkeywords><intid>1535963696</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929459618"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929459618?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929459618&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929459618&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0196978115001448"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929459618</prism:url><dc:identifier>SCOPUS_ID:84929459618</dc:identifier><eid>2-s2.0-84929459618</eid><dc:title>Effects of Apelin on RAW264.7 cells under both normal and hypoxic conditions</dc:title><dc:creator>Yang F.</dc:creator><prism:publicationName>Peptides</prism:publicationName><prism:issn>01969781</prism:issn><prism:eIssn>18735169</prism:eIssn><prism:volume>69</prism:volume><prism:pageRange>133-143</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.peptides.2015.04.025</prism:doi><pii>S0196978115001448</pii><dc:description>© 2015 Elsevier Inc. All rights reserved. Macrophages are an important source of pro-inflammatory and pro-angiogenic factors, which can promote pathological processes involving inflammation and angiogenesis. This study investigated the effects of Apelin on macrophages under both normal and hypoxic conditions. Under normal culture conditions, Apelin down-regulated the mRNA expression levels of monocyte chemotactic protein 1 (MCP1), monocyte chemotactic protein 3 (MCP3), macrophage inflammatory protein 1 (MIP1α, MIP1β), vascular endothelial growth factor A (VEGFA), Angiopoietin 2 (Ang2) and tumor necrosis factor α (TNFα). The supernatant concentrations of MCP1, MCP3, MIP1α, MIP1β, macrophage inflammatory protein 2 (MIP2) and TNFα proteins were significantly decreased in the Apelin treated group. Hypoxia induced profound up-regulations of the angiogenic, chemokine, and inflammatory factors at both the mRNA and protein levels. Apelin suppressed the hypoxia-induced increases in MCP1, MCP3, MIP2, MIP1β and TNFα expression. The underlying mechanism of Apelin inhibit inflammation is regulating NF-κB/JNK signal pathway. Additionally, Apelin can protect macrophages from apoptosis and can enhance cell migration during hypoxia. And cleaved Caspase9/3 pathways were involved in Apelin inhibiting RAW264.7 apoptosis. In conclusion, we showed the effect of Apelin on RAW264.7 macrophage under normal and hypoxic condition, which could further influence the angiogenesis and inflammation process that promoted by macrophages.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014966</affiliation-url><afid>60014966</afid><affilname>Peking University</affilname><name-variant>Peking University</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56647314700</author-url><authid>56647314700</authid><authname>Yang F.</authname><surname>Yang</surname><given-name>Fan</given-name><initials>F.</initials><afid>60014966</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24740700400</author-url><authid>24740700400</authid><authname>Bai Y.</authname><surname>Bai</surname><given-name>Yujing</given-name><initials>Y.</initials><afid>60014966</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55545073200</author-url><authid>55545073200</authid><authname>Jiang Y.</authname><surname>Jiang</surname><given-name>Yanrong</given-name><initials>Y.</initials><afid>60014966</afid></author><authkeywords>Angiogenesis | Apelin | Hypoxia | Inflammation | Macrophage</authkeywords><intid>1785965465</intid><source-id>14222</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929580683"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929580683?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929580683&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929580683&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167639315000400"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929580683</prism:url><dc:identifier>SCOPUS_ID:84929580683</dc:identifier><eid>2-s2.0-84929580683</eid><dc:title>Wavelet leader multifractal analysis of period and amplitude sequences from sustained vowels</dc:title><dc:creator>Leonarduzzi R.</dc:creator><prism:publicationName>Speech Communication</prism:publicationName><prism:issn>01676393</prism:issn><prism:volume>72</prism:volume><prism:pageRange>1-12</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.specom.2015.04.004</prism:doi><pii>S0167639315000400</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Irregularities in the amplitude and period are characteristic of both normal and pathological sustained vowels; they are a product of perturbations inherent in the phonation process. Their analysis provides useful diagnostic information for several vocal pathologies, and their accurate modelling has been shown to improve the quality of synthesized voice. In this work, we propose the application of multifractal analysis for the characterization of amplitude and period fluctuations in sustained vowels. Using a combination of high order statistics, this signal processing tool generalizes previous approaches and provides a rich description of the fluctuation in the regularity of the data. Our results suggest that both amplitude and period fluctuations show a multifractal behavior, independent of the gender of the speaker. We also analyze the problem of classification between healthy and nonhealthy speakers as an example to show the usefulness of multifractal attributes. We conclude that amplitude and period sequences of sustained vowels should be analyzed and modelled by the multifractal paradigm.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025269</affiliation-url><afid>60025269</afid><affilname>Universidad Nacional de Entre Rios</affilname><name-variant>Universidad Nacional de Entre Rios</name-variant><affiliation-city>Concepcion del Uruguay</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004518</affiliation-url><afid>60004518</afid><affilname>Consejo Nacional de Investigaciones Cientificas y Tecnicas</affilname><name-variant>CONICET</name-variant><affiliation-city>Buenos Aires</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36718012900</author-url><authid>36718012900</authid><authname>Leonarduzzi R.</authname><surname>Leonarduzzi</surname><given-name>Roberto F.</given-name><initials>R.F.</initials><afid>60025269</afid><afid>60004518</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36718012900</author-url><authid>36718012900</authid><authname>Leonarduzzi R.</authname><surname>Leonarduzzi</surname><given-name>Roberto F.</given-name><initials>R.F.</initials><afid>60025269</afid><afid>60004518</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56563054800</author-url><authid>56563054800</authid><authname>Alzamendi G.</authname><surname>Alzamendi</surname><given-name>Gabriel A.</given-name><initials>G.A.</initials><afid>60025269</afid><afid>60004518</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56563054800</author-url><authid>56563054800</authid><authname>Alzamendi G.</authname><surname>Alzamendi</surname><given-name>Gabriel A.</given-name><initials>G.A.</initials><afid>60025269</afid><afid>60004518</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6507305027</author-url><authid>6507305027</authid><authname>Schlotthauer G.</authname><surname>Schlotthauer</surname><given-name>Gastón</given-name><initials>G.</initials><afid>60025269</afid><afid>60004518</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6507305027</author-url><authid>6507305027</authid><authname>Schlotthauer G.</authname><surname>Schlotthauer</surname><given-name>Gastón</given-name><initials>G.</initials><afid>60025269</afid><afid>60004518</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7402581540</author-url><authid>7402581540</authid><authname>Torres M.</authname><surname>Torres</surname><given-name>María E.</given-name><initials>M.E.</initials><afid>60025269</afid><afid>60004518</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7402581540</author-url><authid>7402581540</authid><authname>Torres M.</authname><surname>Torres</surname><given-name>María E.</given-name><initials>M.E.</initials><afid>60025269</afid><afid>60004518</afid></author><authkeywords>Amplitude and period sequences | Multifractal analysis | Sustained vowels | Wavelet leaders</authkeywords><intid>1785982850</intid><source-id>23671</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930002072"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930002072?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930002072&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930002072&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930002072</prism:url><dc:identifier>SCOPUS_ID:84930002072</dc:identifier><eid>2-s2.0-84930002072</eid><dc:title>Differences in hematopoietic stem cells contribute to sexually dimorphic inflammatory responses to high fat diet-induced obesity</dc:title><dc:creator>Singer K.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>21</prism:issueIdentifier><prism:pageRange>13250-13262</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M114.634568</prism:doi><dc:description>© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. Womenof reproductive age are protected from metabolic disease relative to postmenopausal women and men. Most preclinical rodent studies are skewed toward the use of male mice to study obesity-induced metabolic dysfunction because of a similar protection observed in female mice. How sex differences in obesity-induced inflammatory responses contribute to these observations is unknown. We have compared and contrasted the effects of high fat diet-induced obesity on glucose metabolism and leukocyte activation in multiple depots in male and female C57Bl/6 mice. With both short term and long term high fat diet, male mice demonstrated increased weight gain and CD11c&lt;sup&gt;+&lt;/sup&gt; adipose tissue macrophage content compared with female mice despite similar degrees of adipocyte hypertrophy. Competitive bone marrow transplant studies demonstrated that obesity induced a preferential contribution of male hematopoietic cells to circulating leukocytes and adipose tissue macrophages compared with female cells independent of the sex of the recipient. Sex differences in macrophage and hematopoietic cell in vitro activation in response to obesogenic cues were observed to explain these results. In summary, this report demonstrates that male and female leukocytes and hematopoietic stem cells have cell-autonomous differences in their response to obesity that contribute to an amplified response in males compared with females.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033182</affiliation-url><afid>60033182</afid><affilname>University of Michigan Medical School</affilname><name-variant>University of Michigan Medical School</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033182</affiliation-url><afid>60033182</afid><affilname>University of Michigan Medical School</affilname><name-variant>University of Michigan Medical School</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025778</affiliation-url><afid>60025778</afid><affilname>University Michigan Ann Arbor</affilname><name-variant>University of Michigan</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025615</affiliation-url><afid>60025615</afid><affilname>Soonchunhyang University</affilname><name-variant>Soonchunhyang University</name-variant><affiliation-city>Asan</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025778</affiliation-url><afid>60025778</afid><affilname>University Michigan Ann Arbor</affilname><name-variant>University of Michigan</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115281021</affiliation-url><afid>115281021</afid><affilname>Division of Pediatric Endocrinology. D1205 MPB</affilname><name-variant>Division of Pediatric Endocrinology. D1205 MPB</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35300925800</author-url><authid>35300925800</authid><authname>Singer K.</authname><surname>Singer</surname><given-name>Kanakadurga</given-name><initials>K.</initials><afid>60033182</afid><afid>115281021</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35300925800</author-url><authid>35300925800</authid><authname>Singer K.</authname><surname>Singer</surname><given-name>Kanakadurga</given-name><initials>K.</initials><afid>60033182</afid><afid>115281021</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56276421600</author-url><authid>56276421600</authid><authname>Maley N.</authname><surname>Maley</surname><given-name>Nidhi</given-name><initials>N.</initials><afid>60033182</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55614338100</author-url><authid>55614338100</authid><authname>Mergian T.</authname><surname>Mergian</surname><given-name>Taleen</given-name><initials>T.</initials><afid>60033182</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55929976100</author-url><authid>55929976100</authid><authname>DelProposto J.</authname><surname>DelProposto</surname><given-name>Jennifer</given-name><initials>J.</initials><afid>60033182</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56658167000</author-url><authid>56658167000</authid><authname>Cho K.</authname><surname>Cho</surname><given-name>Kae Won</given-name><initials>K.W.</initials><afid>60025615</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36652279900</author-url><authid>36652279900</authid><authname>Zamarron B.</authname><surname>Zamarron</surname><given-name>Brian F.</given-name><initials>B.F.</initials><afid>60033182</afid><afid>60033182</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36652279900</author-url><authid>36652279900</authid><authname>Zamarron B.</authname><surname>Zamarron</surname><given-name>Brian F.</given-name><initials>B.F.</initials><afid>60033182</afid><afid>60033182</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:49663800400</author-url><authid>49663800400</authid><authname>Martinez-Santibanez G.</authname><surname>Martinez-Santibanez</surname><given-name>Gabriel</given-name><initials>G.</initials><afid>60025778</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36980864900</author-url><authid>36980864900</authid><authname>Geletka L.</authname><surname>Geletka</surname><given-name>Lynn</given-name><initials>L.</initials><afid>60033182</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56276343800</author-url><authid>56276343800</authid><authname>Muir L.</authname><surname>Muir</surname><given-name>Lindsey</given-name><initials>L.</initials><afid>60033182</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56604121200</author-url><authid>56604121200</authid><authname>Wachowiak P.</authname><surname>Wachowiak</surname><given-name>Phillip</given-name><initials>P.</initials><afid>60025778</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56658634300</author-url><authid>56658634300</authid><authname>Demirjian C.</authname><surname>Demirjian</surname><given-name>Chaghig</given-name><initials>C.</initials><afid>60025778</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:6507222597</author-url><authid>6507222597</authid><authname>Lumeng C.</authname><surname>Lumeng</surname><given-name>Carey N.</given-name><initials>C.N.</initials><afid>60033182</afid><afid>60033182</afid><afid>60025778</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:6507222597</author-url><authid>6507222597</authid><authname>Lumeng C.</authname><surname>Lumeng</surname><given-name>Carey N.</given-name><initials>C.N.</initials><afid>60033182</afid><afid>60033182</afid><afid>60025778</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:6507222597</author-url><authid>6507222597</authid><authname>Lumeng C.</authname><surname>Lumeng</surname><given-name>Carey N.</given-name><initials>C.N.</initials><afid>60033182</afid><afid>60033182</afid><afid>60025778</afid></author><intid>536050835</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929409111"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929409111?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929409111&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929409111&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929409111</prism:url><dc:identifier>SCOPUS_ID:84929409111</dc:identifier><eid>2-s2.0-84929409111</eid><dc:title>Genetic aspects of erectile dysfunction | Genetische Aspekte der erektilen Dysfunktion</dc:title><dc:creator>Eisenhardt A.</dc:creator><prism:publicationName>Urologe</prism:publicationName><prism:issn>03402592</prism:issn><prism:eIssn>14330563</prism:eIssn><prism:volume>54</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>662-667</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00120-015-3793-4</prism:doi><dc:description>© 2015, Springer-Verlag Berlin Heidelberg. Background: Erectile dysfunction (ED) is a common disorder in man that influences the quality of life of the patient and his partner. Known risk factors for ED comprise diabetes, coronary artery disease, hypertension but also lifestyle modifications such as smoking, diminished physical activity as well as obesity. In this manuscript the current scientific literature about genetics and erectile dysfunction is reviewed. Materials and methods: A literature search using the databank PubMed covering the topics genetics and erectile dysfunction was performed and relevant papers selected for presentation. Results: Several aspects of genetics and ED are described in the current literature. Association studies of candidate polymorphisms and ED risk in comparison to healthy controls is a major area of research. Another topic is the genome-wide search for candidate polymorphisms with erectile dysfunction. The paper closes with the presentation of the pharmacogenomic analysis of treatment response to phosphodiesterase-5 inhibitors. Discussion: The heterogeneous results of genetic association studies are possibly due to small sample sizes of the study population and/or due to ethnic differences of the analyzed populations. This underlines the need for validation of this data in larger prospective multinational multicenter studies.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106208247</affiliation-url><afid>106208247</afid><affilname>PUR/R Praxisklinik Urologie Rhein-Ruhr</affilname><name-variant>Praxisklinik Urologie Rhein-Ruhr</name-variant><affiliation-city>Mulheim an der Ruhr</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60077801</affiliation-url><afid>60077801</afid><affilname>Kliniken Maria Hilf GmbH</affilname><name-variant>Kliniken Maria Hilf</name-variant><affiliation-city>Monchengladbach</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007896</affiliation-url><afid>60007896</afid><affilname>Universitats Klinikum Essen und Medizinische Fakultat</affilname><name-variant>Universitätsklinikum Essen</name-variant><affiliation-city>Essen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602750311</author-url><authid>6602750311</authid><authname>Eisenhardt A.</authname><surname>Eisenhardt</surname><given-name>A.</given-name><initials>A.</initials><afid>106208247</afid><afid>60007896</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602750311</author-url><authid>6602750311</authid><authname>Eisenhardt A.</authname><surname>Eisenhardt</surname><given-name>A.</given-name><initials>A.</initials><afid>106208247</afid><afid>60007896</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005715830</author-url><authid>7005715830</authid><authname>Sperling H.</authname><surname>Sperling</surname><given-name>H.</given-name><initials>H.</initials><afid>60077801</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7102090628</author-url><authid>7102090628</authid><authname>Rübben H.</authname><surname>Rübben</surname><given-name>H.</given-name><initials>H.</initials><afid>60007896</afid></author><authkeywords>Genetic association studies | Male impotence | Pharmacogenetics | Phosphodiesterase-5 inhibitors | Risk factors</authkeywords><intid>1785956600</intid><article-number>7</article-number><source-id>20535</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929403125"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929403125?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929403125&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929403125&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0091305715001318"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929403125</prism:url><dc:identifier>SCOPUS_ID:84929403125</dc:identifier><eid>2-s2.0-84929403125</eid><dc:title>Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers</dc:title><dc:creator>Roche D.</dc:creator><prism:publicationName>Pharmacology Biochemistry and Behavior</prism:publicationName><prism:issn>00913057</prism:issn><prism:eIssn>18735177</prism:eIssn><prism:volume>134</prism:volume><prism:pageRange>92-98</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.pbb.2015.04.013</prism:doi><pii>S0091305715001318</pii><dc:description>© 2015 Published by Elsevier Inc. Heavy drinking smokers constitute a distinct sub-population of smokers for whom traditional smoking cessation therapies may not be effective. Recent evidence suggested that combined varenicline (VAR) and naltrexone (NTX) therapy may be more efficacious than either monotherapy alone in reducing smoking and drinking-related behavior in this population. The manner in which individuals smoke a cigarette (i.e., smoking topography) may be predictive of smoking cessation outcomes, yet the effects of smoking pharmacotherapies on puffing behavior have not been thoroughly examined. Therefore, the current double-blind medication study examined the effects of VAR alone (1 mg BID), low dose NTX alone (25 mg QD), the combination of VAR + NTX, and placebo on smoking topography measures in heavy drinking, non-treatment seeking daily smokers (n = 120). After a 9-day titration period, participants completed a laboratory session in which they smoked their first cigarette of the day using a smoking topography device following 12 h of nicotine abstinence and consumption of an alcoholic beverage (BrAC = 0.06 g/dl). The primary measures were puff count, volume, duration, and velocity and inter-puff interval (IPI). Independent of medication group, puff velocity and IPI increased, while puff volume and duration decreased, over the course of the cigarette. The active medication groups, vs. the placebo group, had significantly blunted puff duration and velocity slopes over the course of the cigarette, and this effect was particularly evident in the VAR + NTX group. Additionally, the VAR + NTX group demonstrated lower average IPI than the monotherapy groups and lower average puff volume than all other groups. These results suggest that smoking pharmacotherapies, particularly the combination of VAR + NTX, alter smoking topography in heavy drinking smokers, producing a pattern of less intense puffing behavior. As smoking topography has been predictive of the ability to quit smoking, future studies should examine how smoking pharmacotherapies' effects on puffing behavior relate to smoking cessation outcomes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027550</affiliation-url><afid>60027550</afid><affilname>University of California, Los Angeles</affilname><name-variant>UCLA</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027550</affiliation-url><afid>60027550</afid><affilname>University of California, Los Angeles</affilname><name-variant>UCLA</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031203</affiliation-url><afid>60031203</afid><affilname>University of California System</affilname><name-variant>Univ of California</name-variant><affiliation-city>Oakland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36151397100</author-url><authid>36151397100</authid><authname>Roche D.</authname><surname>Roche</surname><given-name>Daniel J O</given-name><initials>D.J.O.</initials><afid>60027550</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:49663038400</author-url><authid>49663038400</authid><authname>Bujarski S.</authname><surname>Bujarski</surname><given-name>Spencer</given-name><initials>S.</initials><afid>60027550</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55815750600</author-url><authid>55815750600</authid><authname>Hartwell E.</authname><surname>Hartwell</surname><given-name>Emily</given-name><initials>E.</initials><afid>60027550</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56645492300</author-url><authid>56645492300</authid><authname>Green R.</authname><surname>Green</surname><given-name>Rejoyce</given-name><initials>R.</initials><afid>60027550</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8514936000</author-url><authid>8514936000</authid><authname>Ray L.</authname><surname>Ray</surname><given-name>Lara A.</given-name><initials>L.A.</initials><afid>60027550</afid><afid>60027550</afid><afid>60031203</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8514936000</author-url><authid>8514936000</authid><authname>Ray L.</authname><surname>Ray</surname><given-name>Lara A.</given-name><initials>L.A.</initials><afid>60027550</afid><afid>60027550</afid><afid>60031203</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8514936000</author-url><authid>8514936000</authid><authname>Ray L.</authname><surname>Ray</surname><given-name>Lara A.</given-name><initials>L.A.</initials><afid>60027550</afid><afid>60027550</afid><afid>60031203</afid></author><authkeywords>Heavy drinking smokers | Naltrexone | Smoking topography | Varenicline</authkeywords><intid>2035950241</intid><source-id>21197</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930202034"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930202034?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930202034&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930202034&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930202034</prism:url><dc:identifier>SCOPUS_ID:84930202034</dc:identifier><eid>2-s2.0-84930202034</eid><dc:title>C-reactive protein and risk of breast cancer: A systematic review and meta-analysis</dc:title><dc:creator>Guo L.</dc:creator><prism:publicationName>Scientific Reports</prism:publicationName><prism:eIssn>20452322</prism:eIssn><prism:volume>5</prism:volume><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1038/srep10508</prism:doi><pii>srep10508</pii><dc:description>Associations between elevated C-reactive protein (CRP) and breast cancer risk have been reported for many years, but the results remain controversial. To address this issue, a meta-analysis was therefore conducted. Eligible studies were identified by searching the PubMed and EMBASE up to December 2014. Study-specific risk estimates were combined using a random-effects model. Altogether fifteen cohort and case-control studies were included in this meta-analysis, involving a total of 5,286 breast cancer cases. The combined OR per natural log unit change in CRP for breast cancer was 1.16 (95% CI: 1.06-1.27). There was moderate heterogeneity among studies (I&lt;sup&gt;2&lt;/sup&gt; =45.9%). The association was stronger in Asian population (OR=1.57, 95% CI: 1.25-1.96) compared to European (OR=1.12, 95% CI: 1.02-1.23) and American (OR=1.08, 95% CI: 1.01-1.16). Prediagnostic high-sensitivity CRP concentrations (OR=1.22, 95% CI: 1.10-1.35) was superior to common CRP (OR=1.08, 95% CI: 1.01-1.15) in predicting breast cancer risk. The meta-analysis indicated that elevated CRP levels was associated with increased risk of breast cancer. Further research effort should be performed to identify whether CRP, as a marker of inflammation, plays a direct role in breast carcinogenesis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018554</affiliation-url><afid>60018554</afid><affilname>Zhengzhou University</affilname><name-variant>Zhengzhou University of Light Industry</name-variant><affiliation-city>Zhengzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56493564100</author-url><authid>56493564100</authid><authname>Guo L.</authname><surname>Guo</surname><given-name>Lanwei</given-name><initials>L.</initials><afid>60018554</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56298936700</author-url><authid>56298936700</authid><authname>Liu S.</authname><surname>Liu</surname><given-name>Shuzheng</given-name><initials>S.</initials><afid>60018554</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55752565500</author-url><authid>55752565500</authid><authname>Zhang S.</authname><surname>Zhang</surname><given-name>Shaokai</given-name><initials>S.</initials><afid>60018554</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55537052500</author-url><authid>55537052500</authid><authname>Chen Q.</authname><surname>Chen</surname><given-name>Qiong</given-name><initials>Q.</initials><afid>60018554</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56192861200</author-url><authid>56192861200</authid><authname>Zhang M.</authname><surname>Zhang</surname><given-name>Meng</given-name><initials>M.</initials><afid>60018554</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004542645</author-url><authid>7004542645</authid><authname>Quan P.</authname><surname>Quan</surname><given-name>Peiliang</given-name><initials>P.</initials><afid>60018554</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35211577000</author-url><authid>35211577000</authid><authname>Lu J.</authname><surname>Lu</surname><given-name>Jianbang</given-name><initials>J.</initials><afid>60018554</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35212130300</author-url><authid>35212130300</authid><authname>Sun X.</authname><surname>Sun</surname><given-name>Xibin</given-name><initials>X.</initials><afid>60018554</afid></author><intid>1786087902</intid><article-number>10508</article-number><source-id>21100200805</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929583865"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929583865?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929583865&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929583865&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0747563215003490"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929583865</prism:url><dc:identifier>SCOPUS_ID:84929583865</dc:identifier><eid>2-s2.0-84929583865</eid><dc:title>Ethnicity, digital divides and uses of the Internet for health information</dc:title><dc:creator>Lin C.</dc:creator><prism:publicationName>Computers in Human Behavior</prism:publicationName><prism:issn>07475632</prism:issn><prism:volume>51</prism:volume><prism:issueIdentifier>PA</prism:issueIdentifier><prism:pageRange>216-223</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.chb.2015.04.054</prism:doi><pii>S0747563215003490</pii><dc:description>© 2015 Elsevier Ltd. All rights reserved. The present study investigates the influence of racial/ethnic and cognitive factors on use of the Internet as a channel for public health information. A random sample of 310 residents age 18 years or older provided valid survey responses. Multivariate analyses establish the importance of self efficacy in determining online search motivations, outcome expectancies and behaviors, although we fail to confirm the existence of any kind of "racial divide" in Internet use. The relatively modest role played by ethnicity - in determining online uses and self efficacy - underscores the significance of using attitudinal variables alongside traditional demographic and media use measures of communication technology use.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022659</affiliation-url><afid>60022659</afid><affilname>University of Connecticut</affilname><name-variant>University of Connecticut</name-variant><affiliation-city>Storrs</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004154</affiliation-url><afid>60004154</afid><affilname>Cleveland State University</affilname><name-variant>Cleveland State Univ</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56650310100</author-url><authid>56650310100</authid><authname>Lin C.</authname><surname>Lin</surname><given-name>Carolyn A.</given-name><initials>C.A.</initials><afid>60022659</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004652154</author-url><authid>7004652154</authid><authname>Atkin D.</authname><surname>Atkin</surname><given-name>David J.</given-name><initials>D.J.</initials><afid>60022659</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56651004400</author-url><authid>56651004400</authid><authname>Cappotto C.</authname><surname>Cappotto</surname><given-name>Celeste</given-name><initials>C.</initials><afid>60004154</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56650454600</author-url><authid>56650454600</authid><authname>Davis C.</authname><surname>Davis</surname><given-name>Carrie</given-name><initials>C.</initials><afid>60004154</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56650568100</author-url><authid>56650568100</authid><authname>Dean J.</authname><surname>Dean</surname><given-name>Julie</given-name><initials>J.</initials><afid>60004154</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56650954600</author-url><authid>56650954600</authid><authname>Eisenbaum J.</authname><surname>Eisenbaum</surname><given-name>Jennifer</given-name><initials>J.</initials><afid>60004154</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56650797600</author-url><authid>56650797600</authid><authname>House K.</authname><surname>House</surname><given-name>Kenyetta</given-name><initials>K.</initials><afid>60004154</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56650559900</author-url><authid>56650559900</authid><authname>Lange R.</authname><surname>Lange</surname><given-name>Robert</given-name><initials>R.</initials><afid>60004154</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56650872100</author-url><authid>56650872100</authid><authname>Merceron A.</authname><surname>Merceron</surname><given-name>Alexandra</given-name><initials>A.</initials><afid>60022659</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56650595700</author-url><authid>56650595700</authid><authname>Metzger J.</authname><surname>Metzger</surname><given-name>Jacqueline</given-name><initials>J.</initials><afid>60004154</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56650911400</author-url><authid>56650911400</authid><authname>Mitchum A.</authname><surname>Mitchum</surname><given-name>Ariane</given-name><initials>A.</initials><afid>60004154</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56650786100</author-url><authid>56650786100</authid><authname>Nicholls H.</authname><surname>Nicholls</surname><given-name>Heidi</given-name><initials>H.</initials><afid>60004154</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56651006300</author-url><authid>56651006300</authid><authname>Vidican S.</authname><surname>Vidican</surname><given-name>Simona</given-name><initials>S.</initials><afid>60004154</afid></author><authkeywords>Digital divide | Internet-use efficacy | Online health information | Search outcome expectancies and motivations</authkeywords><intid>535982742</intid><source-id>19419</source-id></entry></search-results>
